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Abstract 
Oncolytic measles virus (MV) is being tested in several ongoing 
clinical trials with encouraging results. There is a demonstrable need to 
explore the role of the immune system in addition to the direct oncolytic effect 
of MV. My laboratory has previously shown that neutrophils are involved in 
MV-mediated tumour regressions, becoming activated, upon MV infection. 
This thesis further explores the role of neutrophils, one of the key players of 
the innate immune system in MV oncolysis. 
First, I showed that acute lymphoblastic leukaemia (ALL) shows 
marked sensitivity to MV oncolysis (Patel, Dey et al., 2011). I attempted to 
enhance neutrophil function at tumour sites by generating a novel strain of 
MV expressing the human granulocyte colony-stimulating factor (GCSF), a 
known neutrophil survival factor and enhancer of antibody dependent cellular 
cytotoxicity (ADCC). Evaluating the effects in two different models of B-cell 
malignancy, I showed that neutrophil depletion abrogated the MV therapeutic 
effect in an in-vivo Raji - but not Nalm-6 - tumour model. MVhGCSF 
enhanced the oncolytic capacity of MV in the Raji model in-vivo, whereas in 
the Nalm-6 model, the opposite was unexpectedly the case. MVhGCSF 
replicated within an MV-infectable CD46 transgenic mouse model with 
detectable serum levels of hGCSF but no toxicity. My data suggest that a 
"one-size-fits-all" model of immune response to viral oncolysis is not 
appropriate, and each tumour target will need full characterisation for the 
potential of MV to generate benefit (Dey et al., 2016). 
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Next, I showed that ADCC was NOT a mechanism by which 
neutrophils kill MV-infected cells. 
Finally, I showed that MV infection of target cells can stimulate 
neutrophils to develop a cytotoxic effector phenotype, all aspects of which 
are blocked by fusion inhibition. Hence, I suggest a new mechanism for MV-
mediated oncolysis; fusion between infected target cells and neutrophils. 
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 μl   Microliter 
 ml   Millilitre 
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 min    Minute 
 MMP    Matrix metalloproteinase 
 Mo-DC   Monocyte derived dendritic cell 
 MOI    Multiplicity of infection 
 mRNA  messenger RNA 
 MV    Measles Virus 
 NIS    Sodium iodide symporter 
 NK    Natural killer cell 
 ns    Not significant 
 OD    Optical density 
 OV    Oncolytic virus 
 PAMP   Pathogen associated molecular patterns 
 PB   Peripheral blood 
 PBMC   Peripheral blood mononuclear cells 
 PBS    Phosphate buffered saline 
 PCR    Polymerase chain reaction 
 PD   Programmed cell death protein 
 PD-L   Programmed cell death ligand 
 PE    Phycoerythrin 
 PEG    Polyethylene glycol 
 PFU    Plaque forming unit 
 PI    Propidium iodide 
 PRR    Pattern recognition receptors 
 PVRL4   Poliovirus receptor-related 4 
 RBC    Red blood cell 
 RdRp    RNA-dependent RNA polymerase 
 RIG-I    Retinoic acid-inducible gene 1 
 RLRs    RIG-I-like receptors 
 RNA    Ribonucleic acid 
 RNP    Ribonucleoprotein complex 
 ROS    Reactive oxygen species 
 RPM   Rotations per minute 
 RQ-PCR   Relative quantitative polymerase chain reaction 
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 SC   Subcutaneous/Subcutaneously 
 SCCHN   Squamous cell carcinoma of the head and neck 
 ScFV    Single chain fragment variable 
 SCID    Severe combined immunodeficiency 
 SCR    Short consensus repeat 
 SEM    Standard error of the mean 
 SLAM   Signalling lymphocyte activation molecule 
 SSPE   Subacute sclerosing pan-encephalitis 
 ssRNA   Single stranded RNA 
 STAT    Signal transduction & activator of transcription 
 STING   Stimulator of IFN genes 
 STP    Serine-threonine-proline-rich domain 
 Th1/Th2  Type 1 T helper cell/ Type 2 T helper cell 
 TNF    Tumour necrosis factor 
 TRAIL   TNF-related apoptosis inducing ligand 
 T-VEC   Talimogene Laherparepvec 
 TCID50   50% Tissue culture infectious dose 
 TLRs    Toll-like receptors 
 UV    Ultraviolet 
 VSV    Vesicular stomatitis virus 
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Chapter 1: Introduction 
1.1 CANCER THERAPY OVERVIEW: 
 Conventional cancer therapy: 1.1.1
Non-specific cytotoxic chemotherapeutic agents1, which kill rapidly 
dividing cells and radiation therapy2, that causes DNA damage in turn killing 
the cells, still remain the backbone of current cancer treatment and is used 
on its own or in combination. Though effective, the toxicity of these agents 
can outweigh the benefits, occasionally by a very large margin and chemo-
resistance remains a big hurdle1. 
 Small molecules in cancer therapy: 1.1.2
Understanding of the biology of different cancers and knowledge of 
the defective signalling pathways in cancer has led to an increase in targeted 
therapies. The first example is the use of small molecules for targeted 
molecular therapy3. Tyrosine kinase inhibitors, which inhibit kinase activity by 
competing for the ATP binding site4 of BCR-ABL {the fusion protein product 
of an aberrant chromosomal translocation (t9;22), which is involved in 
chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) 
pathogenesis}, has revolutionised the treatment of CML and ALL5,6. 
Insight into the underlying genetic pathway that helps in maintenance 
of the tumour has helped uncover growth factor receptors that can be 
targeted by small molecule agents. For example, deregulated signalling by 
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the avian erythroblastosis oncogene B (ErbB) family of tyrosine kinase 
receptors is associated with several cancers7 making ErbB1/epidermal 
growth factor receptor (EGFR), ERbB2/human epidermal growth factor 
receptor 2 (HER2/neu), ErbB3/HER3 and ErbB4/HER47,8, excellent targets 
for small molecule therapy. 
 Antibody therapy: 1.1.3
Monoclonal antibodies (mAb) have been included as standard of care 
in cancer therapy. Rituximab, an anti-CD20 antibody, which binds to CD20 
on cell surface, has been used in combination with chemotherapies in Non-
Hodgkin’s lymphoma (NHL) aberrantly overexpressing CD20, with significant 
improvement in overall survival rates9. Another mAb Trastuzumab 
(Herceptin), that targets the ErbB2, has an excellent anti-tumour activity 
against breast cancer10 and prolonged disease free survival and overall 
survival in patients with HER2 positive breast cancer11. 
 Cellular Immunotherapy: 1.1.4
Allogeneic stem cell transplantation, where patients are infused with 
genetically similar haematological stem cells from HLA-matched sibling or 
unrelated donors has played a major role in the treatment of haematological 
malignancies12,13 and clearly demonstrated the ‘graft versus leukaemia effect’ 
mediated by allogeneic T-cells. More recently that concept has been 
developed further to include modification of patient’s T-cells by gene transfer 
technology, giving rise to engineered T-cells with chimeric antigen receptors 
(CARS) that can recognise diverse cell surface antigens and signal through 
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engineered intracellular domains. One of the most commonly targeted 
antigens to date is CD19, which is expressed on all B-cells14-16. CD19 CAR 
T-cells have proven effective at inducing remissions in patients with CD19 
expressing malignancies such as ALL17 albeit with some considerable 
adverse reactions such as cytokine storms. 
T-cells can also be engineered to express receptors (TCR) against 
tumour antigens and used as cancer therapy18. To generate tumour-specific 
TCRs different techniques have been used. Once a suitable target sequence 
is identified it can be isolated from rare tumour reactive T-cells directly from 
patients18; from mice expressing human HLA, immunised with human cancer 
antigen proteins19 or by using in-vitro technologies to alter the TCR to 
enhance their anti-tumour properties20. Early clinical trials have exhibited 
feasibility of genetically modified TCRs directed against MART1 antigen in 
melanoma21. Additional clinical trials have demonstrated prolonged tumour 
regressions in patients with melanoma and sarcoma22-24. 
 Approaches to ‘vaccinate’ patients against cancer are also being 
studied, for example, Sipuleucel-T for the treatment of prostate cancer is an 
autologous dendritic cell (DC) vaccine, that stimulates T-cell specific for 
prostatic acid phosphatase (PAP), a protein overexpressed by prostate 
carcinoma cells25. 
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 Immuomodulating agents in checkpoint blockade: 1.1.5
Other novel therapeutic agents termed immune checkpoint inhibitors 
have gained popularity in the last decade and are being tested in clinical 
trials. For example Ipilimumab, which is approved by US food and drug 
administration (FDA) as a first line therapy in patients with advanced 
melanoma is an antibody that can block the cytotoxic T lymphocytes 
associated antigen 4 (CTLA4) inhibiting an important signal in the T-cell 
response pathway, thereby initiating tumour cell destruction26. Another agent 
Pembrolizumab and Nivolumab, that block the interaction between 
programmed cell death (PD)-1 protein and its ligand PD-L1 has been 
approved by FDA in patients with Ipilimumab refractory melanoma27. PD-
1/PD-L1 interaction acts as a co-inhibitory signal to dampen T-cell response. 
PD-L1 is overexpressed in cancer cells which binds to the PD-1 on activated 
T-cells thereby deactivating them28. One of the limitations of these novel 
agents is that benefit can be limited by the immunosuppressive nature of the 
tumour microenvironment29. Studies in targeted immunotherapy have 
suggested that a combinatorial approach of using targeted agents in 
combination with immunotherapeutic agents is needed to attain a synergistic 
effect that can achieve more potent cytotoxicity28,30. Targeted combinatorial 
therapy can lead to direct tumour regression, breaking the 
immunosuppressive tumour microenvironment and sensitise the tumour cells 
to be targeted by immune therapy29. 
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 Oncolytic Virotherapy - an overview: 1.1.6
In the last decade, oncolytic viruses have also been increasingly 
widely been investigated for cancer therapy and numerous viruses are now 
being tested in early phase clinical trials31. 
Properties of an ideal oncolytic virus32 include: 
 Efficacy: replicates within cancer cells and kills effectively by direct 
lysis. 
 Specificity and selectivity: exclusively infects and preferentially lyses 
cancer cells. 
 Stimulate immune response: can activate an autologous anti-tumour 
immune response. 
 Stable and genetically modifiable: can be engineered to attain 
additional desirable properties and genetically stable to avoid any 
possible genetic recombination with other species in the environment. 
 Safety: must be safe to the recipient, contacts of the recipient and the 
environment. The virus should be associated with no or very mild 
human disease, with no threat to public health. No possibility of spread 
of the virus in individuals in close contact with the patient or any other 
living forms in the environment. Ideally availability of means and 
treatment to control any viral replication is highly desirable. 
Many viruses are naturally oncolytic with more than one of the above 
desirable characters and others can be genetically modified to make them 
suitable for cancer therapy. Early observations date back to the 19th 
century33 where spontaneous tumour regression was observed when 
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patients acquired natural viral infection33-36. In the 1950s and 1960s 
virotherapy for cancer had gained pace and viruses were tested in clinical 
trials37. However, most of these trials were neither successful nor provided 
meaningful data, as the types of tumours treated were diverse and lacked 
consistency with the different viruses used38. Moreover, there was clearance 
of the virus by the immune system and in some cases the uncontrolled viral 
replication proved fatal, while in other patients, sometimes 
immunosuppressed, the virus took hold and the tumours regressed31. In a 
particular study, tumour regression was reported in 37 of 90 patients treated 
with mumps virus, but this work was not continued39 and the field of cancer 
virotherapy stalled. The modern era of virus mediated specific and selective 
killing of cancer cells, with targeted and engineered viruses arguably began 
during the early 1990s40. With the development of molecular virology, viruses 
once again gained relevance as anti-cancer therapies. An illustrative list of 
viruses being tested as cancer therapeutics is shown in Table 1.1. 
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Table 1.1: Illustrative list of oncolytic viruses tested in murine models: 
Virus Structural 
characteristic 
Receptor Illustrative murine models 
Adenovirus ds DNA, 
Non-enveloped 
CAR Sarcoma 41, head and neck carcinoma42, bladder cancer43 
Reovirus dsRNA 
Non-enveloped 
Unknown Melanoma44, pancreatic45, NSCL46, ovarian47, colorectal48, head and neck 
cancers49 
Measles virus 
(MV) 
ss(-) RNA 
Enveloped 
CD46, SLAM, 
Nectin 4 
Ovarian cancer50, glioblastoma multiforme51, multiple myeloma52 
Vesicular 
stomatitis virus 
(VSV) 
ss(-) RNA 
Enveloped 
LDLR Melanoma53, colorectal carcinoma54, breast cancer55 
Newcastle 
disease virus 
(NDV) 
ss(-) RNA 
Enveloped 
Unknown Glioblastoma multiforme56, neuroblastoma57 
Herpes simplex 
virus (HSV) 
ds DNA 
Enveloped 
HVEM, nectin 1, 
nectin 2 
Glioma40, metastatic melanoma58, head and neck cancer59 
Coxsackie virus ss(+) RNA 
Non-enveloped 
CAR/ICAM-
1/DAF 
Multiple myeloma60, melanoma61 
Vaccinia virus dsDNA 
Enveloped 
(complex coats) 
Unknown Hepatocellular carcinoma62, pleural mesothelioma63, melanoma64, ovarian65, 
breast cancer66 
Poliovirus ss(+) RNA, 
Non-enveloped 
CD155 Neuroblastoma67, glioma68 
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 Oncolytic virotherapy and immunotherapy – synergistic roles: 1.1.7
Oncolytic virotherapy can act with both immunotherapy and 
virotherapy playing synergistic roles to eliminate cancer69. Oncolytic viruses 
can directly kill cancer cells, leading to tumour regression70. However, it has 
become increasingly clear that oncolytic virotherapy has a strong 
immunotherapeutic component and can activate several aspects of the 
immune system to attack the tumour. Both the biology of the virus and the 
cancer environment plays a significant role in the success of oncolytic 
virotherapy. 
Tumours need blood supply to grow and metastasise and 
angiogenesis plays an important role in tumour development71. Vaccinia virus 
can disrupt the tumour vasculature by attacking the tumour-related 
endothelial cells in patients with hepatocellular carcinoma, with no evident 
harmful effect on the normal tissues72. In a phase II/III clinical trial of 
melanoma, intra-tumoural (IT) injection of herpes simplex virus (HSV) 
expressing granulocyte macrophage colony stimulating factor (GMCSF) led 
to a potent anti-melanoma immune response73. Moreover, viral replication 
within tumour bed has been shown to attract immune cells, thereby alerting 
the immune system, leading to tumour associated antigen (TAA) 
presentation by cross-priming which leads to a more potent anti-tumour 
response. For example, vaccinia virus infected human melanoma cell line 
(MelanA TAA positive) were phagocytosed by DCs, which in turn were able 
to stimulate a MelanA antigen specific T-cell response74. Another melanoma 
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cell line Mel888 infected with reovirus was able to generate a melanoma 
antigen recognised by T-cells (MART) specific cytotoxic T-cell response75. 
In parallel to the biology of the virus per se, the biology of the cancer 
cells too has a very important role to play in viral selectivity leading to 
success of oncolytic virotherapy. Among other hallmarks of cancer the cells 
accumulate genetic defects to become malignant, which helps them in 
accelerated proliferation76. These specific defects that allow the cancer cells 
to evade detection by the immune system and helps in their proliferation and 
survival can also provide a thriving environment for the virus to replicate. For 
example, defective cell signalling pathways, such as the defects in the 
interferon (IFN) signalling pathways in cancer cells permit better virus 
replication than in the non-transformed cells, where these pathways are 
intact77. Another hallmark of cancer cells is induction of angiogenesis for 
survival of the tumour cells. Oncolytic viruses have been used to target this 
by direct infection of vascular endothelial cells78, or by arming them using 
anti-angiogenic transgenes79. 
With oncolytic virotherapy, one single agent can achieve the 
combinatorial effect of targeted therapy and immunotherapy to produce a 
robust anti-tumour effect. In the current scenario of cancer therapeutics, an 
agent that can specifically target and kill the tumour cells, without harming 
the normal cell, and at the same time generate a long-lasting anti-tumour 
immune response, looks promising, and an oncolytic virus is a good 
candidate to fit in that space69. 
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 Genetic modification of oncolytic virus and their mechanism of 1.1.8
action: 
While many viruses are able to specifically and selectively kill cancer 
cells naturally, genetic modification has been widely used to enhance their 
oncolytic properties. In-vitro passaged strains belong to the first generation of 
oncolytic virotherapeutics, the genetically engineered, selectivity enhanced 
viruses form the second generation, and the third generation of 
virotherapeutics are the ones that are genetically engineered, transgene 
expressing ‘armed’ oncolytic viruses80. 
Modifications focus on several main areas: 
1. Safety - by attenuation of potentially pathogenic properties and targeting of 
entry or replication: 
For example, adenovirus has been modified by deletions of E1B55 
and E3B genes, which facilitates replication of the virus only in p53 deleted 
cells, thereby attenuating it while simultaneously targeting cancer cells 
lacking p53 function81. Another tissue specific, targeted, adenovirus for 
prostate cancer (CG7060 and CG7870) is regulated by prostate-specific 
promoter elements (PSE1A and PSE1B), therefore has transcriptional control 
and replicates only in prostate cells82,83. The ICP34.5 neuro-virulence gene 
deleted herpes simplex virus (HSV) strains (G207, 1716, NV1020, 
OncoVEXGM-CSF)80 are capable of selective replication in tumour cells84. 
2. Enhancement of anti-tumour immune response: 
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The Ad5-CD/TKrep strain of adenovirus uses both oncolytic and 
suicide gene therapy in combination. In addition to the E1B55 gene deletion 
it expresses the dual pro-drug activating fusion protein cytosine deaminase/ 
thymidine kinase (CD/TK), which can convert the pro-drug 5-fluorocytosine 
(5-FC) to more potent 5-fluorouracil (5-FU), and only in cells with p53 
mutation (Freytag SO 1998). The HSV strain OncoVEXGM-CSF (Talimogene 
Laherparepvec/T-VEC) GMCSF, has enhanced immunogenic properties, and 
has deleted ICP34.5 and ICP47 for reduced pathogenicity and to restore 
MHC I presentation, respectively80. JX-594, a vaccinia virus strain has 
deletion of a thymidine kinase gene that enhances cancer selectivity and is 
armed with GMCSF to facilitate immune cells at the site of viral infection85. 
Engineered and non-engineered viruses are being extensively used in 
clinical trials and shown inTable 1.3. 
 Virotherapy clinical trials:  1.1.9
Oncolytic viruses that are being tested in different phases of clinical 
trials are listed in Table 1.3. Some trials have completed whereas others are 
still ongoing31. The first generation oncolytic viruses that were used in clinical 
trials are the strains passaged in tissue culture to make them attenuated but 
without any modifications. Examples of first generation non-engineered 
viruses that have been used in clinical trials are listed in Table 1.2. 
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Table 1.2: Non-engineered viruses in clinical trials: 
In recent times, the clinical trials using viruses have become more 
strict, controlled and rigorous. The second and third generation of oncolytic 
viruses have become more popular, as they are more targeted, replication-
selective and with reduced toxicity80. Clinical efficacy was shown in one of 
the first phase I/II clinical trial that used OncoVexGM-CSF (T-VEC) directly 
administered in patients with metastatic melanoma intra-tumourally (IT), 
which led to complete regression in both injected and non-injected tumours in 
8 out of 50 patients100. Escalated doses of vaccinia virus, modified to express 
GMCSF was given to cutaneous melanoma patients IT, and was shown to be 
safe, effective at expressing functional passenger gene GMCSF and induced 
significant tumour regression85. Additionally, JX594 strain of vaccinia virus 
was administered IT in patients with hepatocellular carcinoma and led to 
regression in 3 out of 10 patients101. Besides, ONYX-015 (Ad2/5 dl1520) - an 
oncolytic adenovirus strain used to treat head and neck cancer, where 
transient anti-tumoural effects were observed81, showed improved anti-
Virus Disease Publication 
Adenovirus Cervical cancer Huebner RJ 195686 
West Nile virus 
Lymphomas and 
carcinomas 
Southam CM 195187, 
Southam CM 195488 
Mumps 
Carcinomas, lymphomas 
and different solid 
tumours 
Asada T 1907-192839, 
Shimizu Y 198889, Okuno 
Y197890 
Parvovirus Osteosarcoma Toolan HW 196591 
Vaccinia virus Metastatic melanoma 
Hunter Craig 197092, 
Roenigk 197493, 
Mastrangelo 199594 
Newcastle disease 
virus 
Myelogenous leukaemia Wheelock EF 196495 
Cervical carcinoma Cassel WA 196596 
Solid tumours 
Csatary 199397, Csatary 
199998, Csatary 200499 
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tumour effect when used in combination with chemotherapy (cisplatin), 
compared to chemotherapy alone102. Recently a phase III randomised 
controlled study, using T-VEC in metastatic melanoma led to its approval by 
FDA. Total 436 patients were recruited in this trial with advanced stage (IIIB, 
IIIC, IVM1a) disease or patients with no prior treatment. T-VEC was well 
tolerated with significantly improved durable response rates and overall 
survival in the treated patients compared to the control groups103. 
Furthermore, non-engineered viruses too have revealed some encouraging 
results. Reolysin®, which is proprietary variant of Reovirus when used in 
combination with paclitaxel and carboplatin showed efficacy and 26.9% 
response rate in a dose escalation Phase III clinical trial of head and neck 
cancer104. In another dose escalation Phase I/II trial in recurrent glioblastoma 
multiforme, unmodified Newcastle disease virus (NDV) used intra-venously 
(IV), led to minimal toxicity and was well tolerated with some initial response 
to therapy105. All the viruses used so far in the different phases of clinical 
trials have shown efficacy and most of them were very well tolerated even 
with very high doses administered80. 
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Table 1.3: Oncolytic viruses from different generation in clinical trials: 
Virus in 
clinical trial 
Genetic 
modification 
Transgene 
expression 
Name Proposed cancer target Tumours Clinical 
trials 
Adenovirus E1B-55K(-) 
(gene bind to 
and inactivates 
p53 gene), 
E3B(-) 
Non-armed dl1520 (ONYX-
015) 
p53 pathway defects; late RNA 
transport defects 
Sarcoma, head and 
neck cancer, bladder 
cancer, lung mets, 
glioma, ovarian 
cancer, solid 
tumours, pancreatic 
cancer, CRC, 
hepatobiliary, 
prostate cancer 
Phase I, 
II and III 
E1B-55K(-), 
E3(-) 
Non-armed H101 
(Oncorine) 
p53 pathway defects; late RNA 
transport defects 
PSE1A, E3B(-) Non-armed CG7060 Prostate specific 
PSE1A, PSE1B Non-armed CG7870 Prostate specific 
E1B-55K(-), 
E3(-) 
CD/TK expression Ad5-CD/Tkrep p53 pathway defects; late RNA 
transport defects 
Coxsackie 
virus 
Non-engineered Non-armed CAVATAK Selective infection of ICAM-1 
expressing cells 
Melanoma, SCCHN, 
solid tumours 
Phase I 
and II 
Herpes 
simplex 
virus 
ICP34.5(-) Non-armed HSV 1716 Defects in tumour PKR/IFN 
pathways, attenuated 
neurotoxicity 
Solid tumours, 
metastatic 
melanoma, head 
and neck cancer, 
glioma, non-CNS 
solid tumours, 
mesothelioma, 
pancreatic cancer, 
breast cancer, 
Phase I, 
II and III 
ICP34.5(-), 
ICP6(-) 
Non-armed G207 Tumour cell complementation of 
ribonucleotide reductase (ICP6-
), defects in tumour PKR/IFN 
pathways, attenuated 
neurotoxicity 
ICP34.5(-), 
UL24(-), UL56(-
); replaced with 
a fragment of 
Non-armed NV1020 Unknown 
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HSV-2 US 
DNA(US2, US3, 
gJ and gG) 
ICP34.5(-), 
ICP47(-), Us11 
upregulation 
GMCSF 
(immunostimulation) 
Talimogene 
Laherparapvec 
(OncoVEXGM-
CSF) (T-VEC) 
Defects in tumour PKR/IFN 
pathways, attenuated 
neurotoxicity 
Measles 
virus 
Non-engineered 
(vaccine strain) 
CEA – helps in 
monitoring of virus 
MV-CEA Unknown Ovarian cancer, 
glioma, multiple 
myeloma, 
mesothelioma, 
SCCHN 
Phase I 
and II 
Non-engineered 
(vaccine strain) 
NIS (sodium iodide 
symporter) – 
facilitates virus 
tracking 
MV-NIS 
Mumps Non-engineered Non-armed -  Carcinoma, 
lymphoma, solid 
tumours 
 
Newcastle 
disease 
virus 
Non- 
engineered 
Non-armed - Unknown Myelogenous 
leukaemia, cervical 
carcinoma, solid 
tumours 
 
Non-engineered Non-armed NDV-HUJ Glioma, solid 
tumours 
Phase I 
and II Non-engineered Non-armed PV701 
Non-engineered Non-armed MTH-68/H 
Parvovirus Non-engineered Non-armed H-1PV Interfering with cell signalling, 
activation of host immune 
responses106 
Glioma Phase I 
and II 
Non-engineered Non-armed   Osteosarcoma  
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Reovirus Non-engineered Non-armed Reolysin Defects in tumour PKR/IFN 
pathways 
Glioma, peritoneal 
cancer, solid 
tumours, CRC, 
sarcoma, melanoma, 
ovarian, pancreatic 
cancer, SCCHN, 
lung cancer 
Phase I, 
II and III 
Retrovirus Cytosine 
deaminase (CD) 
Non-armed Toca 511 Defects in anti-viral response, 
expression of CD by cancer 
cells for later use of Toca FC 
Glioma Phase I 
and II 
Seneca 
Valley virus 
Non-engineered Non-armed NTX-010 Unknown (selectivity towards 
human neuro- endocrine cells) 
Small cell lung 
cancer 
Phase II 
Vaccinia 
virus 
 
Non-engineered Non-armed   Metastatic 
melanoma 
 
Thymidine 
kinase(-), VGF(-
), LacZ, CD 
somatostatin R 
Non-armed (vvDD-CDSR) Unknown (EGFR pathway 
driven) 
CRC, solid tumours, 
HCC, paediatric 
solid tumours, 
melanoma, 
peritoneal 
carcinomatosis, 
SCCHN 
Phase I 
and II 
Vesicular 
stomatitis 
virus 
Non-engineered IFNβ VSV-hIFNβ Defects in host anti-viral 
response 
HCC Phase I 
West Nile 
virus 
Non-engineered Non-armed   Lymphoma, 
carcinoma 
 
CD/TK – cytosine deaminase/thymidine kinase, CEA – carcinoembryonic antigen, CRC – colorectal cancer, EGFR – epidermal growth 
factor receptor, GMCSF – granulocyte macrophage colony stimulating factor, HCC – hepatocellular carcinoma, ICP - infected cell 
protein, ICAM1 – intercellular adhesion molecule 1, IFN – interferon, IRES - internal ribosomal entry site, MV – measles virus, NDV – 
Newcastle disease virus, PKR – double stranded RNA activated inhibitor of translation – known as PKR, PSE1A – prostate-specific 
promoter-driven E1A, PSE1B – prostate-specific promoter-driven E1B, SCCHN – squamous cell carcinoma of the head and neck, VSV 
– vesicular stomatitis virus 
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1.2 MEASLES VIRUS OVERVIEW: 
 Measles virus structure: 1.2.1
Measles virus (MV) is a negative stranded RNA virus of the 
Morbilivirus genus from the Paramyxoviridae family. The schematic 
representation of MV structure is shown in Fig 1-1a. The genome of the virus 
consists of 15,894 bases that encodes for 6 structural and 2 non-structural 
proteins. The terminator region of each gene is followed by a three 
nucleotide-long conserved region (GAA) called intergenic (IG) region. The 
Nucleocapsid (N) protein encapsidates the viral RNA and is closely 
associated with the viral Large protein (L) and Phosphoprotein (P). The N, P 
and L proteins together form the ribonucleoprotein (RNP) complex, which is 
the core virus structure. The L protein is the RNA dependent RNA 
polymerase (RdRp) and the P acts as a chaperone during nucleocapsid 
assembly107. The Matrix (M) protein is on the inside surface of the envelope, 
it helps in anchoring Fusion (F) and Haemaglutinin (H) proteins and aids viral 
assembly and budding108,109. Other than the 6 structural proteins, the P gene 
of the MV also encodes for 2 non-structural proteins C and V. The C protein 
is translated from the P gene by an alternative reading frame at the second 
start codon. The C protein has been implicated in mediating efficient viral 
replication in peripheral blood cells110, RNA synthesis111, virulence 
dependence112 and RdRp activity by blocking type I IFN response113. The V 
protein is produced from the P gene by a frame shift due to incorporation of a 
G residue at the conserved RNA editing site. It is known to bind both to the N 
and L proteins and therefore believed to regulate RNA synthesis114.
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Figure 1-1: MV Structure: (a) Schematic diagram of virion structure showing MV -veRNA genome and viral proteins H, F, M, P, L and N. (b) 
Organisation of MV genome and MV transcription gradient showing mRNA of the genes at the 3’ end are produced more abundantly compared 
to the 5’ end. 
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 MV replication: 1.2.2
MV infection and replication can be broadly seen as 7 steps115 as 
shown in Fig 1-2: 
Step 1 - Attachment: The H and the F are the membrane 
glycoproteins. The H binds to its receptor on the target cell, and this leads to 
conformational change in H and the adjacent F. The hydrophobic fusion 
peptide within the F protein becomes exposed and is inserted into membrane 
of the target cell. 
Step 2 - Cell entry:  Further conformational change leads to fusion of 
virus and target cell membranes and the genomic material enters the cell. 
Step 3 - Viral mRNA transcription: During MV replication, the 
polymerase (L) associates with the MV RNA inside the RNP core structure at 
the 3’ end and the mRNA of the first gene is made and polyadenylated. The 
polymerase dissociates or ‘falls off’ at the junction of the genes, known as the 
IG region and re-starts transcription at the beginning, ultimately producing 
polyadenylated mRNAs. 
Step 4 - Protein synthesis: The polyadenylated mRNAs act as a 
template for protein synthesis. The amount of each protein synthesised 
depends on the position of the gene on the genome, leading to a 
transcription gradient wherein proteins at the 3’ end are synthesised more 
abundantly than at the 5’ end. The viral genome and the transcription 
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gradient are shown in Fig 1-1b. Therefore, the N is the most abundant 
protein synthesised, followed by P, M, F, H and L proteins. 
Step 5 - Viral genome replication: Once sufficient N protein is 
produced, it blocks the IG regions on the MV genome, and prevents the 
polymerase from ‘falling off’. This enables the replication of the entire viral 
genome, which is transcribed to obtain the sense, genomic viral RNA. 
Step 6 - Viral assembly: Once the viral genome is synthesised, it 
initiates the virus assembly. The viral genome, the N, P and L, forms the 
RNP complex to form the core structure. 
Step 7 - Release: The core structure travels towards the cell 
membrane, and along with the M, F and H proteins gets released from the 
cells as virus particles. 
 
    
4
5
 
 
 
 
Figure 1-2: The MV replication cycle: Schematic representation of MV replication cycle and the steps involved. Adapted from Griffin et 
al. 2007107. 
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 MV receptors: 1.2.3
There are three known MV receptors CD46, signalling lymphocyte 
activation molecule (SLAM) also called CD150, and Nectin-4 (also called 
polio-virus-receptor-like 4 or PVRL4). Fig 1-3 shows a cartoon of all the three 
receptors. 
1.2.3.1 CD46: 
CD46 is a type I transmembrane glycoprotein and is ubiquitously 
expressed on all nucleated human cells. CD46 helps to protect cells from 
complement mediated lysis and is often upregulated by tumour cells116. The 
extracellular region of the CD46 receptor comprises of four short consensus 
repeats (SCR1-SCR4)117. The four SCR domains are followed by one or two 
O-glycosylated serine/threonine/proline (STP) rich domain, a transmembrane 
region and have two alternative cytoplasmic tails that result from alternative 
splicing118. The SCR1 and SCR2, present at the N-terminal are known to 
interact with the MV-H glycoprotein117 (Fig 1-3). A system based on inhibition 
of cell fusion by MV glycoproteins was used to screen a library of 3000 
different monoclonal antibodies raised against the cell surface proteins in cell 
lines permissive to MV infection119. This system helped identify one single 
monoclonal antibody (MCI20.6), that blocked MV binding and infection and 
recognised a membrane glycoprotein (57 to 67 kDa) which was sequenced 
and identified to be the human membrane cofactor protein CD46119. 
CD46 is a cellular receptor for many other human pathogens. For 
example human herpes virus 6, pestivirus, different adenovirus serotypes 
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Ad3, Ad11, Ad35 and Ad37 and also two types of bacteria Streptococcus 
pyogenes and Neisseria, all use CD46 for cellular entry120. Different viruses 
interact with different domains of the CD46 to gain cellular entry, and the 
cellular mechanisms that facilitates CD46 dependent cell entry also varies 
between different pathogens and therefore, what makes CD46 a common 
receptor for different pathogens is still not very clear120. It is suggested that 
the two cytoplasmic domains of the CD46 receptor can “fine-tune” T-cell 
mediated response, as it can drive T-cell differentiation121 and T-cell induced 
inflammation118, thereby connecting the innate and adaptive immune 
response120. The pathogens targeting the CD46 receptor can possibly 
interfere with the cytoplasmic tail mediated intracellular signalling pathways 
thereby creating an immune response imbalance120. Engagement of the 
CD46 receptor affects the host immune response and might explain to 
certain extent why viruses use complement receptors for cellular entry116. 
CD46 has been shown to play an important role in MV pathogenesis. 
One proposed mechanism is down regulation of CD46 upon MV infection 
due to interaction between the MV-H and the CD46 receptor, rendering the 
cells more susceptible to complement mediated lysis122. Only laboratory 
adapted MV vaccine strains are able to use this receptor to enter cells. 
1.2.3.2 CD150: 
SLAM or CD150 is a cellular receptor for the wild-type (WT) strain of 
MV123. Nevertheless the vaccine strain can also use this receptor to enter 
cells124. SLAM is a member of the immunoglobulin superfamily of receptor 
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molecules, which is a subset of the CD2 family of receptors. The structure is 
shown in Fig 1-3. It consists of two immunoglobulin (Ig)-like domains, and 
MV binds to the N terminal domain125. The extracellular domain consists of a 
variable region (V) and a constant (C2) region and the cytoplasmic tail is 
made of three repeats of tyrosine-based motifs126. B95a is a marmoset 
lymphoblastoid cell line and was first used to identify SLAM as a receptor for 
WT MV. This cell line is commonly used to isolate WT MV strains and 
therefore was considered a good source of mRNA encoding for the WT MV 
receptor and consequently used to create a cDNA library with the eukaryotic 
expression vector pCAGGS127. 293T cells that are not infectable by WT MV 
strain was transfected with different clones of the cDNA expressing 
pCAGGS. At the same time, the 293T cells were infected with VSVΔG* 
complemented with H glycoprotein of KA WT strain of MV isolated on the 
B95a cells and F protein from Edmonston vaccine strain (VSVΔG*-KAHF)123. 
Extensive screening of more than 400 clones of cDNA, helped in isolating the 
cDNA clone that showed highest level of infection in the 293T cells. DNA 
sequencing revealed that the clone was 91% identical to the human SLAM 
gene in the coding region and hence SLAM was identified to be the cellular 
receptor for the WT strain of MV124. 
SLAM proteins function as co-receptors for lymphocyte activation 
and/or adhesion and mediate tyrosine phosphorylation signals128. SLAM 
receptor expression is mainly restricted to immune cells. It is upregulated on 
immature thymocyte and activated B-cells and T-cells129, mature DCs130,131 
and activated monocytes132, but down regulated on Th2 polarised cells. 
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SLAM ligation promotes the activation of Th0/Th1 cells, B-cells, eosinophils, 
mast cell, and macrophages133. 
1.2.3.3 Nectin-4: 
Nectin-4 is the most recently identified receptor for MV and is 
expressed at the epithelial adherens junction134,135. This is the putative 
epithelial receptor (EpR), which was long proposed136,137 to be the receptor 
used by MV during natural infection, as MV can infect epithelial, endothelial 
and neuronal cells, which are SLAM negative138,139. Nectin-4 shares 
homology with the poliovirus and is involved in the formation of adherens 
junction. MV interacts with the membrane distal domain of the Nectin-4 
protein (Fig 1-3). Two different groups identified this receptor 
independently134,135 using similar approach of comparing upregulated 
membrane-associated genes in WT MV susceptible and non-susceptible cell 
lines using genome wide microarray expression analysis. It has been 
identified as a receptor for other viruses and is involved in differentiation, 
polarisation, movement and other cellular activities. It is expressed on cancer 
cell lines140 and therefore might be relevant to MV oncolytic activity. 
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Figure 1-3: MV receptors: Schematic representation of CD46, SLAM and Nectin 4. STP domain - serine-threonine-proline rich domain; V: 
variable domain; C: constant domain; Ig: Immunoglobulin. Numbers 1-4 represent CD46 short consensus repeat (SCR). Adapted from Dhiman 
et al. 2004116. 
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 MV Strains: 1.2.4
WT MV is highly pathogenic and responsible for numerous deaths 
worldwide among unvaccinated children141. Enders and Peebles first isolated 
MV from a patient David Edmonston in the year 1954142. After serial passage 
in human kidney and human amnion tissue cultures, a strain was adapted to 
growth in the amniotic sac of developing chick embryos. The resultant 
vaccine strains underwent numerous passages in chick embryo-cell cultures, 
at 37°C and then at 32°C which was first used in clinical trials in USA, 
England and Nigeria143,144. The resultant Edmonston strain (Edm) had lost its 
pathogenicity but could still generate an immune response. Vaccination 
against MV infection was introduced in 1960s with both attenuated and killed 
vaccines145, although the killed vaccine strain was soon withdrawn due to 
complications. Safe and efficacious vaccine strains have been now 
developed mostly from the Edm strain as shown in Fig 1-4. AIK-C, Schwarz, 
Moraten, Rubeovax and Zagreb are vaccine strains derived from the Edm 
lineage. Other vaccine strains that were obtained from different WT MV 
strains independently are also available in different parts of the world, for 
example, CAM-70 (Japan), Changchun-47 (China), Leningrad-4 (Russia) and 
Shanghai-191 (China)146. In 1963, the first live attenuated vaccine was 
licensed in the USA under the trade name Rubeovax147. Later, the more 
attenuated Moraten strain replaced it148. The AIK-C strain is used in Japan149 
and the Zagreb, is produced by serum institute of India and is most 
commonly used in the Expanded Programme on immunisation of the World 
Health Organisation (WHO)150. The vaccine strains had good sero-
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conversion rates but still induced fever in 46% of vaccinees and therefore 
were replaced by more attenuated strains147. The Schwarz strain, generated 
in 1962 is more attenuated and is produced in Europe and Brazil151 while 
Moraten strain (Attenuvax, Merck and Co. in the Unites States), generated by 
further passage in chick embryo fibroblasts147 is used in the United Kingdom. 
MV vaccine is given either as a single agent or combined with other vaccine 
viruses such as mumps and rubella (MMR)152,153. In the developed countries 
MV vaccine is usually given in the form of MMR at 12-15 months of age, but 
in countries where MV is endemic, vaccines are typically administered at the 
age of 9 months153. 
Based on the MV-H and MV-N gene sequences, MV is assigned to 1 
of 23 genotypes and one provisional genotype154. All vaccine strains are 
grouped under genotype A155. However, there is only one serotype, and 
serum samples collected from vaccinated individuals can neutralise viruses 
from different genotypes with variable neutralising titres156,157. Reported sub-
optimal sero-conversion after vaccination is possibly due to lack of coverage, 
improper administration, age of the vaccine recipient and transport and 
storage of vaccine158-160. The vaccine strain of MV is not pathogenic in 
healthy individuals, and there is no evidence of the MV vaccine strain 
reverting to a pathogenic phenotype161. Humans are the only known hosts for 
MV, and no other animal or environmental reservoir is known to exist145. 
Some non-human primates are susceptible to MV infection162, but to be 
assigned as a natural reservoir of MV that can sustain and transmit MV 
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infection, the size of the worldwide wild population of primates required, is 
not sufficient145. 
The vaccine strain derived from the Edm strain has an excellent safety 
record of more than 50 years as it is being used in the vaccination 
programmes worldwide, and has been administered to millions of 
people107,163 with rare occurrence of adverse events, the most common one 
being fever and rash at 8-12 days post vaccination151. Rubeovax caused 
fever in 46% and rash in 16% of the recipients147. More attenuated strains 
Zagreb and Schwarz had reduced side effects such as fever in 2% and 21% 
recipients respectively146. Three percent of MV Moraten and 20% of AIK-C 
vaccine recipients presented with rash146. However, there are reports of 
severe adverse effects in vaccine recipients who are severely 
immunocompromised and are incapable of clearing the virus164-166. The 
vaccine is therefore not recommended for immunosuppressed patients, while 
people with HIV infection should have >200 cell/microL count of CD4+ T-cell 
for safe administration of the virus32. WT MV can spread transiently to the 
central nervous system (CNS) in up to 50% of infected patients167, and lead 
to CNS complications soon after infection as in acute encephalomyelitis 
(AME), or years after infection, as in subacute sclerosing panencephalitis 
(SSPE)168, which is a rare, fatal consequence of CNS infection169,170. The 
third MV-induced CNS disease, progressive infectious encephalitis or 
measles inclusion body encephalitis (MIBE), occurs in immunosuppressed 
patients several months post MV infection167. However, there is no evidence 
of the vaccine strain of the virus causing any of the CNS related 
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complications168,169, and immunisation by the vaccine strain has been 
suggested to prevent SSPE168. 
 MVs used as oncolytic virus and relation to vaccine strains: 1.2.5
The different genetically modified strains derived from the MV EdmB 
strains are shown in the red boxes in Fig 1-4. Most MV vaccine strains used 
today comprise of very closely inter-related laboratory strains, derived from 
the 1954 clinical isolate142,171,172. Initially, the commercially available strains, 
such as the Moraten50 and Edm-Zagreb173 were tested as oncolytic viruses 
due to their excellent safety profile and commercial availability174. MV 
Moraten had shown similar anti-tumour potency in an in-vivo model of 
ovarian cancer when compared to the MV-tag-Edm modified strain used at 
1x106 infectious units50. Although the MV Moraten was packaged and 
available commercially at 1x103 infectious doses, it was impractical to use it 
in clinical trials where an effective dose in excess of 1x108 was required. The 
phase I clinical trial using the Edm-Zagreb strain in cutaneous T-cell 
lymphoma had shown some promising results173 but awaits further studies. 
The MV-tag-Edm and its derivatives showed extensive anti-tumour properties 
in mouse models of different human malignancies51,52,175-179. The MVNSe 
was derived from the MV-tag-Edm and has unique NarI and SpeI cleavage 
sites180 to facilitate easier genetic manipulation. MVs has been genetically 
modified to express different gene of interest, for e.g. MV expressing green 
fluorescent protein (MV-GFP), carcinoembryonic antigen (MV-CEA), sodium 
iodide symporter (MV-NIS), all developed from the EdmB vaccine strain and 
are discussed in detail in section 1.3.1. The MVhGCSF strain was derived 
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from the MVNSeGFP strain. The vaccine strains used as a part of this thesis 
are shown in blue in Fig 1-4. 
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Figure 1-4: Edmonston vaccine lineage: MV strains in the red boxes are genetically modified strains derived from EdmB strain. 
Highlighted in blue are the MV strains used in this thesis. Adapted from Rota et al. 1994171. 
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 Rescue of MV by reverse genetics: 1.2.6
MV can be rescued from cloned cDNA by reverse genetics181. Fig 1-5 
shows the schema for this procedure. The full length MV cDNA plasmid is 
under the control of T7 promoter. Vero (African green monkey kidney 
epithelial cells) is first infected with the recombinant modified vaccinia virus 
(Ankara) (MVA). This virus allows expression of the T7 RNA polymerase 
{DNA dependent RNA polymerase (DdRp)} without vaccinia virus replication. 
Next, the cells are transfected with individual plasmids coding MV proteins N, 
P and L under the CMV promoter, and the full length MV, which is under the 
T7 promoter. T7 RNA polymerase help synthesise the anti-genomic RNA 
template from the full-length MV plasmid in the cytoplasm of the Vero cells, 
while the N, P and L proteins are synthesised in the nucleus of Vero cells, 
which encapsidates the RNA template formed from the cloned MV cDNA, to 
form the RNP core structure. Encapsidation initiates MV-N, P and L 
dependent replication of MV genomic RNA. When all the individual 
components of the virus are present in optimum quantities, they are 
assembled and released as viral particles, as during natural infection. In the 
laboratory, successful rescue is recognised by the occurrence of 
multinucleated syncytia, which can be ‘picked’ to further propagate the novel 
clone. 
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Figure 1-5: Rescue of MV from cloned cDNA: Schematic representation of reverse genetics methodology using multiple plasmid transfection 
approach and recombinant Vaccinia Ankara virus to obtain MV particles. Adapted from Radecke F. et al. 1995181. 
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An alternative to the use of MVA is the rescue of MV using a cell line 
(293-3-46 – derived from a human embryonic kidney cell line 293, 
transformed by adenovirus type 5 DNA)182, stably expressing the MV-N, MV-
P and the T7 RNA polymerase181. This cell line is then transfected with the 
full-length MV plasmid and the MV-L plasmids, subsequently forming the MV 
particles as described above. 
 Models for studying MV pathogenesis and vaccination: 1.2.7
Naturally infected humans, naturally and experimentally infected 
macaques, experimentally infected cotton rats and murine models and 
numerous in-vitro systems have contributed to our understanding of MV 
infection and pathogenesis107. 
1.2.7.1 Primates: 
Old world primates were the first animal models used to study MV 
pathogenesis and for vaccine development, as they were highly susceptible 
to MV infection. They are among the non-human primates closely similar in 
their clinical, virological, immunological and pathological parameters 
associated with measles infection in humans115. Two different species, 
Rhesus macaque (Macaca mullata) and Cynomolgus macaques (Macaca 
fascicularis) has been widely used in MV pathogenesis studies and vaccine 
development139,183-187. The macaques develop a measles-like illness when 
challenged with WT MV but not with the attenuated vaccine strain 
(EdmB)183,185,188. However, a drawback of using the macaques as a model to 
study the MVEdmB strain of measles is the abundant expression of MV 
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receptor CD46 in their red blood cells (erythrocytes) as opposed to their 
absence in humans. Therefore, MVEdmB can agglutinate the macaque 
erythrocytes thereby slowing virus dissemination, which potentially abates 
the relevance of virulence study of the vaccine strain of virus in this model189. 
Although they still remain an important model of choice for studying WT 
strains. 
The new world monkeys are even more susceptible to MV infection 
when compared to the old world monkeys, but develop a different 
pathogenesis than in humans, associated with very high rates of 
mortality190,191. Squirrel monkey was chosen to be an ideal model to test 
attenuated MV-NIS in pre-clinical toxicology and bio-distribution study, as 
they express a truncated version of the CD46 that does not bind vaccine 
strain of MV192, and therefore upon infection (via SLAM interaction) can 
cause measles like illness comparable to humans. 
1.2.7.2 Rodent: 
Mice are popular models for scientific research because they are 
small, cost effective, and easy to house and have shorter gestation 
compared to non-human primates. Unfortunately mice are not susceptible to 
MV infection and therefore, several CD46 transgenic mice have been 
generated to study MV pathogenesis193. Among them CD46 transgenic mice, 
which are also lacking the IFN-α/β receptor (IfnrKO CD46 Ge) have been 
used for most toxicology studies. These mice express human CD46 with 
tissue distribution similar to CD46 expression in humans, including low to 
  
61 
absent expression on erythrocytes194. Upon intranasal route of infection the 
virus shows enhanced spread into the lungs and a potent inflammatory 
response due to lack of type I IFN signalling195,196. Though the lack of IFN 
response limits their application in immune response related studies, this 
remains a choice for most toxicology pre-clinical studies. 
Another model for studying WT clinical isolates of MV is transgenic 
mice expressing the CD150 or SLAM receptor as CD46 transgenic mice are 
not susceptible to WT strains. Several transgenic lines expressing CD150 
has been described197-202, which differs in the promoter used to drive CD150 
expression. These mice have proven very successful in studying WT MV, 
and some of them follow the natural routes of MV infection making them very 
desirable115. 
Cotton rats have shown to support MV replication and are more 
practical and less expensive models compared to the macaque. It has been 
evaluated as a pre-clinical model of MV vaccine strains203. Though the 
vaccine strain of MV doesn’t cause overt disease in these animals, they have 
been shown to replicate in the lung tissue, immunosuppress the animal and 
disseminate from the lungs204. Although clinical isolates fail to infect cotton 
rats limiting their utility in replacing non-human primates, they remain one of 
the closest models for studying MV203. 
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1.2.7.3 Ferret: 
Ferrets’ susceptibility to a range of respiratory viruses and their 
relatively small size makes them an attractive animal model to study viral 
pathogenesis. They are not susceptible to MV infection but develop sub-
acute encephalitis upon infection with sub-acute sclerosing panencephalitis 
(SSPE) isolates205. Additionally they are natural host for canine distemper 
virus (CDV), which is closely related to MV and causes measles like 
characteristic rashes in ferrets with all signs of disease seen in MV-infected 
humans206. This model has been used to study the C and V proteins of MV 
and how they contribute in immunosuppression and overall pathogenesis 
upon binding to SLAM115. 
1.2.7.4 Humans: 
Being the only natural host of MV infection, data from humans are 
unparalleled. The peak of viral replication in humans is generally reached 
before the onset of observable symptoms and viral clearance coincide with 
clinical symptoms, which makes it challenging to study MV pathogenesis in 
human cases207. Therefore, current understanding of measles comes from 
studies in macaques208 (see 1.2.7.1). 
 Natural MV infection: 1.2.8
Natural MV infection leads to a complicated cascade of innate, cellular 
and humoral immune response, which helps in clearing the infection. Use of 
the models described above (section 1.2.7) has helped elucidate the immune 
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response to MV. These models are vital in understanding both pathogenesis 
of natural measles infection and the immune response to the use of 
oncolytic, vaccine strains. 
MV infection is initiated at the respiratory tract, from where it spreads 
to local secondary lymphoid tissue most probably after uptake by lung DCs 
or alveolar macrophages209,210. MV replicates in lymphatic tissue efficiently 
and infected cells enter the blood circulation and can be detected by 7-9 
days post infection in peripheral blood mononuclear cells (PBMCs), including 
B-cells, T-cells and monocytes183,185. Infection spreads from the blood to the 
distal lymphoid tissues and to epithelial and endothelial cells in multiple 
organs including liver, brain and skin211,212. 
1.2.8.1 Host immune response to MV infection: 
1.2.8.1.1 Innate immune response: 
MV is transmitted by aerosols and thought to first infect the cells 
located in the respiratory epithelial tissues, including mucosal DCs115. 
Macrophages, DCs and NK cells have all been implicated in the innate 
immune response at the site of primary infection. The macrophages can 
engulf the entire virus and destroy them into pieces115. Furthermore, the viral 
components can be recognised by cellular sensors, which can induce an 
inflammatory response, via type I IFNs. The type I IFNs released by the 
infected cells can activate NK cells to produce type II IFN, IFNγ, which can 
directly kill the infected cells213. 
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1.2.8.1.2  Viral RNA recognition: 
Signature molecules from microorganisms - glycoproteins, 
lipopolysaccharides, proteoglycans, nucleic acids including ssRNA are the 
pathogen associated molecular patterns (PAMPs) that are detected by the 
host innate immune cell receptors - pattern recognition receptors or PRRs. 
PRRs implicated in MV detection are toll-like receptors (TLRs) and retinoic 
acid inducible gene I (RIG-I)-like receptor (RLR)214-216. Recognition of PAMPs 
by the PRRs leads to a type I inflammatory response and plays a central role 
in eradication of the viral infection217. Upon binding to these cellular sensors, 
the viral components induce the JAK/STAT signalling pathway leading to the 
formation of the IFN stimulated gene factor 3 (ISGF3) complex, comprising of 
the STAT1, STAT2 and IFN regulatory factor 9 (IRF9)218,219. The ISGF3 
complex then translocate to the nucleus, where it activates the IFN-
stimulated response element (ISRE) gene mediated transcription leading to 
IFN production and establishment of the anti-viral state220. 
1.2.8.1.3 TLR mediated viral recognition: 
TLR family members play a very important role in initiating an anti-viral 
response. Of the 10 human TLRs, TLR2, 3, 4 7 and 8 are known to be 
involved in RNA virus recognition216. WT MV-H glycoprotein interacts with 
TLR2 on macrophages and activates signalling via a pro-inflammatory 
pathway and stimulates induction of interleukin 6 (IL6) and increases surface 
expression of CD150. The vaccine strain is unable to do this, but a single 
mutation at the H protein at position 481, can turn the vaccine strain back as 
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a TLR2 agonist221. In the plasmacytoid DCs (pDCs), the TLR receptors TLR7 
and TLR8 are present at the endosomal compartment and detect ssRNA via 
internalisation and digestion of the virus222,223. MV infects cells by direct 
membrane fusion, and therefore are less likely to be detected by TLR7 and 
TLR8 in the endosome of pDCs216, and consequently the IFN response to 
paramyxoviruses have been shown to be independent of the TLR7 and 
endosome acidification224. Nevertheless, the MV Schwarz vaccine strain has 
been shown to interact with TLR7 and TLR9 on pDCs and inhibit IFNα and 
IFNβ production by pDCs, which may contribute towards the characteristic 
immune suppression, super infection and Th2 biased immunopathology of 
MV225. 
1.2.8.1.4 RLR mediated viral RNA recognition: 
The RLR family are a group of cytosolic PRRs that can detect PAMPs 
to distinguish between self host RNA from non-self genetic material from the 
RNA viruses thereby leading to activation of downstream effector molecules 
such as type I IFNs and other pro-inflammatory cytokines involved in an 
innate anti-viral and inflammatory gene expression226. The RLR family 
consists of the RIG-I, MDA5 (melanoma differentiation gene 5) and LGP2 
(laboratory of genetics and physiology-2). RIG-I and MDA5 possesses 
caspase activation and recruitment domains (CARDs) on their N-terminal 
that upon activation interacts with the MAVS (mitochondrial antiviral 
signalling) protein present on the mitochondria, and lead to the activation of 
the downstream IFN signalling pathway226. 
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Both RIG-I and MDA5 RNA helicases contribute to the induction of 
IFNα/β in MV-infected human cells227. MV can interact via the RIG-I/MDA5 
signalling pathway with MDA5 preferentially binding to (+) sense RNA of MV, 
while RIG-I binding to the (-) sense RNA within the trailer region and the 
adjacent L, which leads to downstream signalling228. WT MV has been 
reported to inhibit the JAK/STAT mediated type I IFN signalling pathway 
largely than the attenuated vaccine strain229. The MV-C protein of the WT MV 
has been shown to inhibit the production of type I IFNs230 while the P and V 
proteins block the phosphorylation of STAT1 and eventually translocation of 
STAT1/STAT2 complex into the nucleus231-233. Mutant MV deficient in V or C 
genes produce very high levels of IFNβ compared to their parental 
counterpart, and require protein kinase PKR and mitochondrial adapter 
MAVS for maximum IFNβ induction234. Both V and C proteins are important 
in controlling the inflammatory response to the virus and the innate 
immunity235. 
1.2.8.1.5 Adaptive immune response: 
Humoral and cellular immunity play a very important role in MV 
clearance and long-term protection from subsequent infection. MV infection 
leads to a very robust cellular response with activated CD4+ and CD8+ cells 
that can be isolated from the MV-infected epithelial cells. The activated T-
cells play a major role in clearance of the virus in macaques, where depletion 
of CD8+ T-cells leads to prolonged viremia236. This Th1 type response, which 
is associated with, increased level of IFNγ and IL2 is designed to promote 
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clearance of virus infected cells. This switch to a Th type 2 (Th2) response 
later, that leads to the production of type 2 cytokines - IL4, IL10, and IL13 
and helps in generation of anti-MV antibodies and immunological memories. 
The CD8+ cells are rapidly cleared upon clearance of the infection and no 
infectious virus is detected. However, MV RNA can be isolated from the 
patients for weeks after recovery, which is responsible for the presence of 
activated CD4+ T-cells and helps in maintaining long-term protection237. 
Post MV infection, anti-MV antibody is detected within 72 hours of the 
onset of rash, which is mostly IgM. The IgM response lasts for up to 28 days, 
after which an IgG response begins and provides lifelong immunity115,238. The 
antibody response is against the main structural proteins, with anti-N 
antibody at the highest, followed by H, F and very little to the M protein239. 
Anti-MV antibody can be both neutralising and non-neutralising and though 
anti-F neutralising antibody is present, the majority of the neutralising 
antibody is against MV-H240,241. World Health Organisation (WHO) has 
assigned presence of 200mIU/ml of neutralising antibody as a necessary 
level to confer protection to MV242,243. The MV-specific neutralising antibody 
plays a key role in preventing MV infection, and contributes to MV clearance 
with the help of the cellular immune response from the start of MV 
infection244-246. 
1.2.8.1.6 MV-mediated immune suppression: 
MV infection is associated with increase in susceptibility to other 
infections and this is due to the immunosuppressive effects of MV infection 
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and measles related deaths are often caused by secondary infections, most 
commonly diarrhoea or pneumonia247. Evidence of immune suppression is 
first detected with the onset of measles rash and generation of the immune 
response to MV, which eventually results in clearing of the virus and lifelong 
immunity237. A number of MV-induced mechanisms of direct and indirect 
immunosuppression have been proposed which includes lymphopenia, type 
2 skewing of cytokine responses and suppression of lymphocyte 
multiplication237. MV infection is associated with lymphopenia, which is 
caused by susceptibility of the lymphocytes to increased cell death212,248. 
Engagement of the CD150 receptor causes CD95 mediated apoptosis249,250, 
and MV infection per se can induce bystander lymphocyte apoptosis251,252, 
which possibly contributes to lymphopenia. MV infection in-vitro can cause 
inhibition in lymphocyte proliferation by halting lymphocyte cell cycle 
progression associated with G1 arrest253,254. 
1.3 MEASLES VIRUS AS AN ONCOLYTIC AGENT: 
One of the first observation of MV as a potential oncolytic agent was 
spontaneous regression of lymphomas in a 8-year-old boy, after contracting 
natural MV infection255. Almost three decades later, some of the initial work 
was done in B-cell malignancies with MV as an oncolytic virus. In 2001, 
Grote et al175 from my group showed that MVEdm vaccine strain is capable 
of causing regression of large established lymphoma tumours. In this model, 
the effect of the presence of anti-MV antibody was also tested and it did not 
abrogate the anti-tumour effect. In 2004, Dingli et al256 showed the oncolytic 
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effect of MV in myeloma xenografts. Both IV and IT routes of MV 
administration were successful in tumour regression in this model. The 
potential of MV as an oncolytic virus was extrapolated to solid tumours and it 
has been shown to be oncolytic in numerous other tumour models like 
medulloblastoma257 that used the MV expressing green fluorescence protein 
(GFP), in an intra-cerebral murine xenograft model and mesothelioma258 that 
used MV encoding for IFNβ and the sodium iodide symporter (NIS). Different 
routes of MV administration, IV, IT and IP were investigated in several 
studies and various modifications were introduced into MV genome to enable 
tracking of the virus in-vivo conveniently (MV-GFP, MV-CEA, MV-NIS) or 
increase its therapeutic effect (MV-IFNβ). A non-exhaustive list of different 
tumour models, routes of MV administration and several MV modifications 
are shown in Table 1.4. All these models described in Table 1.4, where MV 
was shown to be oncolytic were human xenografts established in 
immunocompromised mice. The limitations to these models are obvious, as 
immune responses cannot be studied. Some efforts have been made to 
address this within immunocompetent syngeneic mouse tumour models 
using MV, with entry re-targeted to murine cells. 
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Table 1.4: MV as an oncolytic agent in different mouse tumour models: 
In a murine colon adenocarcinoma model developed from MC38cea 
cell line (that express the CEA protein) in a C57BL/6 mice, a re-targeted MV 
expressing scFvCEA was used to treat the tumour. The MV-CEA was armed 
with a pro-drug convertase, purine nucleoside phosphorylase (PNP) to 
enhance the oncolytic activity of MV. When pro-drug MeP-dR (9-2-deoxy-
beta-D-ribofuranosyl-6-methylpurine) was used with the MV-CEA-PNP, very 
significant tumour regression was observed when compared to MV-CEA or 
the MeP-dR pro-drug alone. This correlated with pro-longed survival263. 
Another way in which MV has been studied in immunocompetent models has 
provided assistance with the toxicology and bio-distribution studies, which 
are crucial before clinical trials. There are by now several lines of mice 
transgenic for MV receptors including SLAM193,200,202,264-266. Most toxicology 
studies in MV to date267 have been done in CD46 transgenic mice, which are 
also lacking the IFNα/β receptor (IfnrKO CD46 Ge). These mice express 
Tumour model MV modification Routes of MV 
administration 
Publications 
Medulloblastoma MV-GFP  IT Studebaker et al., 
2012257  
Mesothelioma MV-IFNβ; MV-NIS  IT Li et al., 2010258  
Breast cancer MV-GFP  IV; TT 
(intrapleural) 
Iankov et al., 
2009259  
Prostate cancer MV-luc, MV-GFP, 
MV-CEA 
 IT Msaouel et al., 
2009260 
Glioma MV-GFP-H (AA)-
IL-13, MV-GFP,  
 IT Allen et al., 
2008261 
Ovarian cancer MV-CEA IP Galanis E et al., 
2008262  
Myeloma MVEdm IV, IT  Peng et al., 200152  
Lymphoma MVEdm, MV-LacZ  IV, IT Grote et al., 
2001175  
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human CD46 in a tissue distribution that mimics the pattern of CD46 
expression in humans, including low to absent expression on erythrocytes194. 
The different modification strategies of MV to enhance its oncolytic 
properties are discussed in detail in the next section (see 1.3.1). 
 Modifications to MV for more effective cancer therapy: 1.3.1
1.3.1.1 MV targeting: 
MV is one of the few viruses where full re-targeting by modification of 
the envelope glycoprotein has been achieved. Targeting strategies have 
relied upon display of growth factors or single chain fragment variable (scFv) 
antibodies. MV entry targeted via the epidermal growth factor receptor 
(EGFR) and insulin-like growth factor-1 (IGF-1) receptor were the first to be 
reported268. The genes coding for EGF and IGF-1 were cloned into MV-H in 
frame linked by a serine and glycine rich linker sequence and then cloned 
into the MV backbone sequence replacing the H. The new virus was able to 
enter and infect CD46-negative rodent cells - Chinese hamster ovary (CHO) 
stably expressing the hEGFR and mouse NIH-3T3 cells stably expressing 
the hIGF1 receptor. scFv-CD20269, scFv-anti-hCEA270 and scFv-anti-CD38271 
have all been displayed on the MV-H to facilitate targeted entry to CD20, 
CEA and CD38 expressing cancer cells, respectively. 
This targeting strategy, whilst permitting entry to non-permissive target 
cells still allowed MV to enter and infect permissive cells via CD46 and 
SLAM. Therefore, attempts at fully re-targeting MV were carried out by 
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introducing mutations in the receptor-binding domain of MV-H to render the 
H, CD46 and SLAM “blind”. Introducing mutations at amino acids which were 
carefully chosen as being putatively involved in receptor binding within the 
MV-H protein prevented the viral cell entry via CD46 or SLAM, making the 
virus effectively CD46 or SLAM “blind”272. Nakamura et al. employed a 
related set of mutations in the development of a method to rescue fully re-
targeted CD46 and SLAM blind MV. An anti-CD38 scFv was fused to the C 
terminus of the MV-H protein wherein residues involved in binding to CD46 
(451,481) and SLAM (529, 533) were mutated. Paired mutations were 
introduced at positions 451 and 529, or 481 and 533 on the MV-H to make 
the virus blind to both CD46 and SLAM273. These mutations supported fusion 
via the targeted CD38 receptor but not via CD46 or SLAM. The viruses were 
rescued on CHO-CD38 cells. Later, a system was developed to rescue this 
virus by introduction of a His-Tag, a peptide containing 6 histidine residues at 
the C terminus of the mutated H protein273. The virus could now be rescued 
and propagated on Vero cells expressing a receptor for α-His peptide. Other 
MVs, which are fully re-targeted have since been generated which can enter 
the target cells via EGF273, EGFvIII274, and IL-13-Rα2261 receptors. MV 
selectively activated by human tumour cells overexpressing matrix 
metalloproteinases has also shown to have enhanced specificity of 
replication within tumours275,276. 
1.3.1.2 Tracking: 
MV has also been modified to add genes to facilitate tracking of the 
virus in-vivo. Marker genes such as GFP, CEA, luciferase (luc), have been 
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used for tracking, monitoring and imaging purposes both in-vitro and in-vivo. 
CEA antigen is a non-immunogenic soluble glycoprotein, which is present in 
normal mucosal cells and can be over expressed by adenocarcinoma cells. It 
has the advantage of being quantitated by a standardised routine laboratory 
assay. MV expressing human CEA has been used in the ovarian cancer 
clinical trial for non-invasive monitoring of patients after therapy by 
monitoring the CEA level in the serum277. Due to characteristic elevation of 
CEA in certain tumour types, MV expressing NIS was developed as a clinical 
reporter gene. 
1.3.1.3 Therapeutic enhancements: 
NIS has the advantage of potentially facilitating the therapeutic effect 
of oncolytic MV. NIS is normally expressed in the thyroid tissue on thyroid 
follicular cells and facilitates the accumulation of iodine by thyroid follicular 
cells278. When MV-NIS infected cells express NIS, uptake of exogenously 
administered radioiodine can occur and this provides a basis for in-vivo 
radioiodine imaging studies that can reveal the profile of MV-NIS gene 
expression and the location of MV-NIS infected cells. Isotypes like 123I and 
124I were used in a medulloblastoma tumour model279. MV-NIS treatment, 
both on its own and in combination with 131I, enhanced tumour stabilisation 
and regression in treated mice and significantly extended their survival times. 
Radioiodine was concentrated at the tumour sites in mice given 131I. In 
addition, mice with localised tumours that were given 131I after MV-NIS 
treatment exhibited a significant survival advantage over mice given MV-NIS 
alone279. 
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In another approach of enhancing therapeutic activity of MV in our 
laboratory, in an in-vivo model of lymphoma, MV expressing murine GMCSF 
(mGMCSF) led to significant infiltration of neutrophils in the injected tumour 
resection when compared to the unmodified MV. This led to much superior 
tumour regression280. Furthermore, MV expressing neutrophil-activating 
protein (NAP) of helicobacter pylori - a powerful enhancer of inflammatory 
reaction showed Th1-polarised immune response that improved survival in 
breast cancer and aggressive lung metastatic breast cancer models. High 
level of NAP was secreted by the infected tumour cells, which led to high 
levels of TNFα, IL6 and IL12/23 cytokine concentrations in the pleural 
effusion281. 
Arming the MV with pro-drug convertase and cytokines is an 
alternative approach of adding a therapeutic layer to MV-mediated oncolysis. 
Pro-drug convertase are enzymes that can convert a non-toxic substrate to a 
toxic drug. For example, Escherichia coli purine nucleoside phosphorylase 
(PNP) can convert non-toxic fludarabine and purine analogue 6-methylpurine 
2'-deoxyriboside (MeP-dR) to toxic 2-fluoroadenine and 6-methylpurine 
respectively263,282. These are highly diffusible and can inhibit DNA, RNA and 
protein synthesis283. MV have been armed with PNP and has shown 
enhanced oncolytic activity in lymphoma282,284, pancreatic cancer285 and a 
murine colon carcinoma model263. However, fludarabine is considerably 
cytotoxic when administered systemically286. Another example is cytosine 
deaminase (CD), which converts pro-drug 5-fluorocytosine (5-FC) to 5-
fluorouracil (5-FU) and subsequently to 5-fluorouridine-monophosphate. MV 
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armed with CD was shown to improve oncolytic effect of MV in 
cholangiocarcinoma287 and head and neck squamous cell carcinoma288. 
 MV Clinical Trials: 1.3.2
MV is being evaluated in several phase I and II clinical trials (see 
Table 1.5 - modified from Russell 201231, Guillerme 2013289, clinicaltrials.gov 
- NCT02192775). Some trials are completed while others are still recruiting. 
Different routes of administration are being evaluated in these studies. The 
first phase I clinical trial was carried out in Cutaneous T-cell Lymphoma 
(CTCL) and used IFNα to prevent infection in IFNα sensitive healthy cells in 
combination with MVEdm-Zagreb therapy. In this trial, MV induced cytopathic 
effect locally, after IT injections even in the presence of anti-measles 
antibodies. Additionally, tumour regression was observed in three patients 
with notable regression of distant lesions that were not injected173. The data 
from the ovarian cancer trial, which used MV-CEA, showed no dose related 
toxicity in all 21 patients recruited with clinical response observed in 14 out of 
21 patients262,290,291. A recent preliminary report from a phase I clinical trial 
have shown very good response rate in 2 patients with multiple myeloma. 
Both the patients were treated with MV-NIS at 1x1011 dose IV, and one of the 
two patients showed a durable complete remission of 9 months292. There are 
currently 5 Phase I/II clinical trials that are open and recruiting and two that 
are active but not recruiting yet, and one more in the pipeline to start this 
year (clinicaltrials.gov). 
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Table 1.5: MV in Clinical Trials: 
1.4 MECHANISMS OF MEASLES VIRUS MEDIATED ONCOLYSIS: 
The mechanism by which MV selectively kills tumour cells is not 
completely understood. Different mechanisms, both direct and indirect, have 
been proposed and are summarised in Fig 1-6, and is discussed below. 
Virus 
Strain 
Phase Cancer Type Route Combinatio
n 
Status Centre 
MV-CEA I Glioblastoma 
multiforme 
CNS - Recruiting Mayo 
Clinic 
MVEdm
-Zagreb 
I CTCL IT IFNα Complete
d 
Zurich 
Universit
y 
MV-NIS 
and 
MV-CEA 
I Ovarian 
cancer or 
primary 
peritoneal 
cancer 
IP - Complete
d 
Mayo 
Clinic 
MV-NIS I Head and 
neck cancer 
IT - Recruiting Mayo 
Clinic 
MV-NIS I Pleural 
mesotheliom
a 
IP - Active Mayo 
Clinic 
MV-NIS I Peripheral 
nerve sheath 
tumour 
IT - Starting 
June 2016 
Mayo 
Clinic 
MV-NIS I/II Ovarian 
cancer 
IPMSc - Active Mayo 
Clinic 
MV-NIS II Multiple 
myeloma 
IV CTX Recruiting Universit
y of 
Arkansas 
MV-NIS II Ovarian, 
fallopian, 
peritoneal 
cancer 
IP - Recruiting Mayo 
Clinic 
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 MV receptor overexpression by tumour cells: 1.4.1
One of the proposed mechanisms of direct oncolysis is selective entry 
of MV into tumour cells. MV vaccine strains preferentially enter the cells via 
CD46 receptor, which mediates attachment of the virus, cell entry and cell-
cell fusion, and is known to present on all nucleated cells, and is often 
overexpressed on transformed cells119,293. The ability of the attenuated MV to 
enter a cell via CD46 have been shown to help the virus preferentially enter 
and infect transformed cells making it a potential mechanism of oncolysis by 
MV. Anderson et al. showed that cells engineered to express different 
densities of CD46 on their surface, led to progressively increased rate of cell 
infection and cell-cell fusion with higher densities of CD46294. Also, the 
recently identified receptor of MV, Nectin 4, which is considered a tumour 
marker for breast, lung and ovarian cancers, is overexpressed on these cells, 
suggesting the possible MV selectivity in these cells295-297. Other than the 
viral receptors, cancer cells overexpress specific proteases like matrix 
metalloproteinases and MV and other paramyxoviruses require protein 
cleavage of the fusion F protein to facilitate cell entry, suggesting a possible 
mechanism298-300. 
In addition to CD46, all MV strains including vaccine strains retain the 
ability to enter cells via SLAM301 and certain SLAM positive haematological 
malignancies have regressed following natural MV infection255,302. In an in-
vitro study, SLAM was shown to be a dominant oncolytic MV receptor in 
mantle cell lymphoma and blocking SLAM with antibodies reduced MV entry 
by 70%. MV modified to enter via SLAM alone elicited a tumour regression 
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equivalent to unmodified MV, whereas MV modified to enter via CD46 alone 
was comparable to vehicle control. This study showed that MV infection and 
spread in mantle cell lymphoma is entirely SLAM dependent301. 
 Enhancement of apoptosis: 1.4.2
MV infection can also induce direct cytotoxicity by enhancing the 
apoptotic signalling pathway in the infected cells. For instance, MV infection 
of glioblastoma multiforme cells in combination with radiation therapy led to 
higher apoptosis inducing cleavage of the poly ADP-ribose polymerase 
(PARP), mediated mainly by the extrinsic caspase pathway303. In another 
model of mesothelioma, MV infection led to apoptotic cell death of the 
infected mesothelioma cells, which were readily phagocytosed by DCs304. 
 
  
7
9
 
 
 
 
Figure 1-6: Proposed mechanisms of MV-mediated oncolysis: Diagram showing the different mechanisms of MV-mediated oncolysis 
proposed in the literature. 
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 Cellular responses: 1.4.3
Oncolytic MV can elicit a systemic anti-viral/anti-tumour response, 
which can greatly contribute to viral oncolysis. The relatively low infection 
efficiency in-vivo suggests that for complete eradication of any tumour, the 
virus should be able to activate the immune system. In a SCID model of 
Burkitt’s lymphoma, the virus regressed tumours efficiently, but the MV 
distribution in the sections of resected tumours was found to be patchy, 
suggesting some role of the immune system175. Moreover, tumour regression 
was associated with a significant neutrophil infiltration that was enhanced by 
MV expressing murine GMCSF, and correlated with superior tumour 
regression. The role of one of the key players in the innate immune system – 
neutrophils, was very clear in this model280. Both innate and adaptive 
immune system may play a very important role in virus mediated oncolysis70 
but has been difficult to study in MV-mediated oncolysis for the lack of an 
ideal in-vivo model, as MV does not infect murine cells. Although others have 
shown in human in-vitro studies that MV could induce monocyte-derived DC 
(Mo-DC), another important player of the innate immunity, to mature in-
vitro304,305. The Mo-DCs were shown to cross prime CD8+ T-cells specific for 
a tissue-associated antigen (TAA) of mesothelioma tumour cells. This 
showed a possible connection between MV infection and the innate immune 
cells being able to cross talk to the adaptive immune cells to initiate a more 
tumour specific immune response initiated by an oncolytic virus304. In another 
in-vitro study with melanoma cell line, PBMCs treated with MV was shown to 
enhance innate anti-tumour immunity within the PBMC effectors. Besides, 
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Mo-DCs and NK cells were both activated by MV infected melanoma cells, 
and in a killing assay, CTL primed by DCs co-cultured with MV infected 
melanoma cells were shown to be more potent killer of tumour cells 
compared to DCs co-cultured with uninfected melanoma cells alone305. In a 
similar study, plasmacytoid DCs (pDCs), another class of DC, that play an 
important role in an anti-viral immune response, were shown to upregulate 
the pDC maturation marker CD83, and produced high levels of IFNα when 
exposed to MV-infected tumour cells. The pDCs exposed to the MV-infected 
melanoma were also able to cross present another TAA, NY-ESO-1 positive 
melanoma cells to CD8+ T-cells specific for the same TAA, and activated 
them to produce IFNγ. All this was not true for pDCs exposed to UV treated 
tumour cells and showed a potential role of MV-infected tumour cells in 
generating an immune response289. 
1.5 NEUTROPHILS - OVERVIEW: 
The focus of this thesis is the neutrophil response to MV-infected 
cancer cells. An overview of the biology of neutrophils in response to viral 
infection and cancer is given below. 
 Neutrophil biology: 1.5.1
Neutrophils comprise approximately 60% of the white blood cells in 
humans306. They provide first line of defence against infection and are potent 
effectors of inflammation. Neutrophils release soluble factors that act as 
chemo attractants and guide recruitment of both specific and non-specific 
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effector cells307. They are produced in the bone marrow from myeloid 
precursors, controlled in part by granulocyte colony stimulating factor 
(GCSF)308. 
Neutrophils are recruited to sites of tissue injury in a multistep 
process. Cytokines produced by macrophages result in upregulation of the 
transmembrane adhesion molecules, selectins on endothelial cells, which 
tether to the neutrophils’ p-selectin glycoprotein ligand-1 (PSGL-1) (step 1). 
Next, ‘rolling’ occurs, mediated by E selectin. An adhesion step mediated by 
adhesion molecule 1 and 2 (ICAM1 and ICAM2) on the endothelial cells 
binding to neutrophil lymphocyte function-associated antigen 1 (LFA1). 
Finally integrins, ICAM1, ICAM2, vascular cell adhesion protein 1 (VCAM1), 
other junctional adhesion molecules (JAMs), and platelet/endothelial cell 
adhesion molecule (PECAM1) facilitate transmigration of the neutrophil into 
the tissue by a process called diapedesis309. 
 Neutrophils’ mechanism of action to combat viral infection: 1.5.2
Neutrophils are crucial players in defence against bacterial, fungal and 
viral infections. They can respond to both non-self PAMPs and self, danger 
associated molecular patterns (DAMPs). Once triggered, neutrophils activate 
PRRs like, TLRs310, RLRs311 and nucleotide-binding oligomerisation domain 
(NOD)-like receptors (NLRs)312 and mediate downstream inflammatory 
signalling. 
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Activated neutrophils release reactive oxygen species (ROS), which 
are highly damaging to the invading microorganism. ROS production can 
induce degranulation with release of cytotoxic contents to kill 
microorganisms. Neutrophil extracellular traps (NETs) are another way 
neutrophils effectively contain infection. NETs are made of chromatin and 
protein and are released from granules. They have been shown to be quite 
effective in binding with both gram-positive and gram-negative bacteria, and 
against fungal infections. NETs have been mainly studied in relation to 
bacterial and fungal infection313. However, one report documents the role of 
NETs in HIV-1 infection, wherein engagement of HIV-1 with TLR7 and 8, 
induced ROS-triggered release of NETs314. Neutrophils are also part of a link 
with the adaptive immune system and has been shown to act as an antigen-
presenting cell in influenza A infected mouse lungs, where infected 
neutrophils expressing viral antigen, cross-presented to anti-viral CD8+ T 
effector cells315. Neutrophil granule proteins can also activate TLR-9 in DCs, 
which can trigger IFN release313.  The role of neutrophil degranulation and 
ROS generation in the anti-viral response is highly relevant to this thesis and 
merits a more detailed discussion. 
1.5.2.1 Neutrophil granules: 
The four neutrophil granules are:- 
1. Primary (Azurophilic granules): store the most potent hydrolytic 
enzymes, for example elastase, myeloperoxidase (MPO), cathepsins 
and defensins. 
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2. Secondary (Specific granules): enriched in metalloproteinases such as 
lactoferrin, and metalloproteinase 9. Contain some overlapping 
components to tertiary granules but can be separated by gradient 
centrifugation, due to their difference in distinct buoyant densities. 
3. Tertiary (gelatinase granules): contains matrix metalloproteinases and 
microbial lectin ficolin-1. 
4. Secretory vesicles: contain human serum albumin, indicating that they 
are formed via endocytosis. They contain pre-formed cytokines such 
as transforming growth factor alpha (TGFα), TNFα, IL6, IL12 and 
CXCL2316 formed during immune activation. They are able to form 
small golgi structure in mature neutrophils317. 
1.5.2.2 Neutrophil degranulation mechanism: 
The process of neutrophil degranulation is highly regulated, and is 
mediated by a receptor-coupled mechanism318. Firstly, the neutrophil 
granules are recruited onto the cell surface by translocation of the granules, 
which is triggered by signalling of cell surface receptors, in response to a 
potential infection. Once recruited the next step is tethering and docking of 
the granule onto the cell surface, which exposes the granule’s outer surface 
of the lipid bilayer to the neutrophil’s inner surface of lipid bilayer. This is 
followed by granule priming, which helps the granules to rapidly fuse by 
making them fusion-competent. A reverse pore structure is formed that helps 
in complete fusion of the granule membrane to the neutrophil membrane, to 
release its granular content318. Increase in the intercellular Ca2+, hydrolysis of 
ATP and GTP is essential for the translocation and exocytosis of the 
granules. The granules are released in an orderly manner - secretory 
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vesicles first followed by tertiary, secondary and finally the primary granules - 
dependent on the concentrations of Ca2+318. Upon degranulation, contents 
are released into the extracellular or phagolysosomal spaces and fusion of 
membranes319, which aids the killing of engulfed microorganisms320. 
Phagolysosome biogenesis, essential for killing the pathogens, occurs 
through fusion of newly formed phagosomes with other granules and/or 
endosomes321. 
1.5.2.3 Respiratory Burst: 
Respiratory burst by which neutrophils produce ROS is deleterious for 
invading microorganisms. Receptors like formyl peptide receptors (FPRs) 
and G protein coupled receptors (GPCRs) present on neutrophils can 
recognise peptides like N-formyl-Met-Leu-Phe (fMLP) and inflammatory 
proteins like C5a and IL-8, triggering a rapid downstream signalling 
response. This leads to assembly of a multi-protein oxidase complex called 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. The 
individual components of this NADPH oxidase complex are present 
separately in the non-activated cells. Upon activation they assemble on the 
membrane of the cell, which helps catalyse NADPH-dependent reduction of 
O2 to superoxide anions (O2
-) and ROS including hydrogen peroxide (H2O2), 
hydroxyl radical (OH.) and hypochlorous acid (HOCl)322. A fraction of the 
NADPH oxidase (approx. 5%) is located in the plasma membrane and 
phagosomal membrane, the secretory vesicle harbors approximately 10% of 
the NADPH oxidase complex, and the specific and gelatinase granules 
comprises of almost 85% of the NADPH oxidase. The MPO or 
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myeloperoxidase is located in the azurophilic granules, which is essential to 
generate HOCl, from O2
-, and plays an important role in killing phagocytosed 
microorganism. It has been proposed that to generate HOCl, the primary, 
secondary, tertiary granules and the secretory vesicle must fuse, along with 
the phagosome323,324, which is an important step of ROS generation or 
respiratory burst. 
1.5.2.4 Neutrophils and phagocytosis: 
Phagocytosis is another mechanism by which phagocytes (neutrophils 
and macrophages) can eliminate microorganisms, primarily bacteria325. In 
contrast, some microbes including viruses are not directly phagocytosed, 
instead they are eliminated when the infected cells are engulfed by 
phagocytes, and is referred to as indirect phagocytosis. It is initiated by 
recognition of viral components expressed on the host cells bound to 
antibodies. These antibodies are in turn recognised by the Fcγ receptors on 
the phagocytes326. Another example of indirect phagocytosis is when 
phagocytes engulf apoptotic cells, by inherent defence mechanism of cells to 
maintain homeostasis327. Apoptosis induced in virus-infected cells can also 
trigger phagocytosis in a similar way327,328. For instance, in C57BL/6 mice, 
infected with influenza virus, both neutrophils and macrophages were shown 
to phagocytose infected cells, which were apoptotic329. There are several 
reports of neutrophils phagocytosing viruses such as hepatitis C330, hepatitis 
B331,332, HIV-1333 and CMV334. Avian influenza virus H5N1 has been 
suggested to enter neutrophils by phagocytosis as H5N1 cellular receptor is 
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expressed on neutrophils and this might help in viral replication within the 
neutrophils335. 
 Neutrophils in cancer: 1.5.3
Neutrophils plays a crucial role in mediating anti-cancer activity and 
this has been documented both in-vitro and in-vivo336. Neutrophils may 
migrate towards the site of tumour by a regulated multistep interaction 
between neutrophils and endothelial cells in much the same way as occurs 
for pathogens337. They are able to produce the same sort of cytotoxic 
mediators as discussed earlier, like ROS, proteases, membrane perforating 
agents and soluble mediators of cell killing, such as TNFα, IL-1β and IFNs338-
340 which can kill the tumour cells. This is a delicate balance as the pro-
inflammatory activities of neutrophils can also facilitate tumour growth. 
1.5.3.1 Anti-tumour: 
In a murine bladder cancer model, where mycobacterium BCG 
(Bacillus Calmette-Guérin) was used as a treatment, neutrophils were shown 
to play a key role in therapeutic success. The activated neutrophils from BCG 
treated mice attracted monocytes, which in turn resulted in CD4+ T-cell 
migration. Depletion of neutrophils in the same model eliminated the anti-
tumour effect of the BCG treatment341. Neutrophils stimulated with both 
viable and heat killed BCG were shown to release TRAIL/Apo-2L, suggesting 
a direct anti-tumour effect342,343. In relation to virotherapy, in which a model of 
murine colon cancer was treated with vesicular stomatitis virus (VSV)344, shut 
down of blood flow to the tumours was observed, which was proposed to be 
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mediated by neutrophils as shown by the increase in the transcripts encoding 
the neutrophil chemo attractants CXCL1 and CXCL5. This suggested the 
possible role of neutrophils in the recruitment of inflammatory cells that led to 
the shutdown of IT blood flow. Moreover, the shutdown of the blood flow to 
the tumours led to apoptosis in even those tumour cells that were not 
infected by the VSV. Additionally, neutrophil depletion in this model failed to 
stop the blood flow to the uninfected tumour cells, thereby enhanced spread 
of the tumour 344. The same group345 showed that VSV attacks the tumour 
vasculature and induces clot formation in the tumour vasculature that 
correlates with decrease in tumour cell proliferation. This was tested in mice 
after neutrophil depletion and correlated with decrease in clot formation and 
hence proliferation in tumour cells, implying the role of neutrophils in intra-
tumoural coagulation345. 
1.5.3.2 Pro-tumour: 
In spite of the well-documented anti-cancer properties of neutrophils, 
there is a growing body of literature suggesting a dual role of neutrophils in 
cancer where it can be either pro-tumour or anti-tumour depending on the 
microenvironment and cytokine profile of the neutrophils. Several studies, 
primarily in murine models have shown that neutrophils can promote tumours 
by promoting angiogenesis346 and can augment tumour cell dissemination 
and metastatic seeding of tumour cells in distant organs347-349. In contrast, 
other studies have emphasised the role of neutrophils as anti-tumour. They 
have shown that neutrophils can limit progression of disease through direct 
cytotoxicity of tumour cells350,351, by enhancing anti-tumour mediators338, and 
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can limit metastatic seeding by acquiring a cytotoxic phenotype348,349. 
Although reports regarding the role of neutrophils in cancer are conflicting, it 
is getting increasingly clear from different studies that the pro and anti-
tumour characteristic of neutrophils can be attributed to their functional 
plasticity352 and the cancer microenvironment has been suggested to play an 
important role. For example, presence of TGFβ, often available in high 
concentrations in the tumour sites have been shown to switch neutrophils 
from a pro-inflammatory anti-tumour N1 phenotype to anti-inflammatory pro-
tumour N2 phenotype353. More recently Mishalian et al.354 have found that 
the distribution of neutrophils on discontinuous density gradient (Ficoll-
Hypaque) is different from what was believed earlier. Although the 
neutrophils are generally found in the high-density (HD) gradient, there is an 
additional population, which is present in the low-density (LD) gradient and 
co-separates with the PBMCs. They found that this LD fraction increases 
with tumour growth, and in mice when compared to the HD neutrophils that 
has anti-tumour properties, LD neutrophils show reduced chemotaxis toward 
tumour cells, reduced phagocytic ability, augmented oxidative burst and no 
cytotoxicity towards the tumour cells355. In humans, neutrophilia has been 
associated with poor prognosis76,356. Although distinct population of 
neutrophils have been shown to be present in mice and suggested to be 
present in human355, careful and detailed investigation is needed to support 
the notion that the existence of multiple sub-types of neutrophils, and its 
activity in the tumour microenvironment has any role to play in determining 
neutrophil function. 
  
90 
 Neutrophils in MV-mediated oncolysis: 1.5.4
Data from my laboratory has previously implicated neutrophils as 
potential effector cells of MV-mediated oncolysis. In an in-vivo Raji (Burkitt’s 
lymphoma) tumour model, MV infection augmented the host CD45+ 
leukocyte response, which was further elicited in the group where MV 
modified to express murine GMCSF (MVmGMCSF) was used. Further 
analysis showed massive neutrophil infiltration in sections of Raji (Burkitt’s 
Lymphoma) tumours treated with MVmGMCSF when compared to MV 
alone280. However, there was no difference observed in the number of NK 
cells and macrophages in these groups. Additionally, higher neutrophils also 
correlated with a superior anti-tumour response in MVmGMCSF treated 
tumours when compared to the MV alone group.  
In another study from my laboratory357, human neutrophils were 
shown to get infected by the vaccine strain of MV and could replicate within 
them over 24 hours. When compared to a WT strain of MV, the vaccine 
strain was able to activate the neutrophils within 4 hours of infection. 
Besides, the neutrophils infected with the vaccine strain of MV survived 
longer ex-vivo. Upon MV infection, pro-inflammatory cytokines like TNFα, 
which is known to destruct tumour vasculature; IL-8, a potent chemo 
attractant and activator of neutrophils; MCP-1, a monocyte and T lymphocyte 
attractant and IFNα gene expression and protein secretion were upregulated. 
Furthermore, TRAIL, which has a tumour specific cytotoxic activity, was 
secreted in response to MV infection from neutrophil granules because of 
neutrophil degranulation initiated by vaccine MV infection. MFI of three 
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different neutrophil degranulation markers CD35, CD63 and CD66b were 
significantly higher than the uninfected control or the WT MV357. All these 
data from our previous publication suggested that the effect of MV infection 
of neutrophils, specifically the oncolytic vaccine strain of MV might have a 
potential role in MV oncolysis. 
1.6 GRANULOCYTE COLONY STIMULATING FACTOR (GCSF): 
 GCSF: 1.6.1
GCSF was one of the first cytokines to enter clinical trials. The murine 
GCSF was first isolated in 1983 from lung tissue of endotoxin treated 
mice358, which was followed by the human form in 1985 from the bladder 
carcinoma cell line 5637359. In pre-clinical mouse models, GCSF was shown 
to mobilise haematopoietic cells from all lineages in large numbers360. In 
subsequent clinical trials, GCSF treatment was demonstrated to mobilise 
large number of haematopoietic cells into circulation in patients and normal 
donors from where it could be collected for autologous and allogeneic 
haematopoietic cell transplantation respectively361-363. 
Infectious complications due to prolonged chemotherapy treatment in 
leukaemia patients have been one of the main reasons of morbidity and 
mortality. Several trials have looked into the use of GCSF in treatment of ALL 
patients with or after intensive chemotherapy regimens and have shown 
significant improvement in the rates of morbidity and mortality in both 
children and adults364. In some studies, use of GCSF has been shown to 
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accelerate neutrophil recovery, which allows the use of higher chemotherapy 
doses, and may improve survival364. 
 GCSF and neutrophils: 1.6.2
GCSF has been used for more than two decades to manage 
neutropenia in patients after chemotherapy. The mechanism by which GCSF 
helps in neutrophil mobilisation is well studied and shows that GCSF can 
directly stimulate the production of neutrophils from myeloid cells and 
enhance production of mature neutrophils from metamyelocytes358. GCSF 
acts via the GCSF receptor (GCSFr), which is expressed on neutrophils, all 
precursors of neutrophils and on primitive haematopoietic stem cells365. 
GCSF has helped reduce neutropenia after chemotherapy by accelerating 
neutrophil recovery, and is now routinely used in patients with malignancies 
like breast cancer, lymphoma, and leukaemia. Along with neutrophils, GCSF 
treatment could lead to mobilisation of a large number of other progenitor 
and stem cells, and a number of multiple lineage progenitor cells (myeloid, 
erythroid, megakaryocytic) including platelets366. This was proved beneficial 
for patients undergoing chemotherapy, as they receive stem cells from 
normal human donors, and the increased number of the haematopoietic stem 
cell (HSC) in the blood after GCSF administration facilitated the collection of 
these cells from the blood of donors, and since has been routinely used in 
stem cell donors362. 
GCSF has been long thought to be effective in granulopoiesis, but 
studies suggest GCSF to have a much wider role as an immune regulator367. 
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Resting T-cells usually do not express GCSF receptor (GCSFr), though 
some activated T-cells have been shown to express GCSFr368. Exposure of 
GCSF tend to change T-cell function from an Th1 type (IFNγ and TNFα) to 
Th2 type (Secreting IL4 and IL10) thereby reducing their response to allo-
antigens369,370, and this has been shown to inhibit a T-cell mediated graft 
versus host disease (GVHD) in GCSF mobilised stem cell allogeneic 
transplant when compared to standard BM transplants. GCSF was also 
shown to induce production of regulatory DC371,372 and DC like myeloid cells, 
which in turn have an effect on T-cell development and function. With such a 
vast range of functions, GCSF is now recognised as a poly functional 
cytokine, and although it is a key regulator of neutrophil function, elucidating 
the complete signalling mechanism between GCSFr gene expression and 
responses will help in specifically tailoring GCSF treatment in clinical 
settting367. 
1.7 Current Project Hypotheses and Aims: 
In this thesis, I have focussed on the innate immune system, 
specifically looking at the role of neutrophils, and their involvement in MV-
mediated oncolysis of B-cell malignancies – acute lymphoblastic leukaemia 
(Nalm-6) and Burkitt’s lymphoma (Raji). The heterogeneity of the two 
different malignancies has led me to compare the two different B-cell 
malignancies and their susceptibility to neutrophil mediated MV oncolysis 
both in-vitro and in-vivo. 
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 Hypotheses and Aims: 1.7.1
The central hypothesis of the thesis is that neutrophils play an anti-
tumour role in MV-mediated oncolysis in B-cell malignancies. 
Stemming from this hypothesis, we would expect that it would be 
possible to improve the oncolytic effect of MV by enhancing the neutrophil-
mediated immune response towards the MV-infected target cells; first part of 
the thesis addresses that. Understanding the mechanisms of how neutrophils 
may contribute to MV oncolysis is clearly vital; this overall aim has been 
addressed in the second part. 
Chapter 3: The role of neutrophils in measles virus mediated oncolysis differs 
between B-cell malignancies in-vivo and is not always enhanced by GCSF 
Aims:  
1. To determine the therapeutic effect of MV in an in-vivo model of ALL. 
2. To establish the role of neutrophils and determine the therapeutic role 
of the novel MV expressing hGCSF (MVhGCSF) in two different in-
vivo models of B-cell malignancies - Raji (Burkitt’s lymphoma) and 
Nalm-6 (acute lymphoblastic leukaemia) in-vivo. 
Chapter 4: Mechanism of neutrophil mediated cytotoxicity in MV-infected 
target cell, differ between tumour types and the MV strain used 
Aims: 
1. To investigate if neutrophils from healthy human donors can mediate 
killing of MV-infected targets in-vitro. 
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2. To determine whether ADCC is a mechanism by which neutrophils 
may mediate MV oncolysis. 
Chapter 5: Fusion between neutrophils and target cells mediate cytotoxicity 
during measles virus oncolysis - a novel mechanism of oncolysis 
Aims: 
1. To determine the effect of fusion on degranulation and reactive 
oxygen species (ROS) generation in neutrophils when co-cultured with 
MV-infected targets. 
2. To determine the effect of fusion on type I IFN production and RLR 
signalling pathway in neutrophils when co-cultured with MV-infected 
targets. 
3. To visualise fusion between neutrophil and MV-infected targets. 
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Chapter 2: Materials and Methods 
2.1 GENERAL CELL AND TISSUE CULTURE: 
 Cell lines: 2.1.1
 Vero - African green monkey kidney cell line, adherent (CCL-81; 
ATCC). 
 293T - human embryonic kidney cell line, adherent (CRL-11268; 
ATCC). 
 Phoenix AMPHO - human embryonic kidney cell line, adherent (CRL-
3213; ATCC). 
 Raji - human Burkitt’s lymphoma cell line, suspension (CCL-86; 
ATCC). 
 Nalm-6 - human pre-B acute lymphoblastic leukaemia cell line, 
suspension (ACC128; DSMZ). 
 Jurkat - human T-cell acute lymphoblastic leukaemia cell line, 
suspension (TIB-152; ATCC). 
 DND41 – human T-cell acute lymphoblastic leukaemia cell line, 
suspension (ACC 525; DSMZ). 
Adherent cell lines were grown and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) high glucose (Gibco® by life TechnologiesTM) with 
5% heat inactivated Foetal Bovine Serum (FBS) (Gibco® by life 
TechnologiesTM), 100μg/ml streptomycin, 100 units/ml penicillin G (Penicillin-
Streptomycin 10,000U/ml) (Gibco® by life TechnologiesTM) and 2mM L-
glutamine (Gibco® by life TechnologiesTM). 293T and Phoenix AMPHO 
required 10% FBS. 
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Suspension cell lines were all grown and maintained in RPMI (Roswell 
Park Memorial Institute) 1641 medium with L-glutamine (Gibco® by life 
TechnologiesTM), with 10% FBS, 100μg/ml streptomycin, 100 units/ml 
penicillin G and 2mM L- glutamine (R10 complete media). 
Cell lines were grown in a humidified incubator (HERA cell, Thermo 
Scientific, Surrey, UK) at 37C with 5% CO2. The cell lines were passaged 
twice a week, upon reaching 80-90% confluency. 
All the cell lines were grown in tissue culture flasks (T-75, Corning, 
NY, US). The suspension cells were passaged twice a week, when 90% of 
the cells were removed and replaced with fresh medium. The adherent cell 
lines were passaged at 90% confluency. The old media was removed and 
the cells were washed with 5ml of 1X phosphate buffer saline (PBS) (Gibco® 
by life TechnologiesTM) and incubated with 2ml TrypLE™ Express Enzyme 
(Gibco®) for 2-4 minutes (mins) at 37C. Once the cells were detached, they 
were cultured at a dilution of 1:10 in a new T-75 tissue culture flask with new 
medium. 
 Cell culture reagents: 2.1.2
 Dimethyl Sulfoxide (DMSO) (Sigma Aldrich, Poole, UK). 
 Dulbecco’s Modified Eagle Medium (DMEM) – high glucose 4.5g/l 
(Invitrogen, Paisley, UK). 
 Foetal Bovine Serum (FBS), heat inactivated (Invitrogen, Paisley, UK). 
 L-glutamine 200mM, final concentration in media 2mM (Invitrogen, 
Paisley, UK). 
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 OptiMEM® medium (Invitrogen, Pailsey, UK). 
 Penicillin-Streptomycin containing 10,000units/ml penicillin and 
10,000μg/ml streptomycin, final concentration 100units/ml and 
100μg/ml respectively (Invitrogen, Paisley, UK). 
 Phosphate Buffered Saline (PBS) (Invitrogen, Paisley, UK). 
 RPMI-1640 medium (Invitrogen, Paisley, UK). 
 TrypLETM Express Enzyme (Invitrogen, Paisley, UK). 
 Active compounds used in cell culture: 2.1.3
 Z-D-Phe-Phe-Gly-OH – fusion inhibitory peptide (FIP), used at 
40μg/ml (Bachem, Switzerland). 
 IFNα 2b human (Sigma-Aldrich®, UK). 
 IFNβ 1a human (Sigma-Aldrich®, UK). 
 Recombinant human GCSF (Peprotech, UK). 
 Cryopreservation and cell recovery: 2.1.4
Cells were cryopreserved by resuspending in freezing mix consisting 
of 10% DMSO and 90% FBS. The cells were aliquoted at a concentration 
between 1x106/ml-5x106/ml in polypropylene cryovials (Nunc, 
ThermoScientific), and frozen in a freezing container (Nalgene, Rochester, 
US) filled with 100% isopropyl alcohol, at -80C overnight to achieve a -
1C/min freezing rate. The cryovials were transferred to a liquid nitrogen 
cylinder the following day for long-term storage. 
For recovery, cells were rapidly thawed in a 37C water bath and 10ml 
of FBS was added drop wise, with gentle mixing to remove the DMSO. The 
cells were then centrifuged at 1200 RPM for 5mins without brake. The cell 
  
99 
pellet obtained was washed again with the respective culture medium 
supplemented with 50% FBS to remove any traces of DMSO. The pellet was 
transferred into 10ml medium and cultured in a T-25 (Corning, NY, USA) 
tissue culture flask until 80-90% confluency. Cells were then transferred to a 
T-75 flask and maintained and passaged as described previously. 
 Cell counting and viability assay: 2.1.5
Cells were counted by trypan blue (Sigma Aldrich Poole, UK) 
exclusion method on a haemocytometer or a Cellometer Auto T4 Cell 
Viability Counter (Nexcelom Bioscience). 
2.2 MEASLES VIRUS: 
 Measles virus propagation: 2.2.1
MV was propagated on Vero cells, plated in 14cm diameter plates 
(Corning), and grown to 90-95% confluency. Cells were infected in 
OptiMEM® at a multiplicity of infection (MOI) of 0.01 and incubated at 37°C 
for 2 hours. At the end of the incubation, the virus was removed and DMEM 
media (supplemented with 5% FBS, 2mM L-glutamine and 100units/ml 
penicillin G + 100μg/ml streptomycin) was added to the plates. The plates 
were incubated until maximum cytopathic effect was observed and then 
scraped and collected into 1-2ml OptiMEM®. The cells were subjected to two 
rounds of freeze thaw cycle to release the virus. The cell debris was removed 
by centrifugation at 14000 RPM for 10mins and the supernatant containing 
the virus was aliquoted into small volumes. 
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 MV titration: 2.2.2
MV was titrated on Vero cells. 5x103 Vero cells were plated into each 
well of a 96-well plate. Fifty microliters of 10 fold dilutions was dispensed into 
each well. The plate was incubated at 37°C for 4 days and syncytia were 
counted. The 50% tissue culture infectious dose (TCID50) was calculated 
using the modified Kärber373 formula: 
Log10 TCID50 = -[Log10x – d (p-0.5)] + Log10 (1/v). 
x = highest dilution that gives 100% of wells positive for infection. 
d = Log10 of dilution interval (e.g. for 10-fold dilution, d=1). 
p = sum of values of the proportion of wells positive for infection at all  
dilutions. 
v = volume of viral inoculum for each well in milliliters. 
The plaque forming units (PFU/ml) was estimated by multiplying the 
TCID50 value with 0.7 (a factor derived from Poisson distribution). 
The viral stocks were stored at -80°C in small aliquots to avoid 
multiple freeze thaw. 
 Measles virus rescue: 2.2.3
Vero cells were infected with T7 RNA polymerase expressing Vaccinia 
Ankara Virus. After an hour of incubation the virus was taken off and the 
Vero cells were transfected with the full length cloned MV cDNA and the 
plasmids encoding the MV polymerase complex (pCG-N, pCG-P, pCG-L), 
using Lipofectamine® 2000 transfection reagent (ThermoFisher Scientific, 
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UK) in OptiMEM® reduced serum medium, GlutaMAXTM supplement (Gibco® 
by life TechnologiesTM). Twenty-four hours later, the lipofectamine plasmid 
mix was replaced with fresh media. Four to five days later syncytia were 
obtained which are hallmark of MV infection. Individual syncytium were 
picked and propagated for further experiments. 
 Measles virus infection: 2.2.4
Cells were washed with PBS. The viral stock was thawed and diluted 
in OptiMEM® at desired PFU/ml to obtain the required MOI. The required 
number of cells were then resuspended in the virus OptiMEM® mix and 
incubated at 37°C with 5% CO2 for 2 hours. For adherent cell infection, the 
media was removed from the cells, washed with 1xPBS and then the virus-
OptiMEM® mix was added onto it before incubation.  After the incubation, the 
virus-OptiMEM® mix was removed from the cells and they were 
resuspended in fresh media. 
 UV irradiation of MV: 2.2.5
Aliquots of MV were incubated in a UV-cross-linker (CL-1000 
Ultraviolet Crosslinker; UVP, UK) for 3-4 hours to inactivate the virus. 
2.3 PRODUCTION OF RETROVIRAL VECTOR EXPRESSING 
LUCIFERASE GENE: 
The Phoenix AMPHO packaging cell line (CRL-3213; ATCC) was 
used for preparation of retroviral particles by co-transfecting with the 
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retroviral vector plasmid containing the luciferase gene using a high-density 
transfection reagent Fugene® (Roche, Sussex, UK). On Day 1, Phoenix 
AMPHO cells were harvested by trypsinisation, washed and then 
resuspended in fresh medium (2x106 cells resuspended in 8mls of fresh 
media) and plated into 10cm diameter petri dishes. They were then 
incubated at 37°C and 5% CO2 overnight. On Day 2 the following 
transfection mix was prepared: 
Solution A: 10μl Fugene® and 150μl OptiMEM®. 
Solution B: 1.5μg pCL-ampho retrovirus packaging vector (Imgenex, CA, 
USA), 2.6μg vector construct (SFG.Fluc_opt_2A_eBFP2; gifted by Dr. Martin 
Pule, UCL, UK), volume up to 50μl with H2O. 
The Solution B was then added to the Fugene® solution A, and then 
gently mixed by pipetting. The mix was incubated at room temperature for 
15-20mins, after which it was directly added to the Phoenix AMPHO cells 
and returned to the incubator. On day 3, the media was removed from the 
cells and replaced with 5mls of fresh R10 media. The virus supernatant was 
harvested on day 4. 
2.4 RETROVIRAL VECTOR TRANSDUCTION OF NALM-6 AND RAJI 
LUCIFERASE EXPRESSING CELL LINES: 
Six well tissue culture plates were coated with 2.5ml/well of 
Retronectin (Clontech, France) at a concentration of 30ng/ml and incubated 
at room temperature for 2-3 hours. The Retronectin was then removed and 
the wells blocked with 2ml of filter sterilised 2% BSA (Sigma Aldrich; Poole; 
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UK) for 30mins and wells were washed with 3ml/well PBS twice. Pre-cultured 
Raji cells were taken at a concentration of 1x106 cells/ml and 2.5ml of cell 
suspension was added to each well of the Retronectin coated 6-well plate. 
The plate was then incubated at 37°C for 30mins to allow attachment of the 
Raji cells to the plates. Retroviral supernatant prepared in section 2.3 was 
then added to each well of Raji cells and incubated at 37°C overnight. The 
following day, the viral supernatant was removed and fresh R10 media 
added at 5mls/well. The cells were then incubated for 3 days at 37°C, 
harvested, washed and analysed by flow cytometry for eBFP transgene 
expression. The cells were sorted to >95% purity before use. 
2.5 NEUTROPHIL ISOLATION: 
Twenty to 50ml of peripheral blood (PB) was obtained from healthy 
donors in preservative free heparin (100μl per 10ml) {obtained from Royal 
Free Hospital (RFH) pharmacy} after informed consent. It was then incubated 
with 10-25ml (half the PB volume) of 3% dextran (Amersham Biosciences, 
UK) to sediment the red blood cells (RBCs) for 45-60mins. The supernatant 
was collected in a 50ml tube and centrifuged at 290g for 12mins to obtain a 
pellet. The pellet was subjected to hypotonic lysis in 12ml of ice-cold, sterile 
ddH2O and 4ml of 0.6M KCl to eliminate any contaminating RBCs and then 
made up to 50ml with PBS. It was then centrifuged at 393g for 5mins. After 
centrifugation the pellet was resuspended in 1xPBS and overlaid onto 
LymphoPrep™ (Axis-shield, Oslo, Norway). After centrifugation, the 
supernatant was discarded and the pellet containing the neutrophils was 
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washed in RPMI1640 without serum, twice. The neutrophils obtained were 
resuspended in desired volume of RPMI and used for further experiments. 
The purity of neutrophils was determined by light microscopy of Giemsa-
stained cytospin slides. 
2.6 CYTOTOXICITY ASSAY (51CR RELEASE): 
To assess the neutrophil mediated MV cytotoxicity, 51Cr Release 
Assay was used. Cell lines were infected with MV at an MOI of 1.0 or mock 
infected. At 24 hours or 48 hours post infection (hpi), the cells were labelled 
with Chromium-51 radionuclide (sodium chromate) (PerkinElmer) at a 
concentration of 1.85MBq/106 cells. After 1-2 hours incubation at 37°C they 
were washed thrice and resuspended in R10 media. 51Cr labelled cells 
(5x103 cells/well) were aliquoted in 96-well round bottom plates and 
incubated with neutrophils extracted from healthy donors (see section 2.5) at 
different Effector:Target (E:T) ratios (2:1; 8:1; 20:1; 40:1) in triplicates. The 
plates were then incubated at 37°C for another 24 hours. The following day, 
the 96-well plates were centrifuged and 50ul of the supernatant was 
transferred into clear 96-well round bottom (Flexible PET Microplate; 
PerkinElmer) plates containing 150ul of OptiPhase Supermix scintillation 
cocktail (PerkinElmer). The plates were then sealed with TopSeal-ATM 
(PerkinElmer) and placed on a plate shaker for 5mins to ensure complete 
mixing of the supernatant with the scintillation cocktail. The amount of 51Cr 
released was measured in 1450 Microbeta Liquid Scintillation Counter 
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(PerkinElmer). The percent specific lysis was calculated using the following 
formula: 
Percentage (%) of neutrophil-specific lysis = (experimental cpm – 
spontaneous cpm) / (maximal cpm – spontaneous cpm) x 100. 
The spontaneous cpm was the negative control with infected or 
uninfected cells in the absence of neutrophils, and the maximal cpm was the 
positive control where all the cells were lysed using an acid. The minimum 
threshold for % specific lysis was set at 5%. 
To assess the effect of presence of anti-MV antibody, pooled serum 
from individuals with high anti-MV Ab {(titrated using VIDAS® enzyme linked 
fluorescent immunoassay (FIA); Biomérieux, France} was obtained from the 
Virology department at the RFH. The serum was then heat inactivated in the 
lab at 56°C for 30mins to eliminate the complements. The serum was added 
at 1:100 dilution in the experiments. 
Where fusion inhibition was required, the chromium release assay 
was performed in the presence or absence of fusion inhibitory peptide (FIP) 
at 40μg/ml dissolved in 100ul of DMSO before adding to the media, or media 
containing only 100ul DMSO. 
2.7 IN-VITRO RECOMBINANT HUMAN GCSF (rhGCSF) ASSAY: 
Raji and Nalm-6 cells were plated at 2x104/ml in T25 tissue culture 
flasks in R10 media supplemented with 0, 5 and 10ng/ml rhGCSF 
(Peprotech, UK). The cells were incubated at 37°C. They were counted using 
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the trypan blue dye exclusion method to determine the number of viable 
cells/ml at 24 hourly intervals. 
2.8 MOLECULAR BIOLOGY TECHNIQUES: 
 Molecular biology reagents: 2.8.1
 Agar (Sigma-Aldrich®, UK). 
 Agarose (Sigma-Aldrich®). 
 Chloroform (VWE International, UK). 
 DNase/RNase free water (Invitrogen, UK). 
 Ethanol 100% (VWR International, UK). 
 Glycerol (VWR International, UK). 
 HiSpeed Plasmid Midi Kit (Qiagen, UK). 
 Isopropanol (VWR International, UK). 
 LB broth (Invitrogen, UK). 
 One Shot® TOP10 competent cells (Invitrogen, UK) (New England 
Biolabs, UK). 
 pCRII-TOPO TA cloning kit (Invitrogen, UK). 
 pORF9-hGCSFb (Invivogen, USA). 
 QiaexII gel purification kit (Qiagen, UK). 
 QIAprep Spin Miniprep Kit (Qiagen, UK). 
 QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies, UK). 
 Random hexamer (Promega, UK). 
 Restriction enzymes (New England Biolabs, UK). 
 RNasin® Plus RNase Inhibitor (Promega, UK). 
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 SuperScriptTM III reverse transcriptase (Invitrogen, UK). 
 SYBR® safe DNA gel stain (ThermoFisher Scientific, UK). 
 T4 DNA Ligase (New England Biolabs, UK). 
 TRIzol® (Invitrogen, UK). 
 0.1M DTT (Invitrogen, UK). 
 2xYT microbial growth medium (Sigma-Aldrich®, UK). 
 5x first strand buffer (Invitrogen, UK). 
 10mM dNTPs (Promega, UK). 
 Cloning: 2.8.2
Specific details for cloning MVhGCSF are given in chapter 3, section 
3.2.1. 
 Plasmid Preparation: 2.8.3
Bacteria were propagated on 2xYT agar plates overnight, and then 
propagated in 2xYT broth. Plasmid DNA was extracted from 5ml or 50ml 12-
16 hours bacterial culture using QIAprep Spin Miniprep Kit and HiSpeed 
Plasmid Midi Kit. DNA extracted was checked for its concentration and purity 
at 260nm (A260) and 280nm (A280) on a NanoDropTM1000 
spectrophotometer (Thermo Scientific, Essex, UK). DNA preparations with a 
ratio of 1.75-2.0 only were used further for the experiments. All plasmid DNA 
was stored at -20°C. 
Glycerol Stock: Glycerol stocks of the bacterial cultures were prepared 
using 200μl of bacterial culture and 800μl of 99% glycerol and stored at -
80°C. 
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 RNA extraction: 2.8.4
Total RNA was extracted from cells at appropriate time-points by 
using TRIzol®. Cell pellets were resuspended in 1ml of TRIzol® and mixed 
vigorously using a pastette. It was incubated at room temperature (RT) for 
5mins and the 200μl of chloroform was added to it and mixed well till it turned 
cloudy and then incubated at RT for a further 2mins. The tube was then 
centrifuged at 12,000 RPM for 10mins at 4°C. The aqueous layer was 
carefully transferred into a clean tube without disturbing the white middle 
layer. 500μl of isopropanol was added to it and left at -80°C overnight. The 
next day the vial was thawed and centrifuged at 13000 RPM for 10mins. The 
supernatant was removed and the RNA pellet was washed with 70% ethanol 
and centrifuged at 13000 RPM. The pellet was then air dried while still on ice 
for 20mins. Once dried, the pellet was resuspended in 30μl of DNase/RNase 
free water and quantified at 260nm (A260) and 280nm (A280) on a 
NanoDropTM1000 spectrophotometer (Thermo Scientific, Essex, UK). RNA 
with a ratio of 1.75-2.0 were considered good and used further for the 
experiments. All RNA stocks were stored at -80°C. 
 First strand cDNA synthesis: 2.8.5
Total RNA (0.4-1μg) per sample was used for cDNA synthesis. To 
each sample the following was added: Random hexamer - 2μl (334ng), 0.1M 
DTT - 1μl, 10mM dNTPs - 2μl. 
Samples were then incubated at 65°C for 5mins and then incubated 
on ice for a further 5-10mins. Next, to each sample the following was added: 
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5x first strand buffer - 1μl, RNasin® Plus RNase inhibitor - 1μl (40 units), 
SuperScriptTM III reverse transcriptase - 1μl (200 units). The samples were 
transferred onto a PCR machine DYAD (MJ Research; BioRad) and run on 
the following programme: 
25°C for 10 mins 
50°C for 50 mins  
70°C for 15 mins 
The cDNA was stored at -80°C till further use. 
 Relative quantification by RQPCR: 2.8.6
2.8.6.1 RIG-I/MAVS/MDA5 quantification: 
QuantiTect® Primer assay (Qiagen, UK) was used for relative 
quantification of RIG-I, MDA5 and MAVS mRNA. 0.3μM forward and reverse 
primers, 12.5μl of 2x QuantiTect® SYBR Green PCR Master Mix (Qiagen) 
was mixed with the cDNA in 25μl reactions. They were run on an ABI7500 
(Applied Biosystems) according to the following conditions: 
50°C for 2 mins 
95°C for 10 mins 
40 cycles of: 
94°C for 15 seconds; 55°C for 30 seconds; 72°C for 35 seconds 
The primer sequences are as below: 
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RIG-I s 5’-ACCAGAGCACTTGTGGACGCT-3’ 
RIG-I a 5’-TGCCGGGAGGGTCATTCCTGT-3’ 
MDA5 s  5’-GGCACCATGGGAAGTGATT -3’ 
MDA5 a 5’-ATTTGGTAAGGCCTGAGCTG -3’ 
MAVS s 5’-GAGACCAGGATCGACTGCGGGC- 3’ 
MAVS a 5’-AGAGGCCACTTCGTCCGCGA -3’ 
GAPDH was used as a housekeeping gene for all assays. The PCR 
was run in triplicates and non-template control was included for each primer 
sets. Relative expression was determined using the following Ct 
formula374: 
Ct = Ct (experiment) – Ct (GAPDH) 
Ct = Ct (sample) – Ct (calibrator) 
RQ = 2 ∧ (-Ct) 
2.9 FLOW CYTOMETRY: 
 General flow cytometry method: 2.9.1
Cells were pelleted and resuspended in 200μl of PBS and aliquoted 
into FACS tubes (BD Biosciences, UK). Two to three microliter of the desired 
antibody/antibodies conjugated to fluorescein isothiocyanate (FITC), 
phycoerithrin (PE), allophycocyanin (APC) was added to the tube and 
incubated at 4°C for 30-45mins in the dark. For non-conjugated primary 
antibody, goat anti-mouse secondary antibody conjugated to PE (BD 
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Pharmingen) was used. After incubation the tubes were centrifuged at 2000 
RPM for 2mins and then run on a BDTM LSR II or BD LSR Fortessa analyser 
(Beckton Dickinson, Oxford, UK) with 5000-10000 events being recorded. In 
some assays, 2μl of propidium iodide (PI) (BD PharmingenTM), which is a 
DNA binding dye, was used to select out the viable cells by gating on PI 
negative cells. The data was analysed using FLOWJO (Tree Star) single cell 
analysis software (version 7.4.1). Name of antibodies used are listed in Table 
2.1. 
Table 2.1: List of antibodies used for flow cytometry: 
Target Company Clone Conjugate 
  CD35 BD Pharmingen E11 FITC 
CD66b BD Pharmingen G10F5 FITC 
CD63 BD Pharmingen H5C6 FITC 
CD11b BD Pharmingen M1/70 APC 
CD10 BD Biosciences HI10a APC 
CD19 BD Biosciences 4G7 FITC 
CD20 BD Biosciences L27 APC 
Ly6G6C BD Pharmingen RB6-8C5 FITC 
MV-H Millipore CV1, CV4 None 
Pan NK/CD49b BD Pharmingen DX5 PE 
Mac 3 BD Pharmingen M3/84 PE 
 Fluorescent activated cell sorting: 2.9.2
Cell sorting was performed on either a MoFLo XDP (Beckman Coulter, 
Fullerton, CA, USA) or on BD FACS Aria (Beckton Dickinson, Oxford, UK). 
The enhanced blue fluorescent protein (eBFP) marker was excited by the 
350 UV laser (100mW) and the emission was collected by 653/40 filter. 
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2.10 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA): 
Cell culture supernatants were collected at appropriate time-points 
and ELISA performed according to the manufacturer’s guidelines. Optical 
density (OD) was measured at appropriate wavelength using Tecan Sunrise 
absorbance reader (Jencon-PLS, UK). The OD of the standards was plotted 
against their concentration to obtain a standard curve and the sample 
concentrations were extrapolated directly from the standard curves. 
 Human GCSF standard ABTS ELISA Development Kit (Peprotech, 
UK). 
 VerikineTM Human IFNα Multi-Subtype ELISA (PBL Assay Science, 
NJ). 
 VerikineTM Human IFNβ ELISA (PBL Assay Science, NJ). 
 TRAIL/ APO2L/ CD253 ELISA Kit (2BScientific, UK). 
 Measles virus IgG ELISA (IBL International, Hamburg, Germany). 
2.11 ANTI-MV ANTIBODY SERUM HEAT INACTIVATION: 
Anti-MV antibody containing serum, pooled from different donors was 
obtained from the Virology Department at RFH. The serum was then heat 
inactivated at 56°C for 30mins and then titrated by ELISA. The high titre 
antibody containing serum was then aliquoted into small volumes and stored 
at -80°C for future experiments. 
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2.12 ANIMAL METHODS: 
 Animal Strains: 2.12.1
 Six to eight week old CD17 severe combined immunodeficient (SCID) 
mice (Charles River Laboratories, UK). 
 IfnarKO  CD46 Ge mice (provided by Roberto Cattaneo, Mayo Clinic). 
All the mice were housed, bred and cared for in barrier facility in 
accordance with UK home office approved protocol. The establishment of the 
xenograft models and the bioluminescent imaging protocols are described in 
more details in the chapter method (see 3.2.2). 
2.13 STATISTICAL ANALYSIS: 
Prism 5.0 (GraphPad Software) and Microsoft Excel were used to plot 
all graphs. The data are presented as mean±SEM where appropriate. The 
statistical analysis was performed either by paired/unpaired student’s t test or 
Mann Whitney U test as appropriate. In the animal experiments, Kaplan-
Meier curves were used to analyse survival and the different groups were 
compared using the log-rank test. All the P-values quoted are one/two-tailed. 
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Chapter 3: The role of neutrophils in measles virus mediated 
oncolysis differs between B-cell malignancies in-vivo and 
is not always enhanced by GCSF 
3.1 BACKGROUND: 
 MV in B-cell malignancy: 3.1.1
The Edmonston-B derived vaccine strain of measles virus (MV) is 
oncolytic in various tumour models in-vivo and is currently being tested in 
several phase 1 clinical trials (chapter 1, section 1.3.2). MV is naturally 
lymphotropic and B-cell malignancies appear particularly sensitive. In-vivo 
models of B-cell malignancies like Burkitt’s lymphoma175 and multiple 
myeloma176 have been shown to be an excellent target for MV therapy. Our 
laboratory is particularly interested in acute lymphoblastic leukaemia (ALL), 
an immature B-cell malignancy that is largely curable in children but often 
has a poor outcome in adults375. The treatment is long and toxic, and novel, 
non-chemotherapy-based therapies have a clear role. Previous work from 
the Fielding lab376 suggested that ALL might be exquisitely sensitive to MV. 
 Oncolytic MV and neutrophils: 3.1.2
In addition to the direct oncolytic effect of MV, work from the Fielding 
lab has shown that neutrophils are involved in MV-mediated tumour 
regressions in a Burkitt’s lymphoma model. MV treatment led to significant 
neutrophil infiltration in the tumours injected with MV. When a modified MV 
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expressing mGMCSF, which is a known neutrophil survival factor was used 
there was significantly higher neutrophil infiltration, which correlated with 
superior tumour regression280. In further work, Fielding laboratory showed 
that neutrophils from healthy human donors became activated upon oncolytic 
(but not wild-type) MV infection and survived significantly longer in culture. 
Upon oncolytic MV infection, neutrophils produced various anti-tumour 
cytokines like MCP-1, TNFα, IL-8 and IFNα and upregulated neutrophil 
degranulation markers in response to MV infection, resulting in the release of 
TRAIL directly from pre-formed granules357. 
As discussed in chapter 1 section 1.5.3, neutrophils have also been 
implicated by other groups in additional, microorganism-mediated tumour 
regressions338,340. Briefly, in a bladder cancer model, where mycobacterium 
BCG (Bacillus Calmette-Guérin) was used as a treatment, neutrophils were 
shown to play a key role in therapy342. In relation to virotherapy in which a 
model of murine colon adenocarcinoma was treated with vesicular stomatitis 
virus (VSV), shut down of blood flow to the tumours was observed, which 
was proposed to be mediated by neutrophils344. The shut down of the blood 
flow to the tumours led to apoptosis in even those tumour cells that were not 
infected by the VSV. It was also shown that VSV attacks the tumour 
vasculature and induces clot formation, which correlates with decrease in 
tumour cell proliferation345. 
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 Granulocyte colony stimulating factor (GCSF): 3.1.3
Murine GCSF was first isolated in 1983 from lung tissue of endotoxin 
treated mice358. In 1985, the human form was first isolated from the bladder 
carcinoma cell line 5637359. In pre-clinical mouse models, GCSF was shown 
to mobilise haematopoietic cells from all lineages in large numbers360. In 
subsequent clinical trials, GCSF treatment was demonstrated to mobilise 
large number of haematopoietic cells into circulation in patients and normal 
donors from where it could be collected for autologous and allogeneic 
haematopoietic cell transplantation respectively361-363. 
Infectious complications due to prolonged chemotherapy treatment in 
leukaemia patients have been one of the main reasons of morbidity and 
mortality. Several trials have confirmed the role of GCSF in treatment of ALL, 
showing significant improvement in morbidity and mortality in both children 
and adults364. 
 Effect of GCSF on neutrophils and immune function: 3.1.4
GCSF can directly stimulate the production of neutrophils from 
immature myeloid cells and enhance production of mature neutrophils from 
metamyelocytes358, via its action on the GCSF receptor (GCSFr), which is 
expressed on neutrophils, their precursors, and on early haematopoietic 
stem cells365. GCSF binds to GCSFr, which is a single homodimer 
transmembrane protein that upon stimulation signals via multiple signalling 
pathways including Janus kinase/Stat377-379 (JAK/STAT), mitogen-activated 
protein kinases (MAPK) and extracellular signal-regulated kinase (Erk1/2, 
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Erk 5)380,381. GCSF also has a much wider role as an immune regulator367. 
Resting T-cells typically do not express GCSFr, although some activated T-
cells have been shown to express GCSFr368. Exposure of GCSF converts 
Th1 (IFNγ and TNFα secreting) T-cells to Th2 (IL4 and IL10 secreting) 
thereby reducing their response to alloantigens369,370. This can inhibit a T-cell 
mediated graft versus host disease in GCSF mobilised stem cell allogeneic 
transplant when compared to standard BM transplants. GCSF also induce 
production of regulatory DC371,372 and DC-like myeloid cells, which in turn can 
affect T-cell development and function. 
 Hypothesis: 3.1.5
Expressing the human GCSF as an additional transcription unit of MV 
can enhance the therapeutic efficacy of MV. 
3.1.5.1 Aims: 
1. To determine the therapeutic effect of MV in an in-vivo model of ALL. 
2. To establish the role of neutrophils and determine the therapeutic role 
of the novel MV expressing hGCSF (MVhGCSF) in two different in-
vivo models of B-cell malignancies - Raji (Burkitt’s lymphoma) and 
Nalm-6 (acute lymphoblastic leukaemia) in-vivo. 
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3.2 METHODS: 
 Cloning: 3.2.1
3.2.1.1  Plasmid Construction: 
Prior to PCR amplification, site directed mutagenesis was performed 
on the hGCSF gene using QuikChange II XL Site-Directed Mutagenesis Kit 
(Stratagene, Agilent Technologies, UK) to remove an AatII site that was 
present on the gene in order to enable the use of AatII restriction enzyme for 
cloning it into MV genome. The primer sequences used for site directed 
mutagenesis are shown below: 
Forward: 
5’-CACACTGCAGCTGGAtGTaGCCGACTTTGCC-3’ 
Reverse: 
5’GGCAAAGTCGGCtACaTCCAGCTGCAGTGTG-3’ 
hGCSF was PCR amplified using the following primers: 
Forward: FP_MluI+hGCSF (new): 
5’-agtattacACGCGTATGGCTGGACCTGCCACCCAGAGC-3’ 
Reverse: RP_AatII_hGCSF (correct): 
5’-TACAGTCGgacgtcATtcagggctgggcaaggtggcg-3’ 
Replicating MV was rescued from cloned cDNA, as described in chapter 2, 
section 2.2.3. 
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 In-vivo experiments: 3.2.2
All animal experiments were performed according to the UK Home 
Office approved protocols and institutional guidelines. 
3.2.2.1 Nalm-6 disseminated model: 
Disseminated ALL xenografts were established by tail vein injection of 
1x106 Nalm-6 cells. Three days after tumour cell transfer 1x106 PFU of MV 
was administered IV by tail vein injection and repeated at weekly intervals for 
total six doses. Control mice were injected with UV inactivated MV (MVUV). 
Mice were monitored daily and euthanised when pre-defined humane end-
point (hind limb paralysis) was reached. 
3.2.2.2 Raji and Nalm-6 subcutaneous (SC) models: 
Raji (Burkitt’s lymphoma) and/or Nalm-6 (ALL) SC xenografts were 
established in 6-8 weeks old CB17-PrkdcSCID (SCID) mice (Charles River, 
Margate, UK). To establish Nalm-6 xenografts, 5x106 or 10x106 viable Nalm-
6 cells (ATCC, LGC, UK) were mixed with 2μg pre-thawed Matrigel™ (BD 
Biosciences) in a total volume of 200μl and injected into the right flank of 
each mouse. For the Raji xenografts, 10x106 viable Raji cells (ATCC, LGC, 
UK) was injected in 200μl of RPMI 1640 medium. The tumours were 
administered with MV (MVNSe, MVUV, MVhGCSF) IT for 10 doses at an 
MOI of 1.0. 
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3.2.2.3 Neutrophil depletion in-vivo: 
The schematic design of the neutrophil depletion experiment is shown 
in Fig 3-4a and 3-4b. Neutrophils were depleted in-vivo using a rat anti-
mouse Gr-1 monoclonal antibody (anti-Ly6G6C, clone RB6-8C5; BD 
biosciences, UK) via IV, intra-peritoneal (IP) and/ or IT routes, with first 
injection via the IV route on Day 0. The control mice received equivalent 
amount of a rat immunoglobulin isotype antibody (IgG2b, BD Biosciences, 
UK) via the same routes. 35-50μg of antibody was used for IV or IT routes 
whereas 150μg of antibody was used for IP routes per dose. 
Neutrophil depletion was confirmed and monitored by flow cytometry 
regularly. Approximately 50μl of peripheral blood was collected by tail vein 
bleed and red blood cells were removed by hypotonic lysis. The white blood 
cells were then stained with rat anti-mouse CD11b-APC (clone M1/70; BD 
Bioscience, UK) and rat anti-mouse Ly6G6C-FITC (anti-GR1) (clone RB6-
8C5; BD Biosciences, UK). Flow cytometry analysis was performed on the 
stained cells. The neutrophil depletion was repeated every 3-5 days and 
maintained throughout the MV therapeutic window. 
Mice were injected with MV from Day 1 after neutrophil depletion at an 
MOI of 1.0 daily in a total volume of 100μl. A total of 8 and 10 MV injections 
were administered IT to Nalm-6 and Raji tumours respectively. Tumour 
volume was calculated using the formula: 
V=a2b/2 cm3, where a = the shortest diameter and b = the longest diameter. 
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Mice were euthanised by Schedule 1 procedure when they reached 
their pre-determined humane end-points (tumour volume ≥2.5cm3 or 
systemic spread of disease = onset of hind limb paralysis). 
The in-vivo work on the Nalm-6 neutrophil depletion model was partly 
carried out by my colleague Dr. Zhang, and I have received her permission to 
include data obtained from Nalm-6 experiment alongside my own data from 
Raji neutrophil depletion experiment. 
3.2.2.4 Raji and Nalm-6 luciferase disseminated models: 
Disseminated xenografts were established by tail vein injection of 
1x106 Nalm-6/Raji luciferase cells. Three days after tumour cell transfer 
1x106 PFU of MV (MVNSe, MVUV, MVhGCSF) or 120 μg/kg of Pegylated 
hGCSF (Peg hGCSF) (Neulasta - Amgen) was administered at weekly 
intervals for total six doses for Nalm-6 and 3 doses for Raji. The dosage of 
Peg hGCSF was based on the literature382-385. MV was administered via the 
IV route by tail-vein injection while Peg hGCSF was administered SC. Mice 
were monitored daily and euthanised when pre-defined humane end-points 
were reached (on set of hind limb paralysis). At the humane end-point, 
spleens from the mice were analysed for the number of total cells recovered 
and percentage of neutrophil, macrophage and NK cells by flow cytometry. 
Serum from all these mice was collected by exsanguination and hGCSF level 
determined by ELISA. 
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3.2.2.5 In-vivo imaging: 
Nalm-6/Raji luciferase-injected mice were imaged once a week by 
bioluminescent imaging. Mice were shaved and injected IP with 200μL of D-
luciferin (Caliper Life Sciences, Cheshire UK). They were then imaged under 
anaesthetic (Isofluorane) under IVIS® 100 Lumina (Caliper Life Sciences, 
Cheshire, UK). The results were analysed using Living Image® 3.2 software. 
3.2.2.6 Toxicity studies in IfnarKOCD46 Ge mice: 
IfnarKOCD46 Ge mice were kindly provided by Roberto Cattaneo 
(Mayo Clinic), and then bred and housed in caged barrier. They were 
injected with 1x106 PFU of MVNSe or MVhGCSF IV, via tail vein. The mice 
were then monitored twice a week for 35 days for any sign of ill health. On 
day 35, all the mice from both the cohorts were sacrificed and their spleen 
analysed for size and percentage of neutrophils, macrophages and NK cells 
by flow cytometry. Serum from all these mice was collected by 
exsanguination and hGCSF level determined by ELISA (Peprotech, UK). 
 Flow Cytometry: 3.2.3
3.2.3.1 Confirmation of neutrophil depletion: 
Neutrophil depletion was confirmed by flow cytometry. Approximately 
50μl of peripheral blood (PB) was collected by tail vein bleed and RBCs were 
removed by hypotonic lysis. The white blood cells were then stained with rat 
anti-mouse CD11b-APC (clone M1/70; BD Bioscience) and rat anti-mouse 
Ly6G6C-FITC (clone RB6-8C5; BD Biosciences) at 4°C for 30mins. The cells 
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were then washed and resuspended in PBS. The flow cytometry was 
performed on LSRII (BD Biosciences). The data was analysed using Flow Jo 
(version 7.6). 
3.2.3.2 Detection of tumour cells: 
Cells from the BM and spleen of the mice were isolated and stained 
with CD10-APC (BD) and CD19-PE (BD) for Nalm-6 cells and CD19-FITC 
(BD) and CD20-APC (BD) for Raji cells at 4°C for 30mins. The cells were 
then washed and resuspended in PBS. The flow cytometry was performed 
on LSRII and analysed using Flow Jo (version 7.6). 
3.2.3.3 Detection of Neutrophils, NK and Macrophages in mouse 
spleen: 
The spleen from mice was dissected and crushed and then treated 
with ACK lysis buffer (Lonza, UK). The cells were then isolated and stained 
with Pan NK (CD49b; clone DX5; BD biosciences) or rat anti-mouse CD11b-
APC (clone M1/70; BD Bioscience), rat anti-mouse Ly6G6C-FITC (clone 
RB6-8C5; BD Biosciences) and Mac3-PE (BD) or isotype controls. The 
stained cells were washed and resuspended in PBS and then run on LSRII 
and analysed with Flow Jo (version 7.6). 
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3.3 RESULTS: 
 MV is therapeutic in an acute lymphoblastic leukaemia (ALL) 3.3.1
model in-vivo: 
First the therapeutic effect of MV was established in an ALL model in-
vivo. To determine whether MVNSe is oncolytic in an in-vivo model of ALL, 
SC Nalm-6 tumours were established using 10x106 Nalm-6 cells in SCID 
mice. On detection of first palpable tumour, they were treated with 10 IT 
injections of 1x106 PFU of MVNSe or UV inactivated MV (MVUV) (Fig 3-1a). 
Median tumour volumes in both the groups were not significantly different at 
the start of the injections with MV group at 0.22cm3 and in MVUV group at 
0.27cm3. MV treatment had a significant anti-tumour effect as shown in Fig 3-
2a. Eleven of 12 established SC tumours regressed completely in MVNSe 
treated group by day 44 with the single remaining tumour fully disappearing 
by day 62. In contrast, all MVUV treated tumours progressed. The difference 
in tumour growth between the MVNSe treated and MVUV control groups was 
highly statistically significant (p < 0.0001). 
To assess the oncolytic activity of MV in a disseminated model of ALL, 
SCID xenograft was established to evaluate IV MV administration, using 
1x106 Nalm-6 cells IV via the tail vein on Day 0, with MV treatment starting 
from Day 3 post tumour inoculation for total 6 injections (Fig 3-1b). Five of 10 
mice receiving MVNSe survived beyond 100 days whereas all mice receiving 
the non-replicating MVUV succumbed by day 67. The BM of every mouse 
was analysed by flow cytometry for human CD19+/CD10+ cells, which 
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confirmed the presence of leukaemia in all mice (Fig 3-2b, bottom panel). A 
Kaplan-Meier analysis (Fig 3-2b) showed that the median survival was 54 
days in MVUV controls compared to 114 days in the MVNSe group 
(p<0.0001). At the termination of the experiment at 123 days, no evidence of 
leukaemia was observed in the 5 surviving mice, indicating a complete 
remission rate of 42%. 
.
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Figure 3-1: Experimental design of Nalm-6 SC and disseminated SCID xenografts: (a) SC Nalm-6 tumours were established with 10x106 
Nalm-6 cells mixed with MatrigelTM. The tumours were treated with 10 IT injections of MVNSe/MVUV after the first palpable tumour was 
observed. (b) The disseminated tumours were established by IV injections of 1x106 Nalm-6 cells. The mice received a total of 6 MV injections IV 
from day 3 after inoculation of the tumour. (Adapted from Patel, Dey et al. 2011)386. 
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Figure 3-2: Nalm-6 SCID treated with MVNSe: (a) Tumour volumes in cm3 after IT injection of MV (black closed squares) or MVUV (red 
closed circles) into Nalm-6 ALL xenografts, developed from 1x106 Nalm-6 cells. (b) Kaplan–Meier survival curves of mice bearing disseminated 
Nalm-6 xenografts treated IV with a total dose of 6x106 plaque forming unit (PFU) of MV (black line) or MVUV control (red line). Data represent 
the results from three independent experiments (N=3-6 per group). Representative FACS plot of CD10/CD19 positive cells from BM of mice 
confirming leukaemia is shown in the bottom panel. Arrows indicate the period of MV/MVUV administration. Log Rank test and Wilcoxon signed 
rank test was performed to obtain the P-values. (Adapted from Patel, Dey et al. 2011)386. 
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 Neutrophil depletion in-vivo abrogates MV therapeutic effect in 3.3.2
Raji but not Nalm-6: 
Based on the data from others and our own lab suggesting neutrophils 
as a potential effector in different microorganism mediated oncolysis, it was 
hypothesised that, if neutrophils are playing a role in MV oncolysis in-vivo, 
then depleting them should abrogate the MV-mediated oncolytic effect in-
vivo. To investigate this in the Nalm-6 and Raji models, SC tumours were 
established by injecting respective tumour cells on the right flank of the SCID 
mice. When the tumours reached a certain comparable volume (mean 
tumour volume 0.4cm3 in Nalm-6 and 0.8cm3 in Raji) (Fig 3-3a and 3-3b), 
they were divided into the depleted/experimental group and the non-
depleted/control group. A detailed schematic of the experimental design is 
shown in Fig 3-4a (Nalm-6) and Fig 3-4b (Raji). The experimental group 
received the anti-GR1 antibody (RB6-8C5 clone) and the control received the 
isotype antibody by IP, IV or IT routes, on the days shown by the blue, black 
and green arrows respectively. Depletion of neutrophils in the PB was 
monitored on the days shown in red arrows by flow cytometry (Fig 3-4a and 
b) in different representative mouse from each group on each day. As per the 
project license, a mouse can be bled only once a week, and therefore, 
different representative mouse was selected from each group for analysis of 
neutrophil depletion on each day. The flow cytometry plots showing 
neutrophil depletion in both Nalm-6 (Fig 3-5a-f) and Raji (Fig 3-6a-f) models 
on different days, compared to their non-depleted controls are shown in Fig 
3-5 and Fig 3-6. A gate was drawn around the GR1highCD11b+ cell population 
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(mostly neutrophils in this model), in the non-depleted group compared to 
which the %GR1highCD11b+ cells in the depleted group were calculated on 
each day. 
In the Nalm-6 xenografts (Fig 3-5), RB68C5/isotype control antibody 
was administered on Day 0 IV. On day 1 (Fig 3-5a), analysis of PB by flow 
cytometry showed only 0.779% of GR1highCD11b+ cells (red box) (also 
referred to as neutrophils) compared to the controls with 69.7% cells, 
showing effective depletion. Based on the literature387,388, the PB was again 
checked 72 hours after first antibody injection on day 4 (Fig 3-5 b), and the 
percentage neutrophils was 11.7% in the depleted group, which was 
significantly lower than the control group (65.2%), and showed that one IV 
injection (50μg) can maintain neutrophil depletion for 3 days in this model. 
On Day 5, second dose of RB68C5/isotype antibody was administered IV, 
and checked on Day 6 (Fig 3-5c) and Day 7 (Fig 3-5d). On Day 8 and Day 13 
another two doses of RB6/8C5 antibody was administered IT, to maintain 
local neutrophil depletion. The PB was further monitored on Day 8 (Fig3-5e) 
and Day 11 (Fig-3-5f). Throughout the period of antibody administration, the 
GR1highCD11b+ cells were intact in the control population. We noticed a 
GR1lowCD11b+ population in both the control and depleted group, which was 
much higher in the depleted group compared to the control group, but the 
GR1highCD11b+ (neutrophils) was appropriately depleted in the experimental 
group when compared to the control group. 
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Figure 3-3: Tumour volume comparison on Day 0: Graphs showing tumour volumes of Nalm-6 (a) and Raji (b) before start of MV treatment. 
In the Nalm-6 and the Raji models, the mean tumour volumes in the neutrophil depleted (red solid circles) and non-depleted (black solid 
squares) groups were 0.4cm3 and 0.8cm3 respectively. 
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Figure 3-4: Experimental design of neutrophil depletion: (a) Nalm-6 (b) Raji: At 0.4cm3(Nalm-6) and 0.8cm3(Raji) mean tumour volume, the 
mice received IP, IT or IV injections of RB6-8C5/isotype control antibody on days shown by blue, green or black arrows respectively. PB 
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samples were analysed by FACS on days shown by red arrows. Tumours in both the group received 8 (Nalm-6) and 10 (Raji) doses of MV 
injections IT at an MOI of 1.0, between days 1 and 14 after first day of neutrophil depletion. 
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figure continued on the following page 
Figure 3-5: 
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Figure 3-5: FACS plots confirming neutrophil depletion in Nalm-6 SCID xenografts: PB from different mice were analysed for neutrophil 
depletion on day 1 (a), day 4 (b), day 6 (c), day 7 (d), day 8 (e) and day 11 (f) by flow cytometry using anti-Ly6G6C (GR1) FITC (y-axis) and 
anti-CD11b APC (x-axis) antibodies. The percentage of cells in neutrophil gates of the control/non-depleted mice ranged between 59.2% - 
87.4% compared to the depleted mice which showed 0.779 – 25.7% cells in the neutrophil gates (red rectangles) on the specified days during 
the experiment. Anti-GR1/isotype antibody was administered on day 0 and day 5 IV and on day 8 and day 13 IT (shown in the black boxes). 
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In the Raji xenografts (Fig 3-6), the RB68C5/isotype was administered 
IV on Day 0. As we had observed in the Nalm-6 model that IV injection of 
antibody could maintain the depletion for 3 days, the PB was checked on 
Day 2 (Fig 3-6a). The depleted group still showed presence of 45.1% of the 
neutrophils in the PB and therefore, a second dose of RB68C5/isotype 
antibody was administered on Day 2, IV. On Day 4 (Fig 3-6b), the flow 
cytometry analysis of the PB revealed 38.3% of neutrophils remaining. 
Hence a higher dose of the RB68C5/isotype antibody was administered 
(150μg) on the same Day 4, IP389, and the PB was checked on Day 5 (Fig 3-
6c), which showed complete and more effective neutrophil depletion 
(0.317%). After IP administration of the antibody, the percentage neutrophil 
on Day 6 (Fig 3-6d) and Day 7 (Fig 3-6e) remained very low at 0.059% and 
0.788% respectively. The neutrophils remained depleted for 4 days after IP 
administration of the antibody and therefore were administered every 3-4 
days on Day 8, Day 11, Day 15, Day 18 and Day 22. On day 14 (Fig3-6f), the 
percentage neutrophil started rising back and in the depleted group 16.6% 
neutrophils were present, but this was still significantly lower than the control 
group (80.5%). Even in the Raji model, we constantly observed a 
GR1lowCD11b+ population, especially in the depleted group but the 
neutrophils remained depleted when compared to the control group. 
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Figure 3-6: 
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Figure 3-6: FACS plots confirming neutrophil depletion in Raji SCID xenografts: PB from different mice were analysed for neutrophil 
depletion on day 2 (a), day 4 (b), day 5 (c), day 6 (d), day 7 (e) and day 14 (f) by flow cytometry using anti-Ly6G6C (GR1) FITC (y-axis) and 
anti-CD11b APC (x-axis) antibodies. The percentage of cells in neutrophil gates of the control/non-depleted mice ranged between 80.5% - 
95.8% compared to the depleted mice which showed 0.059 – 45.1% cells in the neutrophil gates (red rectangles) on the specified days during 
the experiment. Anti-GR1/isotype antibody was administered on day 0 and day 2 IV and on day 4, day 8, day 11, day 15, day 18 and day 22 IP 
(shown in the black boxes). 
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The overall percentage of GR1highCD11b+ double positive cells, 
collated from all the different mice tested in Nalm-6 and Raji xenografts are 
shown in Fig 3-7a and Fig 3-7b respectively during the period of therapeutic 
MV administration. The representative flow cytometry histogram plots are 
shown in the top panels of Fig 3-7. Though variable, compared to the control 
mice receiving an irrelevant isotype control antibody the neutrophils were 
appropriately depleted in the experimental group (Fig 3-7a) Nalm-6 (43.92 
median in depleted and 75.25 median in non-depleted) and Raji (Fig 3-7b) 
(35.93 median in depleted and 93.05 median in non-depleted) models. The 
Raji and Nalm-6 tumours were treated with MV at an MOI of 1.0 by IT 
injection starting from Day 1 after neutrophil depletion was confirmed. The 
MV was administered between days 1 and 14 starting from the first day of 
neutrophil depletion. 
The Nalm-6 tumours regressed rapidly and completely after MVNSe 
injection in both depleted (N=9) and non-depleted group (N=8) and there was 
no difference in tumour size between non-depleted and neutrophil depleted 
(Fig 3-8a) cohorts. By contrast, in the Raji model the tumours responded less 
well in the neutrophil depleted group (N=8) than the non-depleted group 
(N=9) - all mice in the depleted group had reached the humane endpoint 
(tumour size 2.5cm3 and/or hind limb paralysis) by day 27, whereas only half 
in the non-depleted group (Fig 3-8b). There was a significant difference (p= 
0.0001) in the survival between the two groups in the Raji model (Fig 3-9a) 
but not in the Nalm-6 model (Fig 3-9b). Taken together, the depletion 
experiments suggested that the neutrophil-mediated enhancement of MV’s 
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oncolytic activity is likely to play a more prominent role where the direct anti-
tumour effect is less pronounced as observed in the Raji model. 
 
Figure 3-7: Cumulative neutrophil depletion data: Flow cytometry data for 
neutrophil depletion from all the different mice bearing (a) Nalm-6 and (b) Raji 
tumours tested are shown. For each tumour type, representative histograms plots 
are shown in the upper panels (light grey line = isotype control, dark grey line = 
depleted group, black line = non-depleted group) and in the lower panel box plots 
showing aggregate data of percentage CD11b+GR1+ double positive cells in Nalm-6 
(a) and Raji (b) models. Unpaired t test was performed to obtain the P-values 
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Figure 3-8: 
figure continued on the following page 
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Figure 3-8: Tumour volumes in Nalm-6 and Raji models: Graphs showing tumour volumes in individual mice (each coloured line represent a 
mouse) in Nalm-6 (a) {non-depleted (N=8); depleted (N=9)} and Raji (b) {non-depleted (N=9); depleted (N=8)} after MV treatment. The vertical 
dashed lines in (b) shows Day 27. 
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Figure 3-9: Kaplan Meier survival curve in Raji and Nalm-6: Kaplan Meier survival curves from start of MV injection in the Raji (a) and Nalm-
6 (b) neutrophil depletion models are shown with black line representing the non-depleted group and red line representing the depleted group. 
Log Rank test was performed to obtain the P-value. 
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 Generating novel MV expressing hGCSF: 3.3.3
To disentangle the intriguing and different roles of neutrophil in the two 
models and to enhance neutrophil survival and function at the tumour site, a 
novel strain of MV was generated expressing the cytokine gene human 
GCSF (hGCSF). Figure 3-10 shows the strategy for cloning hGCSF into the 
MVNSe backbone by replacing the GFP using MluI and AatII restriction 
enzymes downstream of the MV-P gene. As the hGCSF gene had an AatII 
site within the gene, site directed mutagenesis was performed first to replace 
the restriction enzyme site AatII - GACGTC with GATGTA, leaving no amino 
acid change (Fig 3-10b). The cloned MV plasmid was then rescued using 
reverse genetics technique described in materials and methods (chapter 2, 
section 2.2.3). Fig 3-11a shows syncytium formed by the MVhGCSF on Vero 
cells from which they were picked and then further propagated and 
characterised. 
 Characterisation of the novel virus: 3.3.4
3.3.4.1 Growth curves: 
One step growth curves were performed to assess the growth pattern 
of the new virus. Vero cells infected with the virus at an MOI of 1.0 were 
collected at different time-point post infection and the virus was titrated using 
TCID50 in a 96-well plate. The virus grew to similar titres (10
6-107 PFU) as the 
backbone MVNSe virus with the viral production peaking at a later time-point 
compared to the MVNSe (48 hour for MVNSe; 62 hour for MVhGCSF) (Fig 3-
11b). 
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3.3.4.2 Cytokine production: 
hGCSF production was quantified in all the cell lines over 5 days and 
neutrophils over 24 hours post infection (hpi) (Fig3-11c and d respectively). 
Supernatants from both infected and uninfected Raji and Nalm-6 cell lines 
and infected and uninfected neutrophils (from healthy human donors) were 
collected and quantified by ELISA for the cytokine production. The three cell 
lines produced hGCSF in the range of 200 – 700ng/ml at different time-points 
(Fig 3-11c). Neutrophils from 3 different donors showed hGCSF (Fig 3-11d) 
production in the range of 2-3ng/ml. No hGCSF was detected in the cell lines 
or neutrophils infected with the control virus MVNSe. 
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Figure 3-10: Construction of MV expressing hGCSF: (a) Schematic showing cloning of DNA encoding human cytokine, hGCSF into p (+) 
MVNSe, upstream of M, using AatII and MluI restriction enzymes. (b) Site directed mutagenesis strategy used to introduce mutations to change 
GAC to GAT and GTC to GTA in the hGCSF gene to remove AatII site within the gene, facilitating easy cloning into MV genome. 
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Figure 3-11: Characterisation of MV expressing hGCSF: (a) MVhGCSF syncytia on Vero cells. (b) One step growth curve of MVhGCSF 
performed on Vero cells {MVhGCSF (orange); MVNSe (blue)}. (c) hGCSF quantitation in supernatant of Nalm-6 (□) infected with MVhGCSF 
(orange) or MVNSe (blue) (N=3) and supernatant of Raji (○) infected with MVhGCSF (orange) or MVNSe (blue) (N=3). (d) hGCSF quantitation 
in supernatant of neutrophils from healthy donors infected with MVhGCSF (orange), MVNSe (blue) or mock infected (black) (N=3). 
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 MVhGCSF is therapeutic in Raji and Nalm-6 SC in-vivo 3.3.5
xenografts: 
After characterisation of the virus, the therapeutic effect of expressing 
hGCSF by MV was determined in-vivo. The therapeutic efficacy of MVNSe 
was compared with that of MVhGCSF in SC models of both Nalm-6 and Raji 
tumours. In these mice, the tumours were allowed to reach 0.2 to 0.4cm3 in 
size (Fig 3-12a and 3-12b), after which they were treated with 10 IT injections 
of MVNSe (N=5), MVhGCSF (N=6) or UV-irradiated non-replicating MV 
control (MVUV) (N=7). In the Raji model, MVhGCSF treated tumours 
regressed very efficiently and completely and generated a highly significantly 
superior (p=0.0020) anti-tumour effect by comparison to MVNSe (Fig 3-13a) 
treated tumours. The Kaplan Meier analysis showed that the MVhGCSF 
treated mice survived significantly longer than MVNSe treated mice 
(p=0.0098) (Fig 3-13b). In the Nalm-6 model, both the MVhGCSF and 
MVNSe treated tumours resulted in complete regression of the tumours in 
both cohorts (Fig 3-13c), and all mice survived tumour free in both the 
groups, hence there was no survival advantage to MVhGCSF therapy (Fig 3-
13d). 
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Figure 3-12: Tumour volume before start of MV therapy in two different SC B-cell malignancies: Raji (a) and Nalm-6 (b) xenografts were 
established SC in SCID mice. Tumour volumes before commencing the MV injections in the three treatment groups MVhGCSF (cyan), MVNSe 
(green) and MVUV (red) are shown in both (a) and (b). 
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Figure 3-13: Tumour volumes and Kaplan Meier survival curves in two 
different SC B-cell malignancies: Raji (a and b) and Nalm-6 (c and d) xenografts 
were established SC in SCID mice. Tumour volume measurement was documented 
after MVhGCSF (cyan), MVNSe (green) and MVUV (red) injections in both the 
model (a - Raji and c – Nalm-6).  Kaplan Meier survival plots in MVhGCSF (cyan 
line), MV-NSe (green line) and MVUV (red line) treated cohorts in Raji (b) and Nalm-
6 (d). MVhGCSF N=6; MVNSe N=5; MVUV N=7. Wilcoxon signed rank test and Log 
rank statistical tests were performed to obtain the P-values in (a) and (b) 
respectively. 
 MVhGCSF play different roles in disseminated model of B-cell 3.3.6
malignancies: 
MVhGCSF was shown to be therapeutic in both Raji and Nalm-6 SC 
models, but B-cell malignancies are disseminated diseases, therefore, the 
therapeutic efficacy of MVhGCSF was tested in systemic therapeutic models. 
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In this experiment, Nalm-6 and Raji tumour cells expressing luciferase (luc) 
were used, in order to enable in-vivo monitoring of disease progression by 
live imaging. In the Nalm-6 luc model, mice were treated with 6 injections of 
1x106 PFU of MVNSe (N=7), MVhGCSF (N=6), or MVUV control (N=3) and 
an additional control of hGCSF alone, using pegylated hGCSF (Peg hGCSF) 
(N=5) at 120μg/kg once a week, for total 6 injections was also included. In 
the Raji luc model, only 3 of the 6 planned weekly injections of 1x106 PFU of 
MVNSe (N=10), MVhGCSF (N=10), MVUV (N=8) and Peg hGCSF (N=9) 
were possible before the mice succumbed. 
Fig 3-14a shows weekly in-vivo images in the Nalm-6 luc experiment. 
In this Nalm-6 luc model (Fig 3-14a), the two non-therapeutic/control groups 
MVUV and Peg hGCSF (Fig 3-14(a)(i)), and the two therapeutic/experimental 
groups MVNSe and MVhGCSF (Fig 3-14(a)(ii)) were carried out at slightly 
different times, so the luciferase signal can only be appropriately compared 
between those groups imaged at the same time, due to threshold setting. In 
the Nalm-6 luc model, signal was detected as early as week 2 in Peg hGCSF 
treated group when compared to the MVUV treated group, and by week 6 in 
the Peg hGCSF treated group, 2 of 5 mice had to be taken down (Fig 3-
14(a)(i)). Similarly, in the MV therapeutic groups, the signal was detected at 
week 5 in the MVhGCSF treated group when compared to the MVNSe 
treated group and by week 10, 2 of 6 mice had to be taken down in the 
MVhGCSF group (Fig 3-14(a)(ii)). Total signal was quantified by plotting 
individual values for luminescence (photons/second) performed on each 
surviving animal in the non-therapeutic groups at week 6 (Fig 3-14b) and the 
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therapeutic groups at week 10 (Fig 3-14c). These data show a significant 
difference between the groups with a higher tumour signal in the mice, which 
had received any therapy including GCSF (either the Peg hGCSF control or 
MVhGCSF). In the Raji luc model (Fig 3-15), tumour signal was detected at 
week 2 (Fig3-15a). Quantification of total signal (Fig 3-15b) at week 2 
showed that, by contrast to the Nalm-6 luc model, the MVhGCSF treated 
mice had significantly lower tumour burden compared to the MVNSe treated 
group (p=0.0457). 
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Figure 3-14: In-vivo imaging of Nalm-6 luciferase disseminated SCID model: Bioluminescent images showing comparison of leukaemia 
signal in Nalm-6 model; (a)(i) non-therapeutic MVUV (middle panel) and Peg hGCSF (right panel) groups at week 2 and week 6 post tumour 
inoculation and (a)(ii) therapeutic MVNSe (middle panel) and MVhGCSF (right panel) groups at week 5 and week 10 post tumour inoculation. 
Both (a) (i) and (a) (ii) images were taken with PBS injected controls (Ctrl) to account for background luminescence. The scales are on the right, 
next to the set of images compared at each week. (b) and (c) Quantification of tumour burden using bioluminescence; Scatter dot plot showing 
individual values for luminescence (photons/second) performed on each surviving animal in each treatment group at week 6 (Nalm-6 luc non-
therapeutic groups) (b), week 10 (Nalm-6 luc therapeutic group) (c). Values are represented minus background activity. Unpaired t test was 
performed to obtain the P-values. 
 
  
1
5
8
 
 
  
1
5
9
 
Figure 3-15: In-vivo imaging of Raji luciferase disseminated SCID model: Bioluminescent images comparing all the groups in the Raji 
luciferase model at week 2, post tumour inoculation (a). Images were taken with PBS injected control (Ctrl) to account for background 
luminescence. The scale is on the right side of the image. (b) Quantification of tumour burden using bioluminescence - scatter dot plot showing 
individual values for luminescence (photons/second) performed on each surviving animal in each treatment group at week 2 (Raji luc). Values 
are represented minus background activity. Unpaired t test was performed to obtain the P-value. 
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The survival and post mortem analysis of the mice in the two different 
B-cell malignancy models Nalm-6 luc (Fig 3-16; 3-17) and Raji luc (Fig 3-18; 
3-19) were compared. The Kaplan Meier curves, shown in Fig 3-16a illustrate 
that, in the Nalm-6 luc model, mice treated with the controls alone 
succumbed to leukaemia the most quickly; the survival was least good in the 
group treated with GCSF alone, where the median survival was 50 days 
compared to 75 days in the MVUV treated group (p=0.0120). Seventy five 
percent of the mice treated with MVNSe responded well and were alive at the 
end of the experiment. Surprisingly, mice receiving treatment with MVhGCSF 
had a significantly inferior outcome with a median survival of 78.5 days 
compared to the MVNSe treated cohort where the median was not reached 
by the end of the experiment (p=0.0149) (Fig 3-16a). At humane end-point, 
CD10+CD19+ cells were detected in the BM of the mice confirming presence 
of leukaemia (Fig 3-16b). hGCSF was detected at comparable levels in the 
serum of the Peg hGCSF and MVhGCSF treated cohorts confirming the 
appropriate dosing of the exogenously administered Peg hGCSF (Fig 3-17a). 
There was no significant difference in total cell numbers recovered from the 
spleens (MVNSe - mean = 2.338, range 2.0-2.675 million; MVhGCSF - mean 
= 5.922, range 0.625-25.0 million; MVUV - mean = 2.275; range 0.5-2.275 
million; Peg hGCSF – mean = 4.450, range 1.75-8.5 million) indicating that 
hyperleucocytosis was not the cause of increased death in the MVhGCSF 
treated ALL mice. Flow cytometric analysis of GR1+ neutrophils (Fig 3-17b) 
and percentage NK and Mac3 (Fig 3-20a) did not show any difference in the 
neutrophil, macrophage and NK cell percentages between the different 
groups. Taken together these data indicate that expression of hGCSF by MV 
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results in a much poorer survival of Nalm-6 ALL leukaemic mice compared to 
MVNSe and that this is due to enhanced tumour progression. 
In the Raji luc model (Fig 3-18; 3-19), the disease progressed very 
quickly in all the groups. The Kaplan Meier survival curve (Fig 3-18a) shows 
that by Day 32 all the mice had reached their humane end-point (hind limb 
paralysis). BM analysis showed the presence of CD19+CD20+ cells in all 
these mice confirming presence of disease (Fig 3-18b) at the time of death. 
Very high levels of hGCSF in the serum of the mice treated with MVhGCSF 
and Peg hGCSF (Fig 3-19a) was detected, which correlated with significantly 
higher levels of GR1+ neutrophils in the spleen of these mice, MVhGCSF 
(median 59.88), MVNSe (median 37.41), MVUV (median 39.64) and Peg 
hGCSF (median 59.48) (MVhGCSF vs. MVNSe; p=0.0016) (MVhGCSF vs. 
MVUV; p=0.0217) (MVNSe vs. Peg hGCSF; p=0.0049) (Fig 3-19b). There 
were also significantly higher levels of macrophages infiltration in the spleens 
of MVhGCSF treated mice when compared to the MVNSe treated groups 
(Fig 3-20b), consistent with the higher levels of circulating hGCSF. 
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Figure 3-16: Survival and %CD10CD19 positive cells in disseminated Nalm-6 model: (a) Kaplan Meier survival curve showing MVhGCSF 
(cyan), MVNSe (green), MVUV (red) and Peg hGCSF (pink) treated mice. (b) At humane end-point (hind limb paralysis), the presence of 
disease was confirmed by flow cytometry by %CD10CD19 in the BM compartment. 
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Figure 3-17: hGCSF levels in serum and %neutrophils in spleen of Nalm-6 disseminated model: (a) hGCSF levels (ng/ml) in the serum of 
the mice quantified by ELISA. (b) %Neutrophils in the spleens determined by flow cytometry. 
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Figure 3-18: Survival and %CD19CD20 cells in disseminated Raji model: (a) Kaplan Meier survival curve showing MVhGCSF (cyan), 
MVNSe (green), MVUV (red) and Peg hGCSF (pink) treated mice. (b) At humane end-point (hind limb paralysis), the presence of disease was 
confirmed by flow cytometry by %CD19CD20 in the BM compartment. 
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Figure 3-19: hGCSF levels in serum and percentage neutrophils in spleen of Raji disseminated model: (a) The level of hGCSF in the 
serum of the mice was quantified by ELISA. (b) Percentage of neutrophils in the spleens was determined by flow cytometry. ***p<0.002; 
*≤p0.04. Unpaired t test was performed to obtain the P-values. 
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Figure 3-20: Spleen analysis in disseminated models of Nalm-6 and Raji: At humane end point, the percentage of NK cells and 
macrophages were determined in the spleen of mice treated with MVhGCSF (cyan), MVUV (red), MVNSe (green) and Peg hGCSF (pink) in the 
disseminated models of Nalm-6 luciferase (a) and Raji luciferase (b) models. ***p=0.0006. Unpaired t test was performed to obtain the P-value. 
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 MVhGCSF does not enhance cell proliferation in-vitro: 3.3.7
To ensure that the in-vivo data did not simply result from a direct effect 
of GCSF on cell proliferation, the cell lines were treated with increasing 
concentrations of recombinant hGCSF in-vitro and the cell numbers were 
enumerated over 4 days (Fig 3-21). No significant difference between GCSF 
treated and control cell lines in-vitro was observed in either Raji (Fig 3-21a) 
or Nalm-6 (Fig 3-21b) cells. 
 MVhGCSF in MV-infectable, CD46 transgenic mice is not toxic: 3.3.8
Finally, MVhGCSF was evaluated in CD46 transgenic mice, in which 
all cells, not just tumour cells, are infectable by MV. To assess this, IfnarKO 
CD46 Ge mice194 were injected IV with either MVNSe or MVhGCSF. They 
were monitored carefully for signs of ill health for 35 days after which spleen 
size, and differential cell count in spleen cells (NK, macrophage, neutrophil 
percentages) as well as serum hGCSF level were determined. There was no 
difference in spleen size (Fig 3-22a) or cellular contents in the spleen 
between the groups (Fig 3-22b). None of the mice became unwell. The mice 
treated with MVhGCSF showed significant levels of hGCSF in the serum at 
Day 35 (Fig 3-22c), but there was no toxicity seen. Taken together these 
data in the disseminated Nalm-6 model, suggests that any adverse effect of 
expressing hGCSF as an additional transcription unit in tumour bearing mice 
relates solely to promotion of tumour growth and not to toxicity of GCSF 
production. 
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Figure 3-21: Effect of human GCSF on Raji and Nalm-6 cells in-vitro: Raji (a) and Nalm-6 (b) cells were treated with increasing amounts of 
rhGCSF and counted every 24 hours by trypan blue exclusion method in-vitro. The number of cells/ml is plotted against the time. 
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Figure 3-22: MVhGCSF treatment in IfnarKO CD46 Ge mice: CD46 transgenic mice were injected IV with MVNSe (N=5) or MVhGCSF (N=7). 
Evaluation was carried out at day 35 after injection for (a) spleen size in mm, (b) percentage of NK cells, macrophages and neutrophils in the 
spleens, and (c) serum hGCSF levels (ng/ml). 
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3.4 DISCUSSION:  
The interest of the lab in developing MV as a therapy in B-cell 
malignancies specifically ALL, led to the investigation of the Nalm-6 model to 
get an insight into the therapeutic efficacy of MV in this model. It was shown 
that like other B-cell malignancies, ALL too is sensitive to MV therapy in-vivo 
in both SC and disseminated xenograft models. 
We know that lymphoid malignancies are disseminated diseases. A 
key component of success of oncolytic virotherapy lies in engendering an 
overall “positive” interaction with the immune system. The ability to deliver a 
replicating virus to individuals with pre-existing adaptive immunity, although 
not the focus of the present work is crucial. However, the stimulation and 
exploitation of positive immune responses to target cells infected by oncolytic 
viruses is a key counterbalance. Just as it was seen in the phase 1 trial of 
MV in multiple myeloma an initial ‘free pass’ for measles viruses, but only in 
patients with highly compromised antibody response292, a balance between 
anti-tumour immune response by the T-cells390 and anti-viral activity of T-
cells may be expected. 
Hence, innate immunity, which may be less compromised and quicker 
to recover after anti-cancer chemotherapy - may play a pivotal role in viral 
oncolysis. On this basis, and taking into account previous work from the lab, 
in which it was clearly demonstrated that oncolytic MV is able to beneficially 
affect their anti-tumour properties, an attempt to augment these properties by 
cloning human GCSF as an additional transcription unit to MV was made, as 
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GCSF is known to stimulate the survival, proliferation and cytotoxic function 
of neutrophils both in-vitro and in-vivo391. 
Two tumour models of relatively similar aggressive B-cell 
malignancies were chosen, both of which are known to respond to MV-
oncolysis. Raji - Burkitt’s lymphoma-derived cells - respond to MV therapy, 
but less quickly and completely than does the Nalm-6 model derived from 
ALL. 
In the initial neutrophil depletion experiments, the therapeutic effect of 
MV in the Raji model was significantly abrogated, whereas in the Nalm-6 SC 
model, depletion of neutrophils did not abrogate the 100% response rate. 
The animal project license at the time of the Nalm-6 experiment allowed only 
2 IV injections of antibody and therefore to maintain the neutrophil depletion, 
2 IT antibody injections were introduced, which was successful in maintaining 
the depletion throughout the course of the MV treatment. By the time the Raji 
experiment was performed the project license had been amended allowing IP 
route of antibody administration along with IV route to deplete neutrophils. 
This facilitated the experiment, as the IP route of administration was more 
straightforward technically. Both the IV and IP routes of neutrophil depletion 
were effective, but the IP administration of the antibody could maintain the 
depletion for 3-4 days and therefore the antibody was given every 4 days in 
the Raji model. In both the Raji and Nalm-6 models, the neutrophils did start 
coming back at a later time-point in the experiment, but the depletion was 
stringently maintained throughout the course of MV treatment in both the 
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models. The observations confirmed that MV was oncolytic in both the 
tumour models as expected, but the role of neutrophils seemed to be 
different between the models. A possible explanation could be the kinetics of 
tumour sensitivity to virus, as the Nalm-6 tumours simply regressed so 
rapidly compared to the Raji tumours, that the direct oncolytic effect of MV in 
the Nalm-6 tumours superseded any involvement of neutrophils in-vivo. It 
may also relate to the initial size of the tumour, as the threshold tumour 
volume of Raji tumours was higher than that of the Nalm-6 tumours at the 
start of therapy. However, it is also possible that the individual targets are 
differentially responsive to neutrophil effects. 
Murine and human GCSF share 73% amino acid sequence homology 
and full cross reactivity392 and hence can be tested in both human and 
murine experimental systems, and therefore was cloned into MV. In the in-
vivo SC tumour models, the MV expressing hGCSF had a significantly 
superior therapeutic effect to MVNSe in the Raji model, but was equivalently 
good at tumour eradication to MVNSe in the Nalm-6 model, both in the 
proportion of responding tumours and time to response, consistent with the 
expectations from the neutrophil depletion experiments. 
As B-cell malignancies are disseminated diseases, systemic tumour 
models of Nalm-6 and Raji were established and the therapeutic efficacy of 
the MV expressing human GCSF was tested in a systemic therapeutic 
approach by delivering the treatment IV. In disseminated Nalm-6 xenografts, 
previous data showed that approximately 42% of mice have complete 
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regression of the tumours with IV delivered MV386, offering a greater 
probability to observe any potential therapeutic benefit to MVhGCSF. In the 
Raji model the previous data showed that neutrophils could play a beneficial 
role in improving therapeutic efficacy of MV280. Surprisingly, in the Nalm-6 
disseminated model, not only was there no benefit to MVhGCSF treatment, 
there was an increased rate of death in those mice, which also occurred with 
the Peg hGCSF alone control conditions. The level of GCSF detected in the 
mouse sera was confirmed to be almost identical between exogenously 
administered and GCSF produced by administration of MVhGCSF 
suggesting an active, productive infection of tumour targets. The disease 
progression rather than GCSF toxicity was suggestive to be responsible for 
these observations and further analysis showed that the immune cell 
composition of the spleens from MVNSe and MVhGCSF did not differ, 
especially, there was no excess of neutrophils, ruling out direct toxicity of 
GCSF. Furthermore, lack of toxicity in the CD46 transgenic model confirmed 
this. In the Raji disseminated model, the disease progressed very rapidly in 
all the groups. By third week all of them had succumbed to hind limb 
paralysis, and had to be sacrificed. In contrast to the Nalm-6 model, the Raji 
disseminated model showed significantly higher level of infiltrating 
neutrophils in the spleen of the mice treated with MVhGCSF or Peg hGCSF 
when compared to the MVNSe and MVUV treated groups. Human GCSF 
levels in the serum of these mice were also very high. At week 2, some 
therapeutic benefit of using MVhGCSF over MVNSe was observed by the 
live in-vivo imaging quantification (Fig 3-15b), but this was short lived. The 
percentage of tumour cells in the BM of the mice at the time of death was 
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similar all across the groups (Fig 3-18b), whereas in the Nalm-6 model, the 
peg hGCSF treated group had significantly high level of tumour cells in their 
BM in comparison to the other groups at the time of death (Fig 3-16b), which 
again showed a proliferating effect of GCSF on Nalm-6 cells in-vivo. But this 
effect was not demonstrated for Raji cells in-vivo. 
It can be concluded that the Raji model can benefit from use of 
MVhGCSF, as neutrophils have consistently shown to play a role in MV-
mediated oncolysis in this model. It is possible that the short-term benefit 
observed in this model was due to the tumour cell inoculation dose (1 million 
cells) and the schedule of weekly injections of MV therapy, which was kept 
similar to that of the Nalm-6 model, to be able to directly compare the two 
models. As Raji is more aggressive than the Nalm-6 model, with lowering of 
tumour inoculation dose and increasing the therapeutic dose and frequency 
of MV, it is possible to see a more robust therapeutic benefit. 
GCSF is widely used in the clinical treatment of patients with 
aggressive B-cell malignancies and has been shown to improve outcome393, 
although it is long known that GCSF when used to mobilise normal 
haematopoietic stem cells can also facilitate mobilisation of leukaemia from 
the bone marrow niche360. However, pre-clinical studies of the CXCR4 
antagonist plerixafor, typically used in conjunction with GCSF, have shown 
promising results in in-vivo models of primary ALL, suggesting that bone 
marrow microenvironment disruption may be therapeutically beneficial394,395 
by increasing chemo sensitivity of resistant, possibly quiescent, leukaemia, 
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clones after removal from their niche. A clinical trial NCT01331590 is being 
conducted, evaluating the role of GCSF in priming the bone marrow of ALL 
patients for subsequent chemotherapy targeting396. By contrast, GCSF 
accelerated disease progression in a sub set of primary ALL patient 
xenografts in NSG mice397. Additionally, microarray analysis in samples 
where disease progression was promoted by GCSF, revealed significantly 
higher expression of cell cycle regulators like cyclin A1 and ALCAM than in 
mice without disease progression. In the same article, no evidence for a 
direct mitogenic effect of GCSF could be demonstrated in any of the 
xenografts using exogenous GCSF in in-vitro cultures in the presence or 
absence of human or murine stromal support. It has also been shown that 
quiescent leukaemia cells can be induced to enter the cell cycle by treatment 
with GCSF398 and then targeted by chemotherapy. 
This chapter echoes the multiple roles of GCSF when used in the 
treatment of B-cell malignancies. It was confirmed that MVhGCSF could be 
used as a potent oncolytic agent in the Raji model. Serum GCSF level was 
comparable to those seen when GCSF is administered to patients399. In this 
model, MVhGCSF potentially carry an advantage, especially in combination 
with non-myelosuppressive chemotherapies. However, based on these data 
that showed an unexpectedly aggressive progression of Nalm-6 leukaemia 
in-vivo by MV expressing hGCSF, future studies would need to proceed very 
cautiously as any benefit from hGCSF as expressed by oncolytic viruses 
could be difficult to predict and may even vary from patient to patient.  
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Chapter 4: Mechanism of neutrophil mediated cytotoxicity in 
MV-infected target cell, differ between tumour types and 
the MV strain used  
4.1 BACKGROUND: 
 Antibody Dependent Cellular Cytotoxicity – ADCC: 4.1.1
In this chapter, my work aims to decipher, whether MV-induced, 
neutrophil mediated killing that was observed in the previous chapter, may 
result from neutrophil-mediated antibody dependent cellular cytotoxicity 
(ADCC). ADCC, is a mechanism by which, antibody coated target cells are 
killed by a cytotoxic effector cell in a non-phagocytic process, by releasing 
cytotoxic cellular contents or by expression of cell-death inducing 
molecules400-402. ADCC is activated when the Fc components of the 
antibodies (IgG, IgA and IgE classes) bind to their respective Fc receptors 
(FcγR, FcαR and FcεR) present on the effector cells. Although typically 
framed as a function of monocytes and NK cells, ADCC has been clearly 
identified as a mechanism by which neutrophils can eliminate cancer 
cells403,404. Neutrophils from healthy donors constitutively express FcγRII 
(CD32) and FcγRIII (CD16), but not FcγRI (CD64), but do not lyse tumour 
cells without activation405. Upon stimulation with GMCSF405, IFNγ406 or 
GCSF407, neutrophils are activated to lyse cells via the different Fc receptors 
(FcRs). Neutrophils can also mediate cytotoxicity via FcαRI (CD89), which 
binds to IgA404. An anti-FcγRI bi-specific antibody directed against the proto-
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oncogene product Her2/neu have shown enhanced lysis of Her2/neu 
expressing tumour cells by GCSF primed neutrophils403. Furthermore, a bi-
specific antibody directed against CD20 and FcαRI was shown to effectively 
kill a broad range of malignant B-cell lines404. 
Challacombe et al. showed that topical PEP005 (ingenol-3-angelate) 
treatment induces primary necrosis of tumour cells and an inflammatory 
response, characterised by a pronounced neutrophil infiltrate. Tumours 
treated with PEP005, led to elevation in anti-cancer antibodies, which could 
induce neutrophil mediated ADCC. Furthermore, in Foxn1 (nu) mice, 
depleted of neutrophils and in CD18-deficient mice (in which neutrophil 
extravasation is severely impaired), PEP005 treatment was associated with a 
>70% increase in tumour relapse rates408. Additionally neutrophils play a 
critical effector role in mAb treatment of cancer. In a SCID xenograft model of 
Burkitt’s lymphoma, when neutrophils were depleted, the therapeutic effect of 
rituximab (chimeric antibody targeted to CD20) was partially lost389. In a 
recent study, reovirus was shown to enhance killing of CLL cells by NK cell 
mediated ADCC when used in combination with anti-CD20 antibodies409. 
Previous published work from my lab has shown that MV Moraten 
(MVMor) (a vaccine, oncolytic strain – see Fig 1-4) infected neutrophils from 
healthy donors were activated and survived longer in culture compared to 
infection with a WT MV strain. Besides, infection with MVMor promoted a 
more cytotoxic effector phenotype, whereby the neutrophils produced pro-
inflammatory cytokines - TNFα, MCP-1, IL8 and IFNα357. Direct MVMor 
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infection of neutrophils also led to the secretion of pre-formed soluble TRAIL 
from granules (i.e. did not require protein synthesis) and induction of 
neutrophil degranulation357. Furthermore, three lines of evidence from the lab 
(Dr. Zhang, unpublished data) suggested that ADCC might be a mechanism. 
First, Dr. Zhang showed that MV-infection of neutrophils lead to FcαRI 
upregulation. Second, while investigating TRAIL mediated killing of MV-
infected Jurkat T-cells in the presence of neutrophils, Dr. Zhang made an 
interesting observation. Upon addition of an antibody (RIK2), which was used 
to block TRAIL-mediated apoptosis410, there was enhancement rather than 
blocking of neutrophil mediated killing. This was completely unexpected, and 
generated the hypothesis that the RIK2 antibody was binding to cell surface 
TRAIL on the Jurkat cells, and to the Fc receptor on the neutrophils, thereby 
mediating ADCC. To test this, Jurkats were infected with MV and co-cultured 
with neutrophils in the presence of anti-MV antibody containing serum (anti-
MV serum), which augmented the neutrophil mediated killing, further 
suggesting ADCC as a possible mechanism (Dr. Zhang, unpublished data). 
In chapter 3, MV expressing human GCSF enhanced the neutrophil 
mediated killing in-vivo resulting in improved therapeutic effect in the Raji 
SCID model and showed increased infiltration of neutrophils in the spleen 
compared to the unmodified MVNSe treatment, and stimulated neutrophil-
mediated oncolysis in B-cell malignancy. GCSF greatly enhances the 
cytotoxic activity of neutrophils; in particular, it can enhance ADCC. In an in-
vivo study of B-cell malignancy, GCSF primed neutrophils were shown to 
efficiently lyse antibody coated malignant B-cells, compared to non-primed 
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neutrophils411 by ADCC. In a different study, neutrophils isolated from 
patients undergoing rhGCSF therapy showed higher cytotoxicity against 
Daudi cells (B lymphoma cell line) in-vitro when compared to the neutrophils 
isolated from non-treated control patients or healthy donors. The neutrophils 
from these rhGCSF treated patients were also shown to express the FcγRI in 
significantly higher proportion than the untreated or healthy controls, which 
correlated with higher cytotoxicity407. 
Hence, based on the literature, preliminary data from my laboratory 
and my own findings in chapter 3, I chose to investigate ADCC as a 
mechanism of neutrophil mediated MV oncolysis in more detail. Two different 
vaccine strains of MV were used; MVNSe and MVMor. MVNSe has been the 
parental virus in most of the in-vivo studies of oncolysis to date and has been 
administered to humans in the completed and ongoing MV clinical trials50. 
The MVMor strain was included in this chapter as a comparator, as this strain 
helped generate some of the preliminary data (Dr. Zhang, 2012357 and 
unpublished data). 
A schematic representation of the hypothesis, that ADCC might be 
involved in MV-mediated tumour cell killing is shown in Fig 4-1. MV-infected 
target tumour cells (dark blue) express MV-H (yellow) and MV-F (red) 
proteins on their cell surface. Anti-MV antibody in the serum, which is 
primarily directed against the MV-H (light blue) and to a lesser extent to MV-
F (brown)241,412 can bind to the MV-H (yellow) and MV-F (red) on the target 
cells whilst also binding by their Fc portions to Fc receptors (green) on 
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neutrophils (orange). Once bound by Fc receptor, the neutrophils can bring 
about target cell lysis by ADCC (grey). 
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Figure 4-1: Schematic representation of neutrophils’ antibody dependent cellular cytotoxicity (ADCC) as a mechanism of MV-infected 
tumour cell lysis: 
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 Hypothesis: 4.1.2
ADCC is a possible mechanism by which neutrophils can eliminate 
MV-infected tumour cells. 
4.1.2.1 Aims: 
1. To investigate if neutrophils from healthy human donors can mediate 
killing of MV-infected targets in-vitro. 
2. To determine whether ADCC is a mechanism by which neutrophils 
may mediate MV oncolysis. 
4.2 RESULTS: 
 Comparison of MVNSe with MVMor at induction of neutrophil-4.2.1
specific lysis: 
To specifically look at the role of neutrophils and mechanisms involved 
in MV oncolysis, in-vitro assays were designed with the B-cell lines of interest 
- Raji and Nalm-6. In the previous chapter, in Raji SCID xenografts, 
neutrophils were shown to play a role and using a MV expressing hGCSF 
(MVhGCSF) significantly improved the oncolytic effect, reiterating the role of 
neutrophils. Nalm-6 on the other hand was not susceptible to neutrophil 
mediated effect. However, data in both Raji and Nalm-6 models were 
obtained in-vivo and the effect observed was with murine neutrophils and 
therefore, to study the effect of human neutrophils in both these model was 
of interest. The human T-cell line Jurkat was also included, as previous work 
in the lab had suggested possible susceptibility to neutrophil mediated ADCC 
in this cell line. 
  
183 
First, the percentage neutrophil mediated specific cell death (called 
neutrophil-specific lysis from here on) in all the three cell lines was 
determined by chromium release assay. Briefly, cells were infected with 
MVNSeGFP or MVMorGFP and imaged to confirm MV infection (Fig 4-2). 
Twenty-four or forty-eight hours post infection they were labelled with 52Cr. 
Neutrophils were extracted from the blood of 10 different individual healthy 
donors, and added to the MV-infected target cells at different E:T ratio. 
Twenty-four hours later, the supernatant was collected and read in a beta 
emission counter. The cells infected with MV alone in the absence of 
neutrophils were used as negative control (spontaneous cpm) to account for 
MV-mediated cell death, and cells treated with 1% tri fluoro acetic acid (TFA), 
which ensured complete lysis was used as positive control (maximal cpm). 
The neutrophil-specific lysis was calculated taking into account both positive 
and negative controls using the formula: % of neutrophil-specific lysis = 
(experimental cpm – spontaneous cpm)/(maximal cpm – spontaneous cpm) 
x100; (cpm – count per min). 
Fig 4-3 shows the neutrophil-specific lysis of the MV-infected cells. 
The cell lines infected with MVMor were not susceptible to neutrophil-specific 
lysis at any E:T ratio, except for Nalm-6 (Fig 4-3a, dark red line). In Nalm-6, a 
maximum of 20% neutrophil-specific lysis was observed, more pronounced 
at the lower E:T ratios. In contrast, MVNSe infection (Fig 4-3b) led to high 
percentage of neutrophil-specific lysis in Jurkat cells (25-45%) (black line) 
and Nalm-6 (10-20%) (dark red line) across all different E:T ratio, and around 
10% in Raji at higher E:T ratio of 20:1 and 40:1 (blue line). 
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These experiments in different cell lines showed that neutrophils were 
playing a role in MV oncolysis in-vitro but similar to the observation in chapter 
3, the neutrophils seemed to play very different roles in different 
malignancies, with some of them less dependent on neutrophil mediated MV 
oncolysis than others. Interestingly and somewhat unexpectedly, MVNSe 
and MVMor had very different effects in the different cell lines and though 
there are not many differences known between the two strains of viruses 
used, difference in fusogenicity might have a role to play50, as it is known that 
MVMor is less fusogenic than the MVNSe strain. Overall in all the cell lines, 
neutrophil-specific lysis in MVNSe infected cells was higher than MVMor 
infected cells. 
 
Figure 4-2: Images confirming MV infection of cell lines: Jurkat cells (left panel), 
Raji cells (middle panel) and Nalm-6 cells (right panel) infected with MVNSeGFP 
(top row) or MVMorGFP (bottom row) and imaged at 24 or 48 hours at 10X zoom. 
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Figure 4-3: Neutrophil-specific lysis in MV-infected cell lines: Percentage neutrophil-specific lysis calculated at different E:T ratio in Jurkat 
cells (black), Raji cells (blue) and Nalm-6 cells (dark red), infected with MVMor (a) or MVNSe (b). The black dashed line shows the minimum 
threshold percentage (5%) of neutrophil-specific lysis used for the experiment. 
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 Investigating ADCC as a mechanism: 4.2.2
Next, ADCC was investigated as a mechanism of neutrophil-specific 
lysis of MV-infected target cells. Neutrophil-specific lysis was determined by 
chromium release assay in the presence or absence of anti-MV anti-serum. 
Pooled serum from individuals with high anti-MV antibody titres {titrated using 
VIDAS® enzyme linked fluorescent immunoassay (EIA) (Biomérieux, 
France)}, was obtained from the virology department at the Royal Free 
Hospital. The serum was heat inactivated in the lab at 56°C for 30mins to 
inactivate complement. The concentration of serum added at 1:100 dilution 
was based on previous experiments in the lab where highest percentage of 
neutrophil-specific lysis was observed in MV-infected Jurkat cells at this 
dilution (Dr. Zhang, unpublished data). 
In the Nalm-6 cell line, infected with MVNSe, there was no change in 
the neutrophil-specific lysis upon addition of serum (Fig 4-4a green line) in 
comparison to the absence of serum (Fig 4-4a black line). When the same 
cell line was infected with MVMor, the neutrophil-specific lysis was abrogated 
upon addition of serum (Fig 4-4c, red line) when compared to no serum 
control (Fig 4-4c black line). 
In the Raji cell line, infected with MVNSe, neutrophil-specific lysis was 
abrogated upon addition of serum (Fig 4-4b, green line) in comparison to no 
serum control (Fig 4-4b black line). However, MVMor infection of Raji cells 
did not show any neutrophil–specific lysis in the presence or absence of 
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serum (Fig 4-4d, red line and black line respectively). Both Nalm-6 and Raji 
cell lines infected with either of the viruses did not show any ADCC. 
The experiments with Jurkat cells demonstrated significant abrogation 
(p≤0.0001) of neutrophil-specific lysis upon addition of serum (Fig 4-5a green 
line), when they were infected with MVNSe in comparison to absence of 
serum (Fig 4-5a black line). By contrast, after infection with MVMor (Fig 4-
5b), the neutrophil-specific lysis was lower than the threshold of 5% in the 
absence of serum (Fig 4-5b black line) but addition of anti-MV serum (Fig 4-
5b red line), significantly enhanced the neutrophil-specific lysis (p≤0.0347) at 
8:1 and 20:1 E:T ratio, showing ADCC as a possible mechanism, and in 
keeping with the previous observation from the lab. 
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Figure 4-4: ADCC as a mechanism of neutrophil-specific lysis in MV-infected 
cell lines: Nalm-6 (a and c) and Raji (b and d) cell lines were infected with MVNSe 
(a and b) or MVMor (c and d) in the presence (black lines) or absence (green or red 
lines) of anti-MV serum. Percentage neutrophil-specific lysis was calculated for all 
with 5% (black dashed line) as minimum threshold of neutrophil-specific lysis. 
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Figure 4-5: ADCC as a mechanism of neutrophil-specific lysis in MV-infected Jurkat cell line: Jurkat cell line was infected with MVNSe (a) 
or MVMor (b) and percentage neutrophil-specific lysis determined in the presence (black lines) or absence (green and red lines) of anti-MV 
serum. 5% was used as the minimum threshold of neutrophil-specific lysis (black dashed line). Paired t test was performed to obtain the P-
values. *** p≤0.0001, *p≤0.0347. 
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 Neutrophil-specific lysis and ADCC is not a T-cell specific 4.2.3
phenomena: 
Substantial neutrophil-specific lysis after MV infection was observed 
only in Jurkat cells after infection with MVNSe. Enhancement upon the 
addition of anti-MV antibody containing serum was observed only when 
Jurkat cells were infected with MVMor. In order to rule out whether this 
observation is related to the fact that Jurkat cells were of T-cell origin, 
another T acute lymphoblastic leukaemia cell line, DND41 was chosen and 
examined for neutrophil-specific lysis and ADCC. 
The chromium release assay was carried out for DND41 as described 
earlier, in the presence and absence of anti-MV serum. No neutrophil-
specific lysis was observed with either strain of MV in the absence of serum, 
as shown in Fig 4-6a and b; black lines, showing that DND41 was not 
susceptible to neutrophil-specific lysis in-vitro. Addition of anti-MV serum too 
did not have any effect - the neutrophil-specific lysis remained below the 5% 
set threshold level (Fig 4-6a and b; green and red lines respectively). Taken 
together these data suggested that the results obtained from Jurkat cells was 
likely to be a non-generalisable finding. 
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Figure 4-6: Neutrophil-specific lysis and ADCC in MV-infected DND41 cell line: DND41 cell line was infected with MVNSe (a) or MVMor (b) 
and percentage of neutrophil-specific lysis calculated in the presence (green and red lines) and absence (black line) of anti-MV serum. 5% was 
used as the minimum threshold of neutrophil-specific lysis (black dashed line). 
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 MVhGCSF infected Jurkat does not enhance the neutrophil 4.2.4
mediated ADCC: 
MV expressing hGCSF has the potential to enhance neutrophil-
mediated ADCC. Since Jurkat cells were the only cells in which possible 
ADCC was observed, they were the only cell line selected for evaluation with 
MVhGCSF. Cytotoxicity assays were performed after addition of neutrophils 
from individual healthy donors (N=10) at different E:T ratios. The neutrophil-
specific lysis was 15-35% at different E:T ratios. This was completely and 
significantly abrogated in the presence of anti-MV serum at all E:T ratios { 2:1 
(p=0.0343), 8:1 (p=0.0045), 20:1 and 40:1 (p≤0.0008)} (Fig 4-7). Hence, 
MVhGCSF showed exactly the same pattern of neutrophil-specific lysis as 
the parental MVNSe (Fig 4-5a). The expression of GCSF by MV did not have 
any additional effect on the neutrophil-specific lysis in the presence or 
absence of serum in-vitro. For this reason, MVhGCSF was not tested on any 
of the other cell lines. 
Taken together, the data make ADCC very unlikely as a possible 
mechanism by which neutrophils may enhance target cell killing by MV. 
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Figure 4-7: Neutrophil-specific lysis and ADCC in MVhGCSF infected Jurkat 
cell line: Jurkat cells were infected with MVhGCSF and percentage neutrophil-
specific lysis determined in the presence (black lines) or absence (brown line) of 
anti-MV serum. 5% was used as the minimum threshold of neutrophil-specific lysis 
(black dashed line). Paired t test was performed to obtain the P-values. *p=0.0343, 
**p=0.0045, ***p≤0.0008. 
 
 Dissecting the difference between MVNSe and MVMor in 4.2.5
provoking neutrophil-specific lysis: 
One interesting finding from these experiments so far was the 
difference in neutrophil-specific lysis observed in Jurkat cells between the 
two different strains of MV which was unexpected and not readily explained. 
It was also unclear why this response was enhanced by serum only with 
MVMor but not MVNSe. Both of these attenuated vaccine strains of MV are 
derived from the MVEdmB strain, and there are very few known differences. 
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MVMor has been sequenced in both their coding and non-coding 
regions413,414 and differs with the MVNSe only in few amino acids, isolated in 
the H and L part of the genome232. There are also phenotypic differences in 
the cytopathic effects between the two strains, which cannot at present be 
directly related to their modest genetic differences. One key difference is that 
MVMor is less fusogenic than MVNSe strain50 and infection results in fewer 
and smaller multinucleated syncytia. At the functional level too, some 
differences in the expression of MV proteins has been reported between 
different vaccine strains415. Whether some of these functional differences in 
fusogenicity are responsible for the difference in the cytotoxicity observed 
between the two strains, were tested further. 
4.2.5.1 Is MV-H expression after MVMor and MVNSe infection 
responsible for the differential stimulation of neutrophil-specific 
lysis? 
It was hypothesised (Fig 4-8) that the surface area of the cell 
membrane expressing the viral envelope protein MV-H, may be higher 
overall in the individually infected cells after infection with the less fusogenic 
MVMor (Fig 4-8a) compared to in the large syncytia formed by the highly 
fusogenic MVNSe (Fig 4-8b). This could be highly relevant to ADCC, as it 
would allow more antibody binding and facilitate greater Fc receptor 
interaction. 
First, the MV-H expression on Jurkat cells after infection with the two 
different viruses was investigated. The Jurkat cells were infected with 
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MVNSe or MVMor at an MOI of 1.0. Twenty-four hours later, the percentage 
of MV-H cell surface expression (Fig 4-9a) and MFI of MV-H expression (Fig 
4-9b) was determined by flow cytometry. There was significant difference in 
both the percentage MV-H expression (p=0.0025) (Fig 4-9a) and MFI MV-H 
expression (p<0.0001) (Fig 4-9b) with higher MV-H in MVMor in comparison 
to MVNSe infected cells. 
The relevance of fusion to H expression was further determined by the 
use of fusion inhibitory peptide (FIP), which blocks cell-cell fusion. After 
addition of FIP, MV-H expression would be expected to result in an increase 
in H expression in MVNSe infected cells. When the percentage MV-H 
expression was determined in the presence of FIP, there was a very small, 
but non-significant (p=0.0652) augmentation observed in the MVNSe infected 
cells (Fig 4-10, dark grey bar), whereas in the MVMor infected cells there 
was significant abrogation (p=0.0071) in MV-H expression (Fig 4-10 dark 
pink bar); this was opposite of the hypothesis, and the reason is not clear. 
The increase in MV-H expression due to blocking of fusion was evident in 
MVNSe infected cells albeit not significant. It was expected that, MVMor 
would either show increase in MV-H expression or no change after FIP 
treatment, but there was decrease in MV-H expression and this was 
unexpected. 
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Figure 4-8: Schematic representation of MV-H expression hypothesis after MVNSe and MVMor infection of Jurkat cells in the 
presence and absence of FIP: 
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Figure 4-9: MV-H expression on Jurkat cells: Jurkat cells infected with MVNSe 
(grey) or MVMor (pink) were quantified for percentage MV-H expression (a) and MFI 
(b) on Jurkat cell surface by flow cytometry. Paired t test was performed to obtain 
the P-values. 
 
Figure 4-10: MV-H expression on Jurkat cells in the presence and absence of 
FIP: Jurkat cells infected with MVNSe (grey) or MVMor (pink) were quantified for 
percentage MV-H expression on Jurkat cell surface by flow cytometry in the 
presence (dark colours) or absence (light colours) of FIP. Paired t test was 
performed to obtain the P-values. 
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4.2.5.2 Effect of fusion inhibition on neutrophil ADCC in MV-infected 
Jurkat: 
It was concluded that ADCC is not a possible mechanism of 
neutrophil-mediated MV oncolysis, but the difference observed in MV-H 
expression in Jurkat cells infected with MVNSe with and without FIP above 
(Fig 4-10) and ADCC observed with MVMor infection earlier (Fig 4-5b) was 
very intriguing and led to the second hypothesis illustrated in Fig 4-8 c and d; 
upon blocking fusion in MVNSe infected Jurkat cells, the higher MV-H 
expression may enable the binding of more anti-MV-H antibody, enhancing 
neutrophil Fc receptors interaction, in turn enhancing the neutrophil mediated 
killing (Fig 4-8c and d). 
To determine whether the difference in the MV-H expression on MV-
infected Jurkat cells between the two viruses was responsible for the 
difference in the ADCC observed earlier in section 4.2.2, FIP was used to 
block fusion. The chromium release cytotoxicity assay was performed in the 
Jurkat infected with MVNSe or MVMor in the presence or absence of FIP. 
These results are shown in Fig 4-11. Upon MVNSe infection (Fig 4-11a), in 
the presence of FIP (black empty triangle) the neutrophil-specific lysis 
disappeared completely and significantly (p≤0.0003) across all the E:T ratios, 
compared to the absence of FIP (black filled triangle) showing abrogation of 
neutrophil mediated killing on inhibition of fusion. Addition of anti-MV serum 
(Fig 4-11a - red empty and filled circle), when the fusion was blocked did not 
show any enhancement in killing by ADCC. After MVMor infection (Fig 4-11b) 
too, there was a significant decrease in the neutrophil-mediated killing in the 
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presence of FIP (black empty triangle) but only in 20:1 (p=0.0421) and 40:1 
(p=0.0017) E:T ratios, compared to the no FIP control (black filled triangle). 
However, there was no enhancement in ADCC by addition of FIP (red empty 
circle) compared to the no FIP control (red filled circle). Overall, though a 
difference in the percentage of MV-H expression was seen on Jurkat after 
infection with the viruses, this did not facilitate ADCC. The main significant 
observation from the work in this chapter was that, upon addition of FIP, the 
neutrophil-specific killing after MVNSe infection of Jurkat was completely and 
significantly abrogated. This suggested a potential role for MV-induced cell-
cell fusion as a mechanism of neutrophil-mediated MV oncolysis. This 
question is investigated in detail in chapter 5. 
 
Figure 4-11: Neutrophil-specific lysis and ADCC in Jurkat cells in the presence 
and absence of FIP: Percentage neutrophil-specific lysis in Jurkat cell line infected 
with MVNSe (a) or MVMor (b) with (red lines) or without (black lines) anti-MV serum 
in the presence (empty symbols) or absence (solid symbols) of FIP using chromium 
release assay. 5% was used as the minimum threshold of neutrophil-specific lysis 
(black dashed line). Paired t test was performed (between MVNSe (a) or MVMor (b) 
treated conditions to their FIP treated counterparts) to obtain the P-values. 
***p≤0.0003, **p=0.0017, *p=0.0421. 
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4.3 DISCUSSION: 
In this chapter, I investigated ADCC as a possible mechanism of 
neutrophil mediated MV oncolysis (neutrophil-specific lysis). Except in Jurkat 
cells infected with MVMor, ADCC was not shown to be a mechanism. 
Neutrophil-specific lysis also varied among the different cell lines used and 
most interestingly, the two vaccine strains of MV used showed unexpected 
and highly significant difference in their ability to mediate a neutrophil effector 
response, specifically in the Jurkat cells. 
ADCC has been established as a mechanism by which effector cells 
can kill target cells infected by different viruses like HSV416,417, VZV418 and 
MV419 after natural infection. The presence of ADCC was shown to correlate 
with reduction in viral load after WT MV infection244,420. Previous data from 
my lab have shown enhanced killing of target tumours in SCID xenografts 
when MV using a murine GMCSF was used, which also correlated with 
higher neutrophil infiltration280. From data in chapter 3, in-vivo observation of 
neutrophil mediated enhancement of MV killing was very clear in the two B-
cell malignancy models, but different susceptibility to neutrophils in the two 
models suggested more than one mechanism of neutrophil mediated MV 
oncolysis in play. SCID mice lack any adaptive immune cells and therefore 
are unable to produce antibodies, also, as murine cells are not susceptible to 
MV infection, the enhancement of MV oncolysis by MVhGCSF in the Raji 
SCID xenografts with increased neutrophil infiltration in the spleen, that was 
observed is unlikely by ADCC in the models described in-vivo. However, 
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there is a report suggesting that certain IgGs can enhance MV entry and 
infection in murine monocytes and macrophages, via a Fc receptor mediated 
mechanism421, and also in older SCID mice presence of mature lymphocytes 
has been reported as they are known to be “leaky”422, and therefore some 
direct infection of the effector cells and presence of ADCC like effect cannot 
be completely ruled out even in the in-vivo models. 
Choosing an appropriate model to test the role of the immune system 
and the mechanisms involved in oncolysis can be tricky due to difference in 
the effector functions between different species423. Though mice are frequent 
experimental tools of choice, and have helped us understand the working of 
the human immune system, there are significant differences and known 
discrepancies in both innate and adaptive immunity424. The overall structure 
of the immune system in mice and humans are similar, but among other 
differences, the balance of lymphocytes and neutrophils is striking, with 
mouse blood more rich in lymphocyte (75-90% lymphocytes, 10-25% 
neutrophils), while human blood more rich in neutrophils (50-70% 
neutrophils, 30-50% lymphocytes)425. Mouse and human neutrophils also 
differ in their Fc receptor expression. In mice a single gene encodes for each 
class of Fc receptors whereas in human eight genes have been identified426. 
Additionally, mice don't express FcαRI, FcγRIIa, FcγRIIIB and FcγRIIC, 
which are important Fc receptors present on human neutrophils, and there is 
also difference in the IgG sub classes that are present in mice and 
humans425. Moreover, mouse FcγRI is mainly expressed on macrophages. 
Further, human FcγRI, which is a high affinity receptor does not bind mouse 
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IgG1423. How these differences can affect their functions in studying the 
effector mechanism is still not very clear. Besides, MV does not readily infect 
and replicate within murine cells, therefore the in-vivo observations in mice 
will not always reciprocate the same mechanisms that may be expected in 
human in-vivo. Human donors were used as the source of neutrophils in this 
chapter due to the wider clinical relevance, in the hope of providing better 
insight into the potential mechanisms in trial scenarios. 
The neutrophil-specific lysis was variable between the three cell lines 
in-vitro. Jurkat cells were particularly susceptible to neutrophil-specific lysis 
with MVNSe infection. However, it was only Jurkat cells infected with MVMor 
that were lysed via an apparent ADCC. The two B-ALL cell lines and the 
other T-ALL cell line DND41 did not show any susceptibility to neutrophil-
mediated ADCC. 
By contrast to the apparent ADCC finding with MVMor infected Jurkat 
cells, there was significant decrease in the neutrophil-specific lysis of MVNSe 
infected Jurkat cells upon addition of serum. One possible explanation is 
neutralisation of the virus by the anti-MV neutralising antibody present in the 
serum174. Pooled serum from donors with high anti-MV antibody was used for 
the ADCC experiments in this chapter. Anti-MV serum contains both 
neutralising and non-neutralising (ADCC and complement-mediated lysis) 
antibodies. Neutralising antibodies against both MV-F and MV-H are present 
in the serum, with majority of neutralising antibody against MV-H240,241. After 
natural MV infection, most robust antibody response is observed against N 
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protein followed by MV-H, MV-F and to a very small extent against MV-M239. 
Though MV-N is an intracellular protein, it has been shown to associate with 
the FcγRIIB in the late endocytic compartment and transported to the cell 
surface, where it interacts with other non-infected cells427 and therefore might 
be important in ADCC. Since antibodies against different MV proteins could 
be capable of mediating ADCC, the purpose and possible advantage of using 
pooled serum from patients in the ADCC experiment was to cover the whole 
repertoire of anti-MV antibodies that might be relevant in ADCC. However, a 
high level of anti-MV IgG would not necessarily reflect a high level of 
antibody with capacity to mediate ADCC419. 
Jurkat cells were the only cell line where neutrophil-mediated lysis 
observed was highest after MV infection. They were first chosen in the lab as 
they belong to the lymphoid lineage and are a cell line of choice for 
cytotoxicity assay studies. They are also sensitive to TRAIL mediated killing 
and MV has been shown to upregulate TRAIL via degranulation of 
neutrophils357. Jurkat cells are often used to study acute leukaemia, cell 
signalling, expression of different surface receptors or studying mechanisms 
of action of anti-cancer drugs and radiation428. They are known to produce 
high levels of IL-2 upon stimulation with phorbol esters, lectins or monoclonal 
antibodies429. After screening several leukaemic T and B-cell lines, Jurkat 
cells were shown to produce 100-300 times more IL2 upon stimulation with 
lectin like phytohaemagglutinin (PHA) and concanavalin A (con A)430. 
Moreover, Jurkat cells have also been shown to produce IL-2, when 
persistently infected with vaccinia virus431. The IL2 receptor is present on 
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neutrophils432, and the binding of the IL2 to the IL2 receptor has been shown 
to have important regulatory effect on neutrophil functions433. It is possible 
that MV infection stimulates Jurkat cells to produce IL2, which can modulate 
the function of neutrophils via the IL2 receptor to induce higher neutrophil 
toxicity in this cell line and not the others, as observed in the experiments in 
this chapter. T-cells do not normally express Fc receptors, however some T-
cell lines like the CD4+ T lymphoblastoid cell line C8166 have been shown to 
express various Fc receptors434. Jurkat cells have also been shown to 
express the FcγRIII receptor in our lab (Dr. Zhang, unpublished data), and 
others have shown that FcγRIII receptor can activate and mediate both 
proximal and distal signalling in Jurkat cells and it is cell type restricted435. 
This allows another possible alternative explanation to ADCC in my findings, 
which are very specific to Jurkat cells. Fc receptors on the Jurkat may be 
able to bind to the Fc portion of the anti-MV-H antibody in the serum, which 
can bind to MV-H proteins expressed on the neutrophils and bring about lysis 
by “reverse ADCC”436. This can lead to induction of signalling through both 
FcγRIII on Jurkat cells and Fc receptors on neutrophils leading to enhanced 
killing of Jurkat cells. 
The two different vaccine strains acting very differently on neutrophils 
to cause different cytotoxic effects in the Jurkat cells, was also unexpected. 
There are few differences between the two vaccine strains of virus. Firstly, 
there are some known differences in the coding and non-coding sequences 
between the MV strains414. MVMor and MVNSe are both derived from the 
Edmonston seed B (see 1.2.4). To obtain MVNSe MV-tag-Edmonston B was 
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slightly modified, to exhibit unique NarI and SpeI sites (MVNSe stands for 
“Nar-Spe eliminiated”)180 to enable easier cloning. MVNSe is derived from 
p(+)MV15894181 which contains the Edmonston molecular clone Genebank 
Z66517 with 13 point mutations including the “tag” AC>GA at positions 1818-
9 of the genome and a point mutation in P gene resulting in 272Cys>272Arg 
mutation in the V coding region, that disables this protein. MVNSe contains 
an additional sequence CGTACGATGACGTCCTAG inserted just after 
nucleotide 3368 to introduce unique restriction sites while maintaining the 
genome length in compliance with the rule of six (www.addgene.org/58799/). 
MVMor also has been sequenced413,414 and differs from the MVNSe only in 
few amino acids, isolated to the H and L genes232. Whether and how these 
minor genetic differences may play a role in my findings is not clear. 
Secondly, the difference could be at the functional level with dissimilarity in 
expression of the MV glycoproteins on the cell surface after infection with 
different strains. Functional differences have been reported between 
polymerase L protein of different vaccine and WT MV strains and might 
depend on the passage history of each attenuated strain437. And thirdly, the 
known difference between the fusogenicity of the two strains could be 
responsible for the differences observed50. 
I was able to explore one of the potential functional differences by 
assessing the MV-H expression on Jurkat cells after infection with either of 
the viruses. MV-H expression was much higher after infection with MVMor 
than with MVNSe. This was in keeping with the hypothesis that the surface 
area of cell membrane expressing the viral envelope protein MV-H may be 
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higher overall in the individually infected cells after infection with the less 
fusogenic MVMor (Fig 4-8a) compared to in the large syncytia formed by the 
highly fusogenic MVNSe (Fig 4-8b). Therefore, blocking of fusion with FIP 
showed slight increased in the %MV-H expression on Jurkat cells infected 
with MVNSe, possibly due to the increase in surface area of cell membrane 
expressing MV-H as hypothesised (Fig 4-8). Interestingly, the MVMor 
infected Jurkat cells showed slight abrogation of %MV-H expression upon 
blocking of fusion, which was unexpected and opposite of the hypothesis. 
One probable explanation could be decrease in the level of infection in the 
cells (and therefore MV-H expression) due to inhibition in viral spread 
resulting from blocking of fusion, as cell-cell fusion is one known way by 
which the virus can spread438. Additionally, as the MV-H expression was 
determined by flow cytometry, there is a possibility of an experimental bias in 
this observation, whereby large syncytia might ‘break’ while passing through 
the flow cytometer, artificially reducing the level of cell surface MV-H 
expression by concentrating the observations to cells which are less well 
infected. Furthermore, determination of syncytia formation by flow cytometry 
requires the capacity to distinguish between simple cell aggregates and 
genuine doublets due to actual syncytium formation. When syncytia are 
observed on a flow cytometer, their FSC/SSC profile should be very similar 
to that of doublets, i.e. they are large (high FSC-A) and have unusual shapes 
(high FSC-W) and granularity (high SSC). These characteristics would 
typically be gated out of the analysis439. So, I have tried to interpret any data 
where cell-cell fusion is estimated by flow cytometry cautiously. 
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In this chapter I began to observe the effects of fusion inhibition and 
its relation to tumour cell cytotoxicity. It has been reported that blocking virus 
mediated cell-cell fusion can lead to abrogation of tumour cell cytotoxicity440, 
where addition of FIP to tumour cells infected with a modified fusogenic 
strain of adenovirus, led to inhibition of syncytium formation, which in turn 
decreased the cytotoxicity. In the experiments in this chapter too, upon 
addition of FIP to the MVNSe infected Jurkat cells, there was significant 
abrogation of neutrophil-specific lysis of the Jurkat cells. 
All the data from this chapter taken together have showed that ADCC 
is not a likely mechanism of neutrophil-mediated MV oncolysis. The results in 
Jurkat cells appear as an exception and have potential alternative 
explanations. Based on the data in this chapter, I have proposed that 
possible cell-cell fusion between the neutrophils and MV-infected target cells 
might have a role to play in MV oncolysis. This will be investigated further in 
chapter 5. 
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Chapter 5: Fusion between neutrophils and target cells 
mediate cytotoxicity during measles virus oncolysis - a 
novel mechanism of oncolysis 
5.1 BACKGROUND: 
 Virus mediated fusion: 5.1.1
Numerous viruses and fusogenic viral envelope glycoproteins - termed 
“fusion membrane glycoproteins” (FMG) are reported in the literature to 
cause cell-cell fusion and multi-nucleated syncytium formation, a cytopathic 
effect (CPE) which may eventually lead to cell death, at least in-vitro. Virus 
mediated cell-cell fusion is a multistage process and is used by enveloped 
viruses primarily to gain host cell entry. For example, during MV infection, the 
interaction of the MV-H protein with its receptors (CD46/ CD150) initiates a 
conformational change in the MV-F glycoprotein, which in turn mediates 
fusion of the viral envelope and the host cell membrane, facilitating cell 
entry441. Although not characteristic of non-enveloped viruses, the oncolytic 
virus Reovirus expresses non-structural, fusion associated small 
transmembrane (FAST) proteins. FAST proteins are not necessary for 
Reovirus entry or replication in host cells; they appear to have evolved to 
mediate cell-cell fusion rather than virus-cell fusion, thereby contributing to 
the rapid dissemination of the infection442-445. 
Virus-mediated cell-cell fusion has been shown to induce apoptosis. 
For instance, HIV infected CD4+ cells show extensive CPE in-vitro. Co-
  
209 
culturing CD4+ cells with HIV glycoprotein or MV glycoprotein-expressing 
cells led to apoptosis, which was exclusively induced by cell-cell fusion446. In 
another study, Sendai virus infection of primary paediatric bronchial epithelial 
cells induced enhanced CPE with evidence of syncytia that led to apoptosis. 
The observed syncytia were associated with secretion of several pro-
inflammatory cytokines - RANTES, TRAIL, IP-10, IL-6, IL-8, etc.447. 
 Measles Virus-mediated fusion: 5.1.2
MV-induced syncytia have been implicated in stimulating anti-viral 
immune responses. In a normal human fibroblast cell line (IMR-90) and in 
A549 cancer cells MV-induced syncytia led to the down regulation of different 
cell cycle regulators of the retinoblastoma protein (pRB) pathway and the 
fused cells showed a senescent phenotype with a halt in cell cycle 
progression448. Furthermore, MV-induced syncytia in human epithelial cells 
and in mature DCs, led to IFNβ amplification in epithelial cells and both 
IFNα/β amplification in mature DCs. Interestingly, IFNβ amplification was 
inhibited in a dose dependent manner by FIP in the epithelial cells. Moreover, 
MV-induced syncytia in epithelial cells showed highly dynamic behavior with 
an unexpectedly long lifespan449. This finding was later echoed by findings 
from our lab, where neutrophils from healthy donors infected with oncolytic 
MV became activated and survived longer ex-vivo than uninfected cells, 
although in this study, syncytia formation between neutrophils was not 
investigated357. 
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Cell-cell fusion within different cells and tissues after MV infection can 
be variable. Our own published data show substantial differences in the 
levels of syncytia formation - as an example there was minimal cell-cell 
fusion in MV-infected primary patient chronic lymphocytic leukaemia (low 
grade B-cell malignancy) cells for which the reasons were not clear; since the 
virus demonstrably replicated within the cells and the MV-H and MV-F 
expression was confirmed in all cases indicating that lack of cell-cell fusion in 
these cells was not due to a failure of viral envelope protein expression386. In 
spite of this, published data on MV therapy in a variety of tumours 
consistently report substantial induction of fusion in tumour targets, at least 
in-vitro51,52,175,176,260,450, and thus regarded as a potential mechanism of MV-
induced oncolysis. 
 Other FMG-mediated fusion: 5.1.3
Virally derived FMGs reported in the literature as having potential 
relevance to cancer therapy include not only F and H glycoproteins of MV, 
but also the rhabdoviral VSV-G envelope451 and retroviral Gibbon Ape 
Leukaemia Virus (GALV) envelope protein452. F/H and GALV delivered by 
adenoviral and lentiviral vectors have shown therapeutic activity in xenograft 
models453. When compared to herpes simplex virus thymidine kinase or 
cytosine deaminase suicide genes, one log more potent cytotoxicity was 
observed by using FMGs in an in-vivo model of human xenograft, with a 
significant bystander effect454. Cell death observed was due to sequestration 
of cell nuclei and nuclear fusion. In this model, syncytia formation was 
accompanied by the induction of immune-stimulatory heat shock proteins, 
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which can act as non-specific stimulants of innate immune system454. FMG 
mediated cell death occurs predominantly by non-apoptotic pathways with 
mitochondrial failure and ATP depletion. With progression of syncytium 
formation, the nuclei fuse; this is associated with premature chromosome 
condensation and autophagic degeneration and the subsequent release of 
the cellular vesicles termed ‘syncytiosomes’ (vesicles reminiscent of 
exosomes)455,456. 
 Fusion mediated immunogenicity: 5.1.4
The immune-stimulatory mechanisms of FMG mediated cell death 
have been exploited therapeutically to enhance anti-tumour immune 
responses457. Loading DCs with fusing tumour cells has been used as a 
strategy to cross present tumour antigens to T-cells457. In a human in-vitro 
model, syncytiosomes from dying syncytia more effectively loaded DCs for 
cross presentation of a melanoma tumour-associated antigen for T-cell 
priming than normal cells or cells killed by irradiation455. Additionally, GALV-
mediated cell fusion reversed the suppressive effect of human melanoma 
Mel888 cells on DC maturation and potentiated IL-12 production by activated 
DCs. These DCs when loaded with fusing Mel888 cells were able to present 
the melanoma specific cytotoxic response against Mel888 in-vitro453. In a 
different mouse melanoma model, tumour cells that were fused ex-vivo acted 
as a potent vaccine against a live tumour challenge and against a pre-
established disease457. 
  
212 
 Replicating fusogenic viruses as oncolytic agents: 5.1.5
The concept of fusogenicity as a therapeutic component of replicating 
virus therapy has also been explored using viruses other than MV. Several 
studies have reported the implication of direct cell-cell fusion to enhance 
oncolytic virotherapy. Bioknife™, a modified Sendai virus (SeV) with 
enhanced fusogenic ability is oncolytic in different tumour types in-vitro 
where cell-cell fusion and cell death were observed458. A single Gly-to-Ala 
substitution in the SeV F protein generates a hyperfusogenic mutant, which 
is more cytopathic in prostate cancer cell lines in-vitro than the non-fusogenic 
counterpart. Additionally, prostate cancer xenografts responded better to 
therapy with the hyperfusogenic mutant SeV compared to the non-fusogenic 
counterpart459. Moreover, oncolytic adenovirus expressing the GALV 
envelope glycoprotein under the control of the adenovirus major late 
promoter (ICOVIR16), induced extensive syncytia formation and enhanced 
tumour cell killing in various tumour types including melanoma and 
pancreatic cancer both in-vitro and in-vivo compared to the non-fusogenic 
virus (ICOVIR15). In-vivo injection of ICOVIR16 led to tumour cell fusion in-
vivo with extensive and enhanced viral spread within the tumour460. Another 
fusogenic adenovirus created by expressing the MV-H and MV-F proteins 
replacing the E1 gene of the adenovirus showed enhanced cytotoxicity in 
HER911 cells (human embryonic retinoblast 911) compared to the non-
fusogenic control440. 
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 Fusion inhibitory peptide: 5.1.6
Fusion inhibitory peptide or FIP (Z-D-Phe-Phe-Gly-OH) is a 
polypeptide originally designed to resemble the N-terminal regions of the 
paramyxovirus F1 polypeptide or the myxovirus HA2 polypeptide
461,462. The 
mechanism of cell-cell fusion relies on a conformational change in the lipid 
bilayer membrane structure, which is temperature sensitive. FIP can raise 
the temperature of the lipid bilayer by 10 degrees thereby disrupting the 
conformational change, which inhibits the cell membranes from fusing461. FIP 
may also compete for the binding sites on the cell plasma membranes and 
inhibit fusion and has been shown to work by stabilising the H-F complex463. 
FIP has mainly been used in-vitro to block cell-cell fusion. The MV-induced 
syncytia are formed by co-ordinated action of MV-H and MV-F glycoproteins. 
MV-H engages with its receptor, which leads to structural transition in MV-F 
that facilitates fusion of MV with target cell membrane. FIP can interfere with 
this structural transition of MV-F thereby inhibiting cell infection at the entry 
stage464. Exploiting this characteristic, FIP has been recently used to prevent 
MV infection in-vivo in animal models, where intra-nasal administration 
results in accumulation of the peptide in the airway epithelium that efficiently 
blocks MV infection464. 
 The current study: 5.1.7
In this chapter, the question of whether fusion between MV-infected 
tumour cells and neutrophils can activate neutrophils and engage their 
cytotoxic mechanisms will be investigated. The hypothesis was derived from 
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findings in chapter 4 in which the neutrophil-specific lysis of MV-infected 
Jurkat cells was higher after target cells were infected with a fusogenic 
MVNSe strain than after infection with the less fusogenic MVMor strain. The 
complete abrogation of neutrophil-specific lysis in the presence of FIP was 
also striking. 
 Hypothesis: 5.1.8
The cytotoxic effector function(s) of MV-infected neutrophils relates, at 
least in part, to fusion between neutrophils and target cells. 
5.1.8.1 Aims: 
1. To determine the effect of fusion on degranulation and reactive 
oxygen species (ROS) generation in neutrophils when co-cultured with 
MV-infected targets. 
2. To determine the effect of fusion on type I IFN production and RLR 
signalling pathway in neutrophils when co-cultured with MV-infected 
targets. 
3. To visualise fusion between neutrophil and MV-infected targets. 
5.2 METHODS: 
 Neutrophil degranulation: 5.2.1
Neutrophils were added to MVNSe infected Jurkat cells (24hpi) at an 
E:T ratio of 8:1, and co-cultured in the presence or absence of FIP. Twenty-
four hours later, the cells were collected, washed and resuspended in 
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1xPBS. To determine neutrophil degranulation, the cells were stained with 
CD35 FITC, CD63 FITC, CD66b FITC or IgG isotype antibodies before 
performing the flow cytometric analysis as described in chapter 2, section 
2.9. The neutrophil population was gated on the forward scatter (FSC)/side 
scatter (SSC) in the co-cultures and the percentage degranulation calculated 
based on the isotype control. The results were compared to the uninfected 
co-culture controls. This experiment was repeated in neutrophils from 3 
donors. 
 ROS production: 5.2.2
Neutrophils were added to MVNSe infected Jurkat cells (24hpi) at an 
E:T ratio of 8:1, and co-cultured in the presence or absence of FIP. Twenty-
four hours later, the cells were collected, washed and resuspended in 
1xPBS. To determine ROS generation, the cells were stained with 5mM 
CellROX® Green reagent (Life TechnologiesTM) according to manufacturer’s 
instructions and then washed 3 times with 1xPBS before performing the flow 
cytometric analysis as described in chapter 2, section 2.9. The neutrophil 
population was gated on the FSC/SSC in the co-cultures and the %ROS 
generation was calculated only in the neutrophil population compared to the 
uninfected controls. This experiment was performed in 3 different neutrophil 
donors. 
 RIG-I/MDA5/MAVS gene expression: 5.2.3
Neutrophils were added to MVNSe infected Jurkat cells (24hpi) at an 
E:T ratio of 8:1, and co-cultured in the presence or absence of FIP. Twenty-
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four hours, later the cells were collected, and total RNA was extracted using 
TRIzol® extraction (chapter 2, section 2.8.4). First strand cDNA was 
synthesised from the total RNA (chapter 2, section 2.8.5) and then the 
relative expression of RIG-I, MDA5 and MAVS was determined by Quanti 
Tect® Primer assay (Qiagen, UK) as described in chapter 2, section 2.8.6. 
 Live cell imaging: 5.2.4
5.2.4.1 Jurkat cells: 
Jurkat cells were infected with MVNSeGFP at an MOI of 1.0. To 
immobilise the cells, they were aliquoted into 24-well plates coated with 
20μg/ml of Fibronectin (R&D Systems, USA). At 24hpi, either neutrophils, 
extracted from a healthy donor or uninfected Jurkat cell controls were stained 
with 3μM concentration of CellTrackerTM Red CMTPX Dye (Molecular 
Probes, Life technologies) for 30-45mins in serum free medium (RPMI1640, 
pre-warmed at 37°C) according to manufacturer’s guidelines. The cells were 
then washed 5-6 times and added onto the infected Jurkat cells at a ratio of 
1:1. The cells in co-culture were then imaged on a Nikon ECLIPSE Ti-S 
inverted microscope system for 2-3 hours every 5mins using the 40X ELWD 
(extra length working distance) objective, to facilitate imaging through plastic. 
The sequence of images was stitched together and analysed using FIJI 
(ImageJ) software. 
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5.2.4.2 Vero cells: 
Vero cells were plated at 0.5x106 per well in a 12-well tissue culture 
plate and infected with MVNSeGFP at an MOI of 1.0. Twenty-four hpi the 
neutrophils were extracted and stained as described before (5.2.4.1) and 
added to the infected Jurkat cells. They were then imaged on a Nikon 
ECLIPSE Ti-S inverted microscope system for the first 3 hours every 5mins, 
and the next 2 hours every 10mins using the 40X ELWD objective and 
analysed using FIJI (ImageJ) software. 
5.3 RESULTS: 
 Neutrophil degranulation when co-cultured with MVNSe infected 5.3.1
Jurkat cells in the presence and absence of FIP: 
Direct MVMor infection of neutrophils has already been shown to lead 
to neutrophil degranulation357. Neutrophil degranulation is a multi-stage 
process, which leads to release of the granule contents into the extracellular 
or phagolysosomal spaces and fusion of membranes319. The granules 
translocate to the neutrophil cell surface, where they interact with the lipid 
bilayer, leading to priming of the granules. This facilitates rapid fusion of the 
granule membrane to the neutrophil membrane, thereby releasing the 
granule contents318, showing fusion as an inherent mechanism during 
neutrophil degranulation. To determine whether co-culture of MVNSe 
infected Jurkat target cells with neutrophils could enhance neutrophil 
degranulation, MVNSe infected Jurkat cells were incubated with neutrophils 
(N=3) from healthy donors in the presence or absence of FIP for 24 hours. 
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The cells were then analysed by flow cytometry for the presence of granule 
markers on the cell surface. The gating strategy is shown in Fig 5-1. 
FSC/SSC was used to gate on the neutrophil population (Fig 5-1a). Based on 
the isotype control (Fig 5-1b), the percentage degranulation (Fig 5-1c) and 
MFI of degranulation were calculated on the neutrophils for degranulation 
markers CD66b (specific granules), CD35 (secretory vesicles) and CD63 
(azurophilic granules). The representative FACS histogram plots for each of 
the degranulation markers are shown in Fig 5-2. FIP did not have any direct 
effect on neutrophil degranulation per se, as is evident from the uninfected 
controls treated with FIP (Fig 5-3, 5-4, 5-5). No significant change in the 
percentage of neutrophils expressing CD66b (Fig 5-3a) and CD35 (Fig 5-4a) 
or in the MFI (Fig 5-3b; Fig 5-4b) of these two markers was observed on co-
culture with MVNSe infected Jurkat targets and FIP did not have any effect 
on those processes. 
By contrast, the percentage of neutrophils expressing azurophilic 
granule markers CD63 on their cell surface (Fig 5-5a) and MFI of CD63 (Fig 
5-5b) significantly increased upon co-culture with MV-infected targets 
(p=0.0073 and p=0.0494 respectively) compared to the uninfected targets. 
Moreover, the percentage of CD63 was significantly abrogated upon blocking 
of fusion with FIP (p=0.0417). However, the MFI reduction upon addition of 
FIP though evident, was not statistically significant. 
Overall, the data showed that neutrophil degranulation was variably 
affected when in contact with MVNSe infected Jurkat target cells compared 
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to the uninfected Jurkat cell controls; more affected was azurophilic granules 
(CD63). When fusion was blocked, there was abrogation in degranulation, 
which was most significant in the percentage of azurophilic granules, 
suggesting that MVNSe infection of Jurkat target cells plays a role in 
neutrophil degranulation upon co-culture. 
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Figure 5-1: Gating strategy to assess degranulation markers on neutrophils in co-culture: Representative FACS plots (from MVNSe 
infected Jurkat cells showing %CD63 expression on the FITC channel) showing the gating strategy used to assess neutrophil degranulation. 
Based on the FSC/SSC in Jurkat cells and neutrophil co-culture, neutrophil subset was gated (a). The degranulation percentage was 
determined on the neutrophil population alone by FITC conjugated antibodies. The quadrant gates for FITC isotype antibody control were set 
(b), based on which the percentage degranulation on neutrophils was determined (c).  
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Figure 5-2: Representative histogram FACS plots for neutrophil granules marker expression on neutrophils in co-culture: 
Representative histogram FACS plots are shown for CD66b, CD35 and CD63 on neutrophils co-cultured with uninfected (light grey and dark 
grey lines) or MVNSe infected (light pink and dark pink lines) Jurkat cells in the presence (darker shades) or absence (lighter shades) of FIP. 
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Figure 5-3: Specific granules marker expression on neutrophils in co-culture: The percentage of cells expressing (% positive cells) (a) 
MFI (b) of CD66b on neutrophils at baseline (white) (n=3), after MVNSe infection (n=3) in the presence (dark pink) or absence (light pink) of FIP 
and uninfected control (n=3) in the presence (dark grey) or absence (light grey) of FIP. MFI of the degranulation marker was normalised against 
the respective isotype controls. ‘Baseline’ represents the expression on freshly isolated neutrophils. The bars show the mean±SEM. Paired t 
test was performed to obtain the P-values. 
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Figure 5-4: Secretory vesicle marker expression on neutrophils in co-culture: The percentage of cells expressing (% positive cells) (a) and 
MFI (b) of CD35 on neutrophils at baseline (white) (n=3), after MVNSe infection (n=3) in the presence (dark pink) or absence (light pink) of FIP 
and uninfected control (n=3) in the presence (dark grey) or absence (light grey) of FIP. MFI of the degranulation marker was normalised against 
the respective isotype controls. ‘Baseline’ represents the expression on freshly isolated neutrophils. The bars show the mean±SEM. Paired t 
test was performed to obtain the P-values. 
  
2
2
4
 
 
 
Figure 5-5: Azurophilic granules marker expression on neutrophils in co-culture: The percentage of cells expressing (% positive cells) (a) 
and MFI (b) of CD63 on neutrophils at baseline (white) (n=3), after MVNSe infection (n=3) in the presence (dark pink) or absence (light pink) of 
FIP and uninfected control (n=3) in the presence (dark grey) or absence (light grey) of FIP. MFI of the degranulation marker was normalised 
against the respective isotype controls. ‘Baseline’ represents the expression on freshly isolated neutrophils. The bars show the mean±SEM. 
Paired t test was performed to obtain the P-values. 
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 ROS generation by neutrophils when co-cultured with MV-5.3.2
infected Jurkat cells in the presence and absence of FIP: 
ROS generation precedes neutrophil degranulation465. In order to 
investigate if MV infection of targets cells had any effect on ROS generation 
by neutrophils, Jurkat cells were infected with MV, and 24hpi, neutrophils 
from healthy donors (N=3) were added at 8:1 E:T ratio. Experiments were 
carried out in the presence or absence of FIP to test the role of cell-cell 
fusion. Freshly extracted neutrophils were used to determine the baseline 
ROS levels. The gating strategy is shown in Fig 5-6 on representative FACS 
plots. Within the neutrophil and target cell (infected/uninfected) co-culture, 
the percentage of cells expressing ROS was calculated on the neutrophil 
population alone (Fig 5-6a). The gates were set on the ROS production by 
neutrophils in co-culture with uninfected Jurkat cells (Fig 5-6b) in the 
presence or absence of FIP, based on which, the ROS percentage and MFI 
in FIP (Fig5-6c) and no FIP (Fig 5-6d) infected conditions were determined. 
Figure 5-7a and b show the percentage cells expressing ROS and the 
MFI of ROS expressing cells, respectively. Neutrophils co-cultured with MV-
infected Jurkat cells showed a higher MFI and percentage of cells stained 
positive for ROS compared to neutrophils co-cultured with uninfected Jurkat 
cells. The increase in ROS production was abrogated upon blocking of cell-
cell fusion with FIP. However, the observations were not statistically 
significant possibly due to the low power of the experiment. 
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Figure 5-6: Gating strategy to assess ROS production by neutrophils in co-culture: Representative FACS plots showing the gating 
strategy used to assess ROS production. Based on the FSC/SSC in Jurkats and neutrophil co-culture, neutrophil subset was gated (pink gate) 
(a). The ROS percentage was determined on the neutrophil population alone by CellROX® green reagent in the FITC channel. The quadrant 
gates for uninfected co-culture control was set to determine the baseline ROS production (b), based on which the percentage ROS production 
by neutrophils in FIP (c) and no FIP (d) conditions were determined. 
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Figure 5-7: ROS on neutrophils in co-culture: The percentage of cells expressing (% positive cells) (a) and MFI (b) of ROS on neutrophils at 
baseline (white) (n=3), after MVNSe infection (n=3) in the presence (dark pink) or absence (light pink) of FIP and uninfected control (n=3) in the 
presence (dark grey) or absence (light grey) of FIP. ‘Baseline’ represents the ROS expression on freshly isolated neutrophils. The bars show 
the mean±SEM. 
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 Neutrophils produce significant amounts of IFNα and IFNβ when 5.3.3
co-cultured with MV-infected Jurkat cells, which disappears in 
the presence of FIP: 
To test whether fusion between the MV-infected Jurkat target cells 
and neutrophils can lead to type I IFN production, infected Jurkat target cells 
were co-cultured with neutrophils for 24 hours in the presence or absence of 
FIP and the supernatant from the cultures was collected and quantified for 
IFNα/β production by ELISA. A number of important control conditions were 
included to ensure that any IFN produced was from the neutrophils and not 
the target cells and that it was definitely a response to MV infection; target 
cells alone, MV-infected target cells alone, neutrophils alone, MV-infected 
neutrophils alone and target cells with neutrophils but no MV were all 
included as experimental conditions and each was repeated with the addition 
of FIP (N=3). Figure 5-8a shows the results for IFNα production. Neutrophils 
produced 161-5594 pg/ml of IFNα but only when co-cultured with MV-
infected Jurkat cells (light pink bars). None of the other experimental control 
conditions generated any IFNα, confirming that the virus, target cells and 
neutrophils were all necessary for the interferon response. There was a very 
substantial reduction in IFNα production upon addition of FIP (0-315pg/ml). 
The experiment failed to reach significance due to very low IFNα produced 
by one donor (161pg/ml). Therefore, the absolute quantities of IFNα 
produced in the infected Jurkat cell/neutrophil co-culture in the presence or 
absence of FIP were analysed separately and are shown in Fig 5-8b. Figure 
5-8c shows the data for IFNβ. Neutrophils co-cultured with MV-infected 
Jurkat cells secreted IFNβ in the range of 54-92pg/ml (light pink bar), which 
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was significantly (p=0.0111) abrogated upon addition of FIP (0-2.9pg/ml). 
Again, there was little or no IFNβ production without the presence of both 
MV-infected target cells plus neutrophils. The absolute quantities of IFNβ 
produced in the infected Jurkat cell/neutrophil co-culture in the presence or 
absence of FIP were analysed separately and are shown in Fig 5-8d. 
These data indicated that neutrophils are the source of IFNs after 
contact with MV-infected target cells and that IFN is produced specifically 
when the neutrophils are in contact with the MV-infected Jurkat target cells. 
The substantial reduction in the IFN production in the presence of FIP 
suggested that fusion between neutrophils and MV-infected Jurkat cells 
might be involved in the generation of an IFN response. 
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Figure 5-8: Effect of FIP on type I IFN production in Jurkat/neutrophil co-
culture: IFNα (a) and IFNβ (c) production in infected and uninfected Jurkats, 
neutrophils and Jurkat/neutrophil co-culture in the presence or absence of FIP in all 
conditions by ELISA. IFNα (b) and IFNβ (d) production only in MV-infected 
Jurkat/neutrophil co-culture conditions in the presence (dark pink dots) or absence 
(light pink dots) of FIP. The bars in (a) and (c) show the mean±SEM. Paired t test 
was performed to obtain the P-values. 
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 The (RIG-I like receptor) RLR signalling pathway is upregulated 5.3.4
when MV-infected Jurkat cells are co-cultured with neutrophils 
compared to neutrophils and Jurkat cells alone. 
To determine the upstream events of the type I IFN production, the 
induction of genes in the RLR signalling pathway was quantified by RQPCR. 
Similarly to the previous experiments, this was carried out in the presence 
and absence of FIP in order to evaluate the contribution of fusion. Jurkat 
cells and/or neutrophils were infected and either co-cultured or incubated on 
their own for 24 hours and the RIG-I/MDA5 and MAVS gene expression 
determined. The level of expression was normalised to the uninfected 
controls of each condition. The data are shown in Fig 5-9. Both RIG-I and 
MDA5 were very modestly upregulated in neutrophils but not Jurkats after 
direct infection with MV. However, after co-culture of neutrophils with infected 
Jurkat cells, expression of both RIG-I and MDA5 were increased 20-40 fold 
with some reduction upon FIP addition. There was no significant upregulation 
of MAVS in any of the conditions. These data show that the presence of both 
MV-infected target cells and neutrophils together is important for activation of 
the RLR signalling pathway. Since minimal upregulation was observed in 
Jurkat cells infected with MV compared to neutrophils infected with MV, it can 
be speculated that when in co-culture, MV-infected Jurkat cells stimulate the 
RLR signalling pathway particularly in the neutrophils. The relative lack of 
change upon FIP addition suggests that this upstream step is not fusion-
related. 
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Figure 5-9: Quantification of genes of the RLR signalling pathway in Jurkat/neutrophil co-cultures: RIG-I, MDA5 and MAVS genes 
quantified by RQPCR in MV-infected Jurkat cells on their own (grey bars), neutrophils on their own (blue bars) and Jurkat/neutrophil co-culture 
(pink bars) in the presence (dark shades) or absence (light shades) of FIP. The data is normalised to uninfected controls and represented as 
relative quantities to GAPDH house keeping gene by ΔΔCt method. N=3. The data is represented as mean±SEM.  
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 IFN does not have any direct cytotoxic effect on MV-infected or 5.3.5
uninfected Jurkat cells 
In order to test whether type I IFN generation by neutrophils could be, 
in part, responsible for the target cell cytotoxicity observed, exogenous IFN 
was added in increasing concentrations to Jurkat cells which had been 
infected with MV or mock-infected. Both cell numbers (Figs 5-10a and b) and 
percentage cell viability (Fig 5-11a and b) in uninfected controls were 
significantly higher than the MVNSe infected cells but did not change with 
increasing concentrations of IFNα or IFNβ. Taken together the data suggest 
that the production of IFN by neutrophils does not directly result in the Jurkat 
target cell cytotoxicity we observed. 
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Figure 5-10: Effect of exogenous type I IFN on Jurkat cell number: Jurkat cell numbers counted by trypan blue in uninfected (grey) and 
MVNSe infected (pink) conditions, 24hpi in variable concentrations of IFNα (a) and IFNβ (b). Paired t test was performed to obtain the P-values. 
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Figure 5-11: Effect of exogenous type I IFN on Jurkat cell viability: Percentage Jurkat cell viability determined by trypan blue in uninfected 
(grey) and MVNSe infected (pink) conditions, 24hpi in variable concentrations of IFNα (a) and IFNβ (b). Paired t test was performed to obtain 
the P-values. 
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 Neutrophils produce a significant quantity of soluble TRAIL when 5.3.6
cultured with MV-infected Jurkat cells, which is abrogated in the 
presence of FIP: 
Tumour necrosis factor (TNF) – related apoptosis-inducing ligand 
(TRAIL) is a member of the TNF superfamily, which is selectively cytotoxic in 
cancer cells and its production by neutrophils is known to be consequent on 
IFNα stimulation466. In our previous publication, MV infection of neutrophils 
was shown to induce TRAIL secretion in the absence of de novo synthesis, 
by triggering release of pre-fabricated TRAIL, via direct effect upon 
degranulation357. To test whether the observed upregulation of type I IFNs 
can lead to soluble TRAIL production, infected Jurkat target cells were co-
cultured with neutrophils for 24 hours in the presence or absence of FIP and 
the supernatant from the cultures was collected and quantified for soluble 
TRAIL production by ELISA (Fig 5-12). Important control conditions similar to 
IFN secretion ELISA experiment were included – target cells alone, MV-
infected target cells alone, neutrophils alone, MV-infected neutrophils alone 
and target cells with neutrophils but no MV. Neutrophils co-cultured with MV-
infected Jurkat cells produced significantly high levels of soluble TRAIL (1000 
– 1200pg/ml) compared to neutrophils in the presence of uninfected Jurkat 
cells (200pg/ml) (p=0.0290). In the presence of FIP, TRAIL production was 
significantly reduced (p=0.0119) to that seen in uninfected conditions (250-
500pg/ml), suggesting again that fusion between Jurkat target cells and 
neutrophils may be a key component of the cytotoxic response of 
neutrophils. 
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Figure 5-12: Effect of FIP on soluble TRAIL production in Jurkat/neutrophil co-
culture: Soluble TRAIL production determined in infected and uninfected Jurkats, 
neutrophils and Jurkat/neutrophil co-culture in the presence or absence of FIP in all 
conditions by ELISA. The bars in (a) and (c) show the mean±SEM. Paired t test was 
performed to obtain the P-values. 
 
To determine whether this quantity of TRAIL may be responsible for 
the neutrophil-mediated cytotoxicity, a dose response experiment to evaluate 
the direct effect of recombinant human TRAIL (rhTRAIL) on Jurkat cells was 
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performed. (This experiment was carried out by my colleague Dr. Zhang, and 
I have permission to include the data here). Data in Fig 5-13 shows that 
soluble TRAIL below 5000pg/ml did not induce significant cell death in Jurkat 
cells when compared to the untreated negative control (0pg/ml) in-vitro. This 
implies that, even though contact with MV-infected Jurkat cells clearly 
induces neutrophils to release soluble TRAIL, release into the supernatant in 
these experiments (or the cell milieu, in-vivo) might not be the mechanism by 
which a significant biological effect is exerted. The abrogation in TRAIL 
secretion in the presence of FIP further suggests that possible fusion 
between MV-infected Jurkat cells and neutrophils may be at least in part 
responsible for the neutrophil-mediated cytotoxicity that was observed. 
 
  
2
3
9
 
 
 
Figure 5-13: A dose response experiment of Jurkat cells to recombinant human TRAIL: Jurkat cells treated with increasing concentrations 
of soluble TRAIL in-vitro and flow cytometry analysis done to determine percentage of AnnexinV-PI positive cells. 
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 Live cell imaging show possible fusion between neutrophils and 5.3.7
MV-induced syncytium: 
All the data so far with FIP suggested, but did not prove that fusion 
between neutrophils and MV-infected target cells is an important element of 
the effects found. Therefore to be certain, live cell imaging was used to 
determine whether fusion between the infected Jurkat cells and neutrophils 
could be visualised. 
5.3.7.1 Optimisation: 
5.3.7.1.1 Basic conditions for observation of cell-cell fusion using target cells 
alone: 
To optimise the basic conditions for observation of cell-cell fusion and 
to understand the timing of the events, Jurkat cells were infected with 
MVNSeGFP and immobilised onto fibronectin-coated plates. Uninfected 
Jurkat cells, stained with 3μM CMTPX red, were added to the immobilised 
cells. Cells were imaged every 5 mins for 1.5 hours from start of co-culture at 
40X to create a time-lapse video (for full video see Appendix – SV5-1). 
Snapshots from the SV5-1 show a fusion event between the MV-GFP 
infected green Jurkat syncytium and a red uninfected single Jurkat cell at the 
20th min post start of co-culture (shown by the white arrows in Fig 5-14 and a 
purple arrow in SV5-1). The observed fusion between target cells was rapid 
and occurred within 15-20 mins of start of the co-culture. Based on this 
experiment, the infected vs. uninfected cell ratio of 1:1 was set to be the 
optimal ratio. 
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Figure 5-14: Images from MVNSeGFP infected and uninfected Jurkat cell co-culture: Uninfected Jurkat cells stained with CMTPX red dye 
(red cells) were added at 1:1 ratio to 24-well fibronectin coated tissue culture plates containing MVNSeGFP infected Jurkat cells (green), 24hpi. 
Images were taken at 40X zoom using an ELWD lens. Images from SV5-1 (Appendix) showing a fusion event (white arrows) are shown over a 
time period of 30 mins. 
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5.3.7.1.2 Basic conditions for observation of Jurkat-neutrophil fusion: 
Next, MVNSeGFP infected Jurkat cells were immobilised onto 
fibronectin coated plates and then CMTPX-stained neutrophils extracted 
freshly from a donor were added at 1:1 ratio. Imaging was carried out every 
5mins for 2.5 hours at 40X. Fig 5-15 shows snapshots from SV5-2 between 
5th and 130th min. Unlike the previous experiment with target cells alone, 
neutrophils were not observed to fuse with MVNSeGFP infected Jurkat 
syncytia. Instead, neutrophils were seen interacting and clustering beneath 
the green Jurkat syncytia at later time-points, suggesting ongoing interaction 
between the MV-induced target syncytia and uninfected neutrophils. 
However, even 2.5 hours later, no hetero-fusion events were detected. The 
whole series of events are shown in SV5-2 (white arrows) (for full video see 
Appendix). 
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Figure 5-15: Images from MVNSeGFP infected Jurkat cells and uninfected 
neutrophils in co-culture: Uninfected neutrophils stained with CMTPX red dye (red 
cells) were added to MVNSeGFP infected Jurkat cells (green) attached to 
fibronectin coated 24-well tissue culture plates, 24hpi. Images were taken at 40X 
zoom using an ELWD lens. Images from SV5-2 (Appendix) showing neutrophils 
clustering under green GFP positive MV-infected Jurkat cell syncytia (white arrows) 
are shown over a time period of 130 mins. 
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5.3.7.1.3 Fusion between neutrophils and MV-infected adherent Vero cell 
line: 
Jurkat cells and neutrophils are both non-adherent cells, making their 
visualisation on the same focal plane somewhat challenging. Therefore, as a 
proof of principle, the next experiment was designed to determine whether 
neutrophils could fuse with MV-induced syncytia. To achieve that, adherent 
Vero cells that can form a monolayer were plated onto a 12-well tissue 
culture plate and infected with MVNSeGFP at an MOI of 1.0. Red CMTPX 
stained neutrophils were added to the infected Vero cells at 1:1 ratio and 
then imaged every 5 mins for 3 hours at 40X zoom. SV5-3a and SV5-3b (for 
full video see Appendix) suggested that the neutrophils (red) might be 
adhering to the syncytia, which may be indicative of an interaction of the 
neutrophil cell membrane with the membrane of the target syncytia. The 
interacting neutrophils then collapsed and flattened on the surface of the 
syncytia (shown by the white arrow), appearing to be fusing with the syncytia. 
Finally, the dying green Vero syncytium in the same experiment shrunk and 
completely collapsed at the end of 5 hours of co-culture (for full video see 
Appendix - SV5-4), along with the interacting neutrophils, indicating 
attachment and interaction of neutrophils with the syncytia. This experiment 
suggested that neutrophils can actively interact with the MV-induced syncytia 
and possibly fuse with them, but this fusion is delayed when compared to 
target-target cell fusion. Whether the constantly changing morphology of the 
neutrophils that was observed is related to a fusion event is yet to be 
established. This is however a preliminary observation that needs to be 
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confirmed by more quantitative methods. An important consideration in this 
experiment is whether this fusion event between neutrophil and Vero 
syncytia is real and occurring at the same focal plane. Since Vero syncytia 
form a monolayer, it can therefore be presumed that the neutrophils are in 
the same plane as the syncytia. This can be further elucidated with Z-stack 
confocal imaging at different focal planes, to visualise the entirety of the 
sample. 
Preliminary imaging data indicated that visualisation of two target cells 
fusing after MV infection is possible. Additionally, neutrophils were clearly 
shown to interact closely with infected target cells (Jurkat and Vero) with 
possible fusion. 
5.4 DISCUSSION:  
In this chapter, viral infection induced fusion between infected target 
cell and effector cell was investigated as a possible novel mechanism of MV-
mediated oncolysis. Addition of FIP, which was used to block fusion, 
abrogated neutrophil mediated killing of MV-infected Jurkat cells. It was a 
significant and very consistent observation across all the 10 neutrophils from 
different healthy donors that were tested, suggesting fusion as a possible 
mechanism of target cell killing. 
Degranulation and ROS generation are two crucial mechanisms that 
activated neutrophils use to combat infection467. In a previous publication, 
MVMor infection of neutrophils was shown to lead to neutrophil degranulation 
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and neutrophil activation357. Another paramyxovirus – respiratory syncytial 
virus (RSV) that is also known to cause cell-cell fusion, has also been shown 
to stimulate neutrophil degranulation, which was determined by 
myeloperoxidase release, though the effect of fusion blocking was not 
investigated468. It was later reported that the fusion protein of RSV causes 
NADPH oxidase derived ROS production and ERK and p38 MAPK 
phosphorylation469. The effect of target-neutrophil cell fusion on neutrophil 
degranulation and ROS generation was assessed in this chapter. Typically, 
azurophilic granules undergo very limited and controlled exocytosis, due to 
their highly toxic and pathogenic content320. When MVNSe infected Jurkat 
cells were co-cultured with neutrophils, the most significant degranulation 
was of azurophilic granules, which was abrogated in the presence of FIP. 
The other granules exhibited some upregulation upon infection, which was 
also associated with fusion. However, differences in their expression levels 
were not statistically significant requiring further investigation. Furthermore, 
neutrophils, in the presence of Jurkat cells, produced higher levels of ROS 
compared to untreated neutrophils at baseline. This was further increased 
when Jurkat cells were themselves infected. The blocking of fusion led to 
reduced ROS generation by neutrophils. These experiments suggested that 
fusion between MV-infected Jurkats and neutrophils might be able to 
enhance the cytotoxic phenotype of the neutrophils, thereby making it a 
potent killer of cancer cells. 
Other players of the neutrophil cytotoxic effector response, such as 
Neutrophil Extracellular Traps (NETs), incorporated by neutrophils, might 
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also play a role in neutrophil-specific MV oncolysis470. Traditionally thought to 
be involved in bacterial infections, NETs have now emerged as important 
contenders in viral infections. NETs are comprised of sticky, complex mesh 
of de-condensed strands of nuclear DNA formed by the release of granular 
and nuclear contents of neutrophils in the extracellular space in response to 
bacterial or viral stimuli470. The fusion protein of respiratory syncytial virus 
(RSV) has been shown to promote TLR4 dependent NET formation by 
human neutrophils469. Whether NET formation is induced by measles virus 
infection of Jurkat cells is of interest and might have an effect that needs to 
be elucidated. 
The components of the IFN response pathway were investigated in 
the target cells infected with MV in the presence of neutrophils in this 
chapter. An early response to viral infection is the generation of IFNα/β, but 
the role of IFN in MV infection is not very clear237. RNA viruses induce IFNβ 
production in the cytoplasm through RIG-I, MDA5 or LGP2 or through the 
TLR3 in the endosome471. The RIG-I of the RLR pathway can recognise the 
5’-triphosphate-ended RNA of MV small RNA leader transcript. This leads to 
activation of the pathway downstream via activation of the IRF genes (IRF 
1,3,7) leading to IFN production449. Both RIG-I and MDA5 gene expression 
were significantly increased in the co-culture conditions compared to the 
individually infected cells, but addition of FIP did not have any significant 
effect. Whether other pathways involving proteins like STING, a recently 
identified adaptor molecule found on the mitochondrial membrane and 
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believed to act in conjunction with RIG-I and MAVS, have any role to play still 
needs to be elucidated472. 
In a different study, MV infection of mature DCs (mDCs) induced 
multinucleated syncytia that led to enhanced production of IFNα/β, which 
was inhibited by addition of FIP. This clearly showed the contribution of MV-
induced syncytia in an anti-viral immune response449. In this chapter, the high 
expression of the RIG-I and MDA5 genes, irrespective of low MAVS 
expression, in the co-culture experiments correlated with very high amounts 
of type I IFNs, and FIP completely abrogated the IFN production in these co-
cultures. Although production of type I IFN has been long believed to be a 
hindrance in anti-cancer virotherapy, there is growing body of evidence 
showing that they contribute to the induction of tumour associated antigen 
(TAA) specific tumour responses473. Newcastle disease virus treatment 
combined with CTLA4 blockade was reported to eradicate B16 melanomas 
through immune responses that require IFNAR1474. Also Semliki Forest virus 
was shown to elicit an anti-tumour CTL response only if the host expresses 
IFNAR1475. Type I IFN has been reported to have anti-cancer function and 
contribute in immune-surveillance and the success of conventional 
chemotherapy473. Moreover, targeted anti-cancer agents, radiotherapy and 
immunotherapy rely on type I IFN signalling, which may mainly function by 
stimulating anti-cancer immune responses473. In this chapter, infected 
neutrophils or Jurkat cells on their own, uninfected neutrophils and Jurkat 
cells in co-culture, did not produce any detectable levels of IFN, suggesting 
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neutrophils are only able to elicit an IFN response when in co-culture with 
infected Jurkat cells. 
Type I IFNs are known to directly inhibit the proliferation of tumour and 
virus infected cells and increase class I MHC expression, enhancing antigen 
recognition and is approved for systemic therapy in a variety of diseases 
including solid and haematological malignancies, multiple sclerosis and 
chronic viral hepatitis476. Nevertheless, high levels of IFN in the co-culture 
experiments were not found to be directly toxic to the infected Jurkat cells as 
treatment with increasing amounts of exogenous IFN did not have any effect 
on the target cell number and percentage of target cell viability, suggesting 
that IFN did not have a direct cytotoxic effect on the Jurkat cells in these 
experiments. 
Immune cells, such as monocytes and neutrophils, can be stimulated 
by IFNα to release biologically active soluble TRAIL. This, in turn, can exert 
selective apoptotic activities towards tumour cells and virus-infected cells477. 
MV infection of neutrophils has been shown to induce neutrophils to produce 
pre-formed soluble TRAIL from their granules357. Besides, MV-infected 
human DCs were also shown to produce functional TRAIL478. In the co-
culture experiments in this chapter, significant levels of soluble TRAIL was 
detected in the conditions where high IFNα/β levels were produced, which 
decreased in the presence of FIP. However, from previous un-published data 
from the lab, we know that soluble TRAIL below 5ng/ml is not sufficient to 
induce significant death in Jurkat cells in-vitro. Therefore, the level of soluble 
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TRAIL produced (1-1.25ng/ml) in these experiments, might not have been 
responsible for a direct cytotoxic effect on the target cells. 
All the experiments where addition of FIP abrogated the neutrophil-
specific lysis of MV-infected target cells suggested that fusion between target 
and effector cells was possibly playing a crucial role in target cell killing. 
However, the downstream event of fusion that might have a direct role in 
killing of target cells was not clear. Neutrophils have been shown to bind and 
fuse with Epstein Barr Virus (EBV) followed by penetration and subsequent 
localisation to the nucleus of the neutrophils. Visualising the fusion of the 
viral envelope with the neutrophil cell membrane by electron microscopy 
showed the presence of EBV particles inside the vacuoles, suggesting 
phagocytosis of the virus particles by the neutrophils, which was followed by 
apoptosis479. It was therefore postulated that the visualisation of neutrophils 
co-cultured with infected Jurkat cells might provide some insight into the 
actual mechanism of neutrophil mediated MV cytotoxicity of Jurkat cells. To 
investigate that, imaging experiments were designed. As both Jurkat cells 
and neutrophils are suspension cells, the main technical challenge was to 
make one adhere to the plates to form a monolayer, which needs further 
optimisation. Some of the preliminary experiments with an adherent cell line, 
Vero (which forms large syncytia upon infection with MV) and neutrophils, 
showed possible fusion events across all the area of the syncytium. This was 
a proof of principle experiment showing that neutrophils are capable of fusing 
with MV-induced syncytia. However, it was evident that MV-infected Jurkat 
cells can clearly fuse with uninfected Jurkat cells in a very short span of time. 
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Nonetheless, multiple experiments trying to show fusion between the infected 
Jurkat cells and neutrophils were not very successful due to technical 
reasons and needs further optimisation and experimentation. At the same 
time, these experiments need to be repeated in the presence of FIP, to 
attribute any of the observation to be fusion related. 
Overall, data in this chapter suggest that MV infection of Jurkat target 
cells stimulate neutrophils to develop a cytotoxic effector phenotype. All 
aspects of which are blocked by fusion inhibition and hence, may be and is 
potentially mediated by fusion between infected Jurkat cells and neutrophils. 
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Chapter 6: General Discussion 
Measles virus (MV) has been established as a candidate for oncolytic 
virotherapy of haematological malignancies480. Data from this thesis has 
contributed to adding acute lymphoblastic leukaemia (ALL) to the list of 
applicable therapeutic uses and indeed has shown that ALL is particularly 
sensitive to MV oncolysis386. Data from phase I/II clinical trials indicated use 
of oncolytic MV as a safe and well tolerated oncolytic agent173,277,292,390. 
While there is much advancement in this field, the mechanisms of oncolysis 
remain unclear. Understanding the mechanism by which MV kills cancer cells 
holds a crucial key to its continuing success. This thesis has tried to address 
some of the mechanisms that might be playing a role in MV-mediated 
oncolysis. My data show, it is extremely likely, that more than one single 
credible mechanism is in play and ‘one size fits all’ model of “MV therapy for 
cancer” probably does not exist. 
Once the virus is delivered to the specific location of tumour, direct 
oncolysis of the cancer cells alone is very unlikely to deplete all malignant 
cells satisfactorily due to the heterogeneity of the cancer microenvironment. 
The involvement of the immune system will be indispensable to generate a 
more potent response70. In previous work from my host laboratory the 
distribution of the virus within the tumour environment, even after IT injection 
was very patchy. However, the tumours regressed completely, suggesting a 
role of an anti-tumour immune response induced by the MV infection175. The 
tumours were infiltrated with neutrophils but not NK cells or macrophages. 
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This led us to the initial investigation of the role of neutrophils in MV-
mediated oncolysis in detail. 
6.1 GCSF AS A POTENTIAL ENHANCER OF MV ONCOLYSIS IN-VIVO: 
MV modified to express hGCSF was used in chapter 3 to enhance the 
oncolytic activity of MV by stimulating one of the important members of the 
innate immune system – neutrophils. Unexpectedly, the role of neutrophils 
was remarkably different, even in two different models of B-cell malignancy. 
While it was already established by previous work from our lab280 that Raji 
model is sensitive to neutrophil-specific lysis enhanced by MV in-vivo, this 
was reiterated by extended findings in chapter 3. Firstly, in the neutrophil 
depletion experiments the efficacy of MV therapy was abrogated in the 
depleted conditions only in Raji model, showing their importance in MV-
mediated killing. Secondly, MV expressing GCSF in the Raji disseminated 
model enhanced the neutrophil infiltration in the peripheral blood of mice and 
correlated with improved survival when compared to the unmodified MV. By 
contrast, the results in the Nalm-6 disseminated model were unexpected; no 
enhanced effect of addition of the hGCSF gene was observed in MVhGCSF 
treated mice when compared to MVNSe. Besides, unpredictably, the Nalm-6 
ALL progressed rapidly in the disseminated groups treated with hGCSF 
(expressed by MV or on its own). 
GCSF is widely used in the clinical treatment of patients with 
aggressive B-cell malignancies and has been shown to improve outcome393. 
A clinical trial NCT01331590 is being conducted, evaluating the role of GCSF 
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in priming the bone marrow of ALL patients for subsequent chemotherapy 
targeting396. Additionally, in an AML trial, GCSF has been used as a growth 
factor primer as it has been indicated to sensitise the leukaemia cells to 
chemotherapy. In this clinical trial the four-year cancer free survival was 
improved in patients treated with GCSF at induction, compared to the non-
treated group (42% to 33%). In the Raji model, MVhGCSF might carry an 
advantage, especially in combination with non-myelosuppressive 
chemotherapies. However, based on our data that showed an unexpectedly 
aggressive progression of Nalm-6 leukaemia in-vivo by MV expressing 
hGCSF, future studies would need to proceed very cautiously as any benefit 
from hGCSF as expressed by oncolytic viruses could be difficult to predict 
and may even vary from patient to patient. 
6.2 MECHANISMS OF MV ONCOLYSIS IN-VITRO: 
 ADCC as a mechanism of MV oncolysis: 6.2.1
The difference in neutrophil mediated response to MV infection in-
vivo, led to investigation of the mechanisms in detail in chapter 4 and chapter 
5. However, an in-vitro model was used to probe into the mechanisms using 
human neutrophils. In chapter 4, ADCC was explored as a mechanism based 
on previous data from the lab. ADCC, a mechanism by which antibody 
coated cells can induce cytotoxicity via a network of immune effector cells is 
also implicated in virus eradication after natural infection. More than 18 
different mAbs are approved for clinical use for treating cancer481 and can kill 
cancer cells by ADCC482,483. Monoclonal antibody bound to the effector cells 
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and in case of viral infection, the antibodies directed against the viral-infected 
cells can be recognised by effector cells and lead to cell killing by ADCC484-
487. Furthermore, systemic administration of virus hidden in immune-cells in 
combination with mAb like rituximab and cetuximab therapies can facilitate 
NK cell mediated ADCC488. The presence of anti-MV antibody in the 
serum239-241 can be a potential facilitator of ADCC during measles oncolytic 
virotherapy427 and previous data from the lab using Jurkat cells had indicated 
ADCC to be a likely mechanism of MV oncolysis. Nevertheless, after 
elaborate study in different other cell lines in chapter 4, ADCC could not be 
proven as a mechanism of MV oncolysis in-vitro in the cell lines examined 
except in Jurkats. 
 Fusion between neutrophils and MV-infected target cells as a 6.2.2
potential mechanism of oncolysis: 
Chapter 5 focussed on fusion as a mechanism of MV-mediated 
oncolysis. The hypothesis was derived from findings in chapter 4 in which the 
neutrophil-specific lysis of MV-infected Jurkat cells was higher after target 
cells were infected with a fusogenic MVNSe strain, than after infection with 
the less fusogenic MVMor strain. The complete abrogation of neutrophil-
specific lysis of MV-infected Jurkat cells in the presence of FIP was also 
prominent. Therefore, it was proposed that the neutrophils might possibly 
fuse with the MV-infected tumour cells thereby generating a cytotoxic 
neutrophil phenotype that can ultimately kill the tumour cells. 
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In chapter 5, addition of FIP in neutrophil and MV-infected Jurkat cell 
co-culture was shown to abrogate the neutrophil cytotoxic phenotype and 
showed reduced cytotoxicity towards MV-infected Jurkat cells. This was 
suggestive of neutrophil fusing with MV-infected target cells leading to target 
cell killing. Cytotoxic phenotype included neutrophil degranulation, ROS 
production and activation of type I IFN signalling pathway and there was a 
trend observed, where addition of FIP reduced induction of neutrophil 
cytotoxic phenotype. Certain components of the RLR signalling pathway 
tested were shown to be involved (RIG-I, MDA5), whereas others were not 
(MAVS) and hypothetically several others that might be playing important 
role still require testing. 
Sendai virus, a ssRNA virus which can also induce syncytia formation, 
has been shown to induce a pro-apoptotic phenotype in cancer cells via the 
RIG-I/MDA5 pathway activation, by regulated balance between pro and anti-
apoptotic members of the BCL-2 protein family489. Furthermore, ssRNA of 
MV is known to activate the RIG-I/MDA5 signalling 490, which can potentially 
lead to IRF gene expression – this remains to be elucidated. It can be 
hypothesised that this may either directly upregulate pro-apoptotic genes like 
Noxa and TRAIL489, leading to cell death, or could lead to activation of the 
anti-viral and anti-tumoural immunity via production of type I IFN and 
CXCL10. Additionally, as I have shown in chapter 5, a type I IFN response 
consequent on encountering MV-infected target cells can directly induce 
neutrophils to produce soluble TRAIL. Fusion blocking significantly reduced 
both type I IFN and TRAIL production by neutrophils. 
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 In the in-vivo system of cancer therapy, where other members of the 
innate immune family will be present, the type I IFN could further activate NK 
cells to produce IFN gamma, which in turn can attract and activate a CTL 
mediated adaptive immune response against the tumour cells489. 
6.2.2.1 Technical challenges and considerations: 
Attempts to visualise a fusion event between neutrophils and MV-
infected target cells was not successful. However, live cell imaging did 
indicate clear interaction between the MV-induced syncytia in target cells and 
the neutrophils which needs further experimentation. 
To determine fusion formation, various different methods have been 
used, including reporter assays491, spectrofluorometric measurement of 
fluorescent probe redistribution, such as fluorescence dequenching, 
photosensitised labelling, and fluorescence resonance energy transfer 
(FRET)492,493. These methods provide an overall estimation of fusion. 
Although, methods and assays, which can help understand the detailed 
mechanism of fusion by monitoring the detailed kinetic changes in the lipid 
and cytosolic compartments have been used494, they don't allow 
understanding of the functional and biological features of fusion and what 
effect this has on the surrounding environment, which should also be the 
subject of further work. Flow cytometric methods have also been used to 
determine cell-cell fusion495. However, determining the fusion and syncytia 
formation by flow cytometry needs expertise in analysing and being able to 
distinguish between cell aggregates and doublet due to actual syncytium 
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formation. The syncytium, on a flow cytometer show up with an FSC/SSC 
profile very similar to doublets, i.e. they are large (high FSC-A) and have 
unusual shapes (high FSC-W) and granularity (high SSC) that most people 
would typically gate out of their analysis439. All these will need to be taken 
into account before further experiments are designed to be certain that fusion 
between effector cells and MV-infected target cells is a possible mechanism 
of oncolysis. 
 Final Conclusions: 6.2.3
The concept of fusing immune cells with cancer cells has been used 
previously to make cancer vaccines, where hepatoma cells were fused with 
activated B-cells. The hybrid cells produced, lost their tumourigenicity and 
became immunogenic496. If the neutrophils are fusing with MV-infected 
cancer cells, they have the potential to generate a potent immunogenic 
effect, in turn alerting the immune system of the presence of tumour cells. 
Although conventionally, neutrophils are not seen as antigen presenting cells 
(APCs), there are reports that after virus infection they can prime naïve CD8+ 
T-cells and cross-present antigens from the virus infected cells497. They can 
also acquire an APC phenotype in the presence of GMCSF by upregulating 
MHC class II and CD80/CD86 co-stimulatory molecules498. Therefore, upon 
fusion of neutrophils with MV-infected cancer cells, in addition to direct, 
neutrophil-mediated cytotoxicity, I would hypothesise, will generate a more 
specific immune response by presenting the tumour antigens of the virally 
infected cells. This will be a potential benefit, especially in a tumour 
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microenvironment known for their immunosuppressive properties499. This 
should be the subject of further work. 
An additional potential value to MV-mediated target-immune cell 
fusion is the induction of cellular senescence, which has recently been 
shown to occur after MV-infection448. This is a robust mechanism that causes 
permanent cell cycle arrest of potentially harmful cells500,501. 
Chemotherapeutic drugs can induce tumour cell senescence502-504, which 
leads to the phenomena called therapy induced senescence (TIS). TIS have 
been suggested to halt cancer cell progression by different dysfunctional 
apoptosis signalling mechanisms such as overexpression of anti-apoptotic 
BCl-2 proteins and caspase inhibition504-507. Senescent cells, which exhibit 
profoundly altered phenotype, support enhanced MV replication when 
compared to non-senescent cells508. Fusion mediated by MV might be able 
to generate a senescent phenotype in tumour cells enabling enhanced 
replication and more efficient direct killing of the tumour cells. 
Overall the findings in this thesis suggest that neutrophils play an 
important role in MV-mediated killing of B-cell malignancies demonstrating 
specific toxicity against MV-infected target cells. This role can be enhanced 
by GCSF in very specific circumstances. However, I demonstrated that 
MVhGCSF would not be a safe and reliable tool for cancer therapy as the 
high levels of GCSF expressed by this virus can adversely affect tumour 
progression. My data indicates likely fusion induced by MV infection between 
cancer cells and neutrophils, which can potentially contribute to the 
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cytotoxicity. Further work is needed to confirm this fusion by direct 
visualisation. An investigation into the broader immunogenic effect of fusion 
of target cells and neutrophils and into MV-induced senescence would be an 
appropriate direction for further work. 
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Appendix: Live cell imaging (CD-ROM) 
Supplementary Video 1 (SV5-1): Time-lapse video with uninfected 
and MVNSeGFP infected Jurkat cells: Jurkat cells stained with CMTPX red 
dye were added at a ratio of 1:1 to MVNSeGFP infected Jurkat cells that are 
attached to fibronectin coated 24-well tissue culture plates. The plates were 
then imaged at 40X using ELWD lens every 5 mins for 1.5 hours. The purple 
arrow shows a fusion event. 
Supplementary Video 2 (SV5-2): Time-lapse video with uninfected 
neutrophils and MVNSeGFP infected Jurkat cells: Uninfected neutrophils 
stained with CMTPX red dye (red cells) were added to MVNSeGFP infected 
Jurkat cells (green) attached to fibronectin coated 24-well tissue culture 
plates, 24hpi. Images were then taken at 40X zoom using an ELWD lens. 
Neutrophils clustering under green GFP positive MV-infected Jurkat cell 
syncytia (white arrows) are shown over a time period of 2.5 hours. 
Supplementary Video 3 (SV5-3a and 3b): Time-lapse video with 
uninfected neutrophils and MVNSeGFP infected Vero cells: Vero cells 
cultured in 12-well tissue culture plates were infected with MVNSeGFP. 
Twenty-four hours post infection, neutrophils stained with CMTPX red dye 
were added to the infected Vero cells at 1:1 ratio. The videos 3a (green, red 
and bright field image overlay) and 3b (red and bright field overlay) were 
taken over a period of 3 hours and show neutrophils (red) interacting with the 
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Vero syncytium (green), alongside constant changing morphology before 
collapsing completely (white arrows). 
Supplementary Video 4 (SV5-4): Time-lapse video with uninfected 
neutrophils and MVNSeGFP infected Vero cells: Vero cells cultured in 12-
well tissue culture plates were infected with MVNSeGFP. Twenty-four hours 
post infection, neutrophils stained with CMTPX red dye were added at 1:1 
ratio. The video was taken between 3 and 5 hours of co-culture and show 
neutrophils (red) with flattened morphology on the surface of the green 
syncytium (shown by blue arrows). The green syncytium collapses at the end 
of 5-hour co-culture dragging along the red neutrophils. 
